An Independent Licensee of the Blue Cross and Blue Shield Association

August 17, 2023
Ms. Lindsi Swartz, MBA, MCM, Director
Bureau of Life, Accident \& Health Insurance
Commonwealth of Pennsylvania Insurance Department
1311 Strawberry Square
Harrisburg, PA 17120
Re: Highmark Coverage Advantage 2024 ACA Rate Filing (Individual Market)
Filing \# 1A-DP-23-HCA (SERFF \# HGHM-133630381)

This constitutes Notice pursuant to Section 707 of the Pennsylvania Right-to-Know Law that the attached Highmark Coverage Advantage (HCA) 2024 Individual Market Rate Filing contains Trade Secret and Confidential Proprietary Information. Therefore, HCA must, prior to the release of any portion of this Filing, be notified of any request by a third party for access to this Filing, and the Trade Secret and/or Confidential Proprietary Information identified by HCA should be redacted before release.

Dear Ms. Swartz:
This Filing includes the Highmark Coverage Advantage ("HCA", "Company") Individual Market rates and the supporting rate development for policies with effective dates on or after January 1, 2024.

As a result of the Department's review of this filing, the following changes have been made to the prior version of the filing:

- The statewide average premium assumptions used in the development of the projected risk adjustment transfer PMPM found in Attachment B have been updated to utilize an underlying assumed statewide average rate increase of $5.5 \%$ for 2023 and $4.2 \%$ for 2024.
- The estimated 2022 medical impact of the COVID-19 Capacity component found in Attachment G has been revised from (2.9\%) to (1.5\%).

The remainder of this cover letter and all of the supporting documents have been revised to reflect the changes described above.

In the event the Department decides to publish this Filing in the PA Bulletin, the company information requested in the Department's 2024 ACA-Compliant Health Insurance Rate Filing Guidance, Section B, is provided below:

## Requested Company Information

1. Company Name \& NAIC \#: Highmark Coverage Advantage, NAIC \# 15507
2. Market: Individual
3. On or Off Exchange: The Company anticipates selling plans on and off of the exchange.
4. Effective date of coverage: January 1, 2024
5. Average rate change requested: $\mathbf{8 . 0 \%}$ increase
6. Range of rate change requested: $\mathbf{3 . 7 \%}$ to $\mathbf{9 . 9 \%}$
7. Total additional annual revenue generated from the proposed rate change: $\mathbf{\$ 8 , 7 0 6 , 6 4 3}$
8. Product(s): EPO
9. Rating Areas and the change from 2023: Rating Areas 1 and 4

There are no changes in our covered Rating Areas from the 2023 rate filing.
10. Metal Levels and Catastrophic Plans: The Company anticipates selling Gold, Silver, Bronze, and Catastrophic plans in 2024
11. Current number of covered lives as of February 1, 2023: 18,548 covered lives
12. Number of plans offered in 2024 and the change this represents from 2023: 16

The Company offered 17 plans in 2023. For 2024, the Company is offering 1 new plan in the Market and removing 2 plans from the Market.

Please note that inclusion of premium rates in this filing for a given offering should not be construed to mean that the offering will ultimately be made available for sale in the Market. Final offering decisions will be made consistent with and within the timelines set forth in CMS rules and/or ACA regulations.
13. Corresponding contract form \#, SERFF and Binder ID\#s: The corresponding SERFF binder number is HGHM-PA24-125116298, affecting the following Company products and forms:

| Product Name / Type | Contract Form \& SERFF\# |
| :--- | :--- |
| Together Blue EPO | TB/EPO/HCA/DP-4; HGHM-133665362 |
| Together Blue EPO Premier | TB/EPO/Premier/HCA/DP-2; HGHM-133665363 |


| Together Blue EPO HDHP | TB/EPO/HDHP/HCA/DP-4; HGHM-133665391 |
| :--- | :--- |
| Together Blue Major Events EPO | TB/CAT/EPO/HCA/DP-4; HGHM-133665364 |
| Together Blue EPO Adult Dental and Vision | TB/EPO/ADV/HCA/DP-4; HGHM-133665365 |
| Together Blue EPO Premier Adult Dental and | TB/EPO/Premier/ADV/HCA/DP-2; |
| Vision | HGHM-133665394 |

## 14. HIOS Issuer ID \# and submission tracking number: HIOS Issuer ID \#79279, Company Filing \#1A-DP-23-HCA (SERFF Filing \# HGHM-133630381)

## Additional Filing Disclosures

The Company has submitted all Required Documents stipulated by the Department, including the federal documents related to this filing, in its SERFF submission. In addition to the Required Documents, the Company has submitted a Supplemental Exhibits file containing additional detailed exhibits on items referenced in the PA Actuarial Memorandum. All tables, exhibits, and detail in support of this filing and the PA Actuarial Memorandum have been included in Excel format. To assist in the Department's review, the Excel files have retained their formulas to the extent possible.

## Potential for Material Unforeseen Impacts

In accordance with the Department's updated recent rate filing guidance, the impact of the state 1332 Reinsurance program is captured using the prescribed parameters of \$60,000 attachment point, $50 \%$ coinsurance rate, and $\$ 100,000$ reinsurance cap. If the final parameters should change from those described in this filing, a revised submission would be required.

Other assumptions in the filing account for the ongoing impact of COVID-19 and the lack of Federal CSR funding. Finally, modifications to the rate development may be necessary if significant unforeseen events occur. Examples include, but are not limited to, changes in legislation/regulations (including rules, regulatory guidance, etc.), changes in the participation of QHP issuers that would materially impact risk adjustment transfer amounts, Medicaid redetermination policy impacts, or material developments in COVID-19 impacts. As a result, Highmark reserves the right to submit a revised filing.

## Request for Confidentiality

Please note that the rates and the supporting rate development contained in this Filing are competitively sensitive, are not in the public domain, and constitute business confidential proprietary/trade secret information that would cause harm to the competitive position of HCA if disclosed to the public.

Public disclosure of any information contained in this Filing would allow HCA competitors to better understand or discover its confidential and proprietary rating, pricing and/or marketing practices, would undermine competition in the Individual market and could have negative
consequences for the operation of HCA's business. Therefore, HCA asserts that this Filing, in its entirety, constitutes Trade Secret and Confidential Proprietary Information and should not be disclosed.

It is our understanding that the Department does not intend to publish the confidential \& proprietary information contained in this Filing or to otherwise permit this Filing and its confidential information, other than the redacted information and final approved rates, to be disclosed or released.

Furthermore and pursuant to the Pennsylvania Right-to-Know Law ("RTKL"), HCA must be notified prior to release of information contained in this Filing and be given the opportunity to respond to requests for such information. Should the Department receive such request or require the release of information contained in this Filing for its own purposes, HCA asserts its right to release a redacted version of the Filing. In accordance with the RTKL, please contact the HCA RTKL representative identified below prior to release of any information contained in this Filing:

RTKL Representative
Director Privacy \& Data Ethics
Highmark Health
120 Fifth Avenue, Suite 2114
Pittsburgh, PA 15222
Furthermore, it should be noted that HCA is equally concerned that even if this information is released in aggregate form, it still may be easy to identify the carrier that submitted it.

Should you have any questions regarding the attached Filing, please feel free to contact me at or via e-mail at:

Sincerely,


Director, Actuarial Services
Highmark Inc.

## Actuarial Memorandum

## 1. Basic Information and Data

## A. Company Information

The appropriate company information has been provided in Table 0 . General information pertaining to this rate filing is summarized below:

- Company Name: Highmark Coverage Advantage ("HCA", "Company")
- NAIC \#: 15507
- HIOS Issuer ID: 79279
- State: Pennsylvania
- Market: Individual
- Effective Date: $1 / 1 / 2024$
- SERFF Rate Filing \#: HGHM-133630381

In accordance with the Department's updated recent rate filing guidance, the impact of the state 1332 Reinsurance program is captured using the prescribed parameters of $\$ 60,000$ attachment point, $50 \%$ coinsurance rate, and $\$ 100,000$ reinsurance cap. If the finalized parameters differ from those described in this filing, a revised submission would be required.

Other assumptions in the filing account for the ongoing impact of COVID-19 and the lack of Federal CSR funding. Finally, modifications to the rate development may be necessary if significant unforeseen events occur. Examples include, but are not limited to, changes in legislation/regulations (including rules, regulatory guidance, etc.), changes in the participation of QHP issuers that would materially impact risk adjustment transfer amounts, Medicaid redetermination policy impacts, or material developments in COVID-19 impacts. As a result, HCA reserves the right to submit a revised filing.

## B. Rate History and Proposed Variations in Rate Changes

The three most recent rate changes in Pennsylvania for HCA are as follows:

| Year | Avg. Increase | SERFF ID\# |
| :--- | :--- | :--- |
| 2023 | $4.3 \%$ | HGHM-133249767 |
| 2022 | $-3.6 \%$ | HGHM-132820368 |
| 2021 | $3.1 \%$ | HGHM-132324161 |

Historical rate changes varied by plan due to updated cost sharing levels to meet federal AV requirements as well as updates to AV and other pricing factors.

The proposed 2024 rate changes vary by plan. This is primarily due to updates in the pricing AV factors and benefit richness factors. The plan level rate changes can be found in Table 10.

As requested by the Department, a historical MLR Exhibit is included as Attachment H. MLR results reflect any amounts attributed to the applicable benefit year. As an example, Risk Adjustment paid in mid-2020 for the 2019 benefit year is attributed to the 2019 benefit year.

## C. Average Rate Change

The average rate changes as presented in the filing are:

- Table 10: 8.0\%
- Table 11: 8.0\%

Table 10 calculates the percentage change in the member weighted average rate for 2023 and the member weighted average rate for 2024. Table 11 calculates the percentage increase for each geographic rating area and then member weights the percentage increases.

Worksheet 2 of the URRT also shows a submission level rate change. This value is used in the development of the average rate change shown in the Federal Part II justification. A demonstration of this calculation is included in Attachment F.

## D. Membership Count

Please see Table 1 for the average age, age breakdown, and total membership for the periods shown.

## E. Benefit/Cost Sharing Changes

The majority of Highmark Coverage Advantage's renewing 2024 plans contain cost sharing that differs from the 2023 offering.

The screenshots from the HHS AV calculator, showing the plan benefits and the resulting actuarial values, can be found as a separate attachment within the Supporting Documentation section in SERFF. Also, the PA Plan Design Summary and Rate Tables along with the HIOS Plan IDs can be found within the Rate/Rule Schedule section in SERFF.

## F. Experience Period Claims and Premium

Please see Table 2 for the experience period data for the most recent calendar year. The experience period paid claims data represents the 2022 calendar year results for all policies in the single risk pool, with run out through February 2023. This data is consistent with the data reported in Section I of Worksheet I of the URRT.

Table 2 is populated with the experience period data as follows:

- The Earned Premium represents actual revenues earned in the experience period.
- Incurred Claims represent claims paid by HCA. Note that the URRT includes capitated services and is net of $R x$ Rebates. Those values are not included here as they are listed as separate items.
- The Allowed Claims represent our best estimate of the total claims prior to member cost sharing incurred during the experience period. The Allowed Claims include:
- Two months of run out from the end of the experience period,
- Claims processed outside of the Company's claims system (e.g., claim settlement costs), and
- Our best estimate of claims incurred but not paid as of the end of the run out period. Note that allowed claims in the URRT include capitation and are net of drug rebates. They are not included here as they are called out separately in the exhibit.
- Allowed Charges for non EHB services are included in column G. The amount of non EHB included is shown in column H .
- Prescription Drug Rebates are used to reduce the level of Incurred Claims in the experience period.
- Total EHB capitation includes $\$ 0.15$ PMPM for the pediatric vision benefit.
- Estimated Risk Adjustment includes the transfer dollars and an estimate for the High Cost Risk Pool for the experience period. The Risk Adjustment transfer portion of the total is consistent with the results of the Department's RATEE analysis using the files dated May 3, 2023.


## G. Credibility of Data

The experience period data for HCA is large enough to be fully credible. The results are based $100 \%$ on the experience period data.

## H. Trend Identification

Table 3 identifies the annual medical and prescription drug allowed claims cost and utilization trends. The underlying total annual trend is $9.00 \%$. Additionally, there is an induced utilization adjustment of $0.15 \%$ per year applied to reach the overall trend of $9.17 \%$ shown in Table 3 column $G$. The definitions of service categories, cost, and utilization in Table 3 are consistent with the URRT instructions. The numbers entered in the Cost and Utilization columns are consistent with those entered in Worksheet I, Section 2 of the URRT, except as noted below.

The cost trends presented in Table 3 reflect the Company's expectations regarding increases in in-network contractual reimbursement, as well as projected out-of-network costs. The significant changes observed in the volume, demographics and morbidity of the ACA population from 2019 to 2022 yield component trends that are generally not directly applicable for trend analysis. The trend components in Table 3 therefore represent the same blended average for all types of service and are applied to the aggregate experience for pricing.

A multi-year regression analysis was developed by the Company's valuation team to analyze the ACA individual population trend levels. The analysis was completed at the medical and pharmacy level, then combined to develop a total trend assumption. The regression tool removes components of trend that are more explainable from the observed trend rates and then uses regression analysis to isolate the underlying trend rate. Some of the more explainable variables include high dollar claims, workdays, provider contracting, demographics, and seasonality. The total trend is the sum of the explainable components and the estimated underlying trend rate. The valuation regression tool primarily informed the trend selection with the final requested trend also based on actuarial judgment.

## I. Historical Experience

Table 4 presents the most recent 48 months (4 calendar years) of HCA data with run-out through February 2023. This data was not used to develop the trend in Table 3. Please see Section H for further details.

## 2. Rate Development \& Change

## A. Development of Projected Index Rate, Market-Adjusted Index Rate, \& Total Allowed Claims

The development of the Projected Index Rate, Projected Market-Adjusted Index Rate, and Projected Total Allowed Claims, shown in Table 5, closely follows the methodologies discussed in the Part III Actuarial Memorandum submitted in the Rate Filing Justification. Please refer to the Part III Memorandum for further details.

Some of the items separately identified in Table 5 include:

- The Change in Morbidity adjustment of 0.991 is comprised of the following: the morbidity impact from claims experience and an adjustment to account for the impact of Covid-19. In accordance with the Department's guidance, the morbidity change related to the Reinsurance program is set to 1.000. Each of the components is described in more detail below.


## The Morbidity Impact from Claims Experience

This adjustment reflects the change in the population mix/claim levels from the experience period to the projection period. We continue to observe a high degree of membership churn from year-to-year, which impacts the morbidity. This factor also takes into consideration the effects of adverse selection inherent to guaranteed issue markets. The Individual ACA risk pool continues to have a significantly higher proportion of older members with a high prevalence of chronic conditions compared to group business, which adds to the uncertainty of any future claim projections.

## Covid-19 Impact

In order to account for the impact of COVID-19 on projected claim costs, the Company took the following steps:

1. Adjusted the claims in the base experience period to a non-COVID-19 baseline. This was done to stabilize the base from which claims are being projected. The base period adjustment accounts for the impacts of testing, treatment, vaccines, capacity constraints, and deferred/rescheduled/induced care. Claims in the base experience period were decreased by a factor of 0.999 to remove the impact of COVID-19.
2. Projected claims to the projection period using trends with the impact of COVID-19 excluded. Again, this provides for a more stable projection of future claims, before applying the anticipated impact of COVID-19 in the projection period. This was
accomplished by applying a trend of 9.00\% (which excludes any impact from COVID-19) to our adjusted BEP claims.
3. The projected claims were then further adjusted by applying the anticipated impacts of COVID costs expected in the projection period. The following components were accounted for:
a. COVID Testing ( $0.7 \%$ medical claim impact) - Proportional to new cases, which are assumed to diminish over time and be lower in the projection period than in previous years.
b. Vaccines ( $0.1 \%$ medical and $2.1 \%$ drug claim impact) - The federal public health emergency ended on May 11, 2023, resulting in a shift in costs for the COVID-19 vaccine to the private market. Since COVID-19 vaccines will remain free as long as federally purchased supply is available, we expect costs to increase over time, starting at the end of 2023 and grading upward through 2025. Due to a decline in demand, we also assumed utilization will decrease through 2024.
c. Actuarial Judgement ( $-0.7 \%$ claims impact) - The Company reviewed the composite CY2024 COVID impact resulting from the components outlined above and elected to temper the adjustment in light of the inherent unpredictability of these estimates.
The application of the above COVID claim adjustments to the rating period results in a COVID adjustment factor of 1.004. Please see Attachment $G$ for a more detailed calculation of the of these factors.

- The Change in Demographics adjustment of 1.006 reflects the change in age and geography factors we expect from the experience period to the projection period.
- There is no Change in Network adjustment.
- There is no Change in Benefits adjustment.
- The Change in Other adjustment of 0.956 reflects changes in pharmacy rebates and expected changes in hospital/physician settlements.

Please see Attachments A and E for a more detailed calculation of these factors. These factors can also be found in the accompanying spreadsheet.

The projected paid-to-allowed ratio is 0.812 . The formula found in Table 5 cell C28 was overwritten because, unlike the average factor found in Table 10 cell K16, the Company's paid-to-allowed factor is dampened by items such as capitation.

The quantitative development of the projected risk adjustment transfer amount for the Company is shown in Attachment B and included in the accompanying spreadsheet. The transfer amount is developed based on an analysis of the claims data underlying the rate development for this filing (risk scores as defined in the HHS Notice of Benefit and Payment Parameters, as well as other risk transfer formula components) and an estimate as to the market-wide risk profile. This market-wide risk profile is developed from available market data, including prior years' risk adjustment transfer results, publicly available data, and outside expertise from actuarial consultants. Applying the federally prescribed transfer formula at the
level of granularity available in Attachment B yields a projected gross risk adjustment transfer of (\$55.11) PMPM on a billable member month basis. This amount is then converted to a total member month basis of (\$55.05) PMPM in order to be used in the rate development. The expected risk adjustment payable reflects that the Company anticipates its average risk score (net of allowable rating factors) to be lower than the statewide average.

The (\$56.85) PMPM value in cell C31 of Table 5 equals the (\$55.05) PMPM value from Attachment B, a charge of (\$2.68) PMPM for the projected net impact of the High Cost Risk Pool program, and a further adjustment for the composite effect of catastrophic eligibility and benefits in addition to EHB. Please note that the risk adjustment user fee is captured in the taxes and fees portion of administrative costs.

The exchange user fee in cell C32 of Table 5 is developed by taking the required user fee percentage of $3.0 \%$ and multiplying by the percentage of total members expected to be on exchange of $90 \%$. This results in a percentage of $2.7 \%$. The PMPM of $\$ 12.94$ is calculated as $2.7 \%$ of the total required premium adjusted further for the composite effect of catastrophic eligibility and benefits in addition to EHB.

The projected incurred reinsurance recoveries of $\$ 15.99$ PMPM is found in cell C33 of Table 5. The reinsurance recoveries PMPM was developed by trending Highmark PA individual ACA CY2022 incurred claims by member to the CY2024 rating period, applying the parameters defined in Tab II.b, and calculating the amount of incurred claims expected to be reimbursed by the program. Highmark PA individual ACA business was considered due to its level of credibility. The modeling produced an estimated incurred claims savings of $4.5 \%$. This percentage was converted to a PMPM and adjusted further for the composite effect of catastrophic eligibility and benefits in addition to EHB.

The Company intends to offer several plans that include benefits in addition to EHB. Five plans have an adult dental and vision benefit, and four plans have a hearing and an OTC benefit. The Company relied on cost estimates from other departments for the following non-EHB benefits:

- Adult dental benefit - United Concordia Dental (UCD) estimated this benefit to be worth \$28.88 PMPM on a paid basis.
- Adult vision benefit - Davis Vision estimated this benefit to be worth \$2.45 PMPM on a paid basis.
- Hearing benefit - TruHearing estimated this benefit to be worth $\$ 0.03$ PMPM on a paid basis.
- OTC Benefit - Fieldtex estimated that benefit to be worth $\$ 1.93$ PMPM on a paid basis.


## B. Retention Items

Table 6 has been completed with the requested retention elements for the proposed rates for the rating period. The amounts presented separately sum to the total administrative expenses and taxes and fees presented in the rate development.

Administrative costs reflect internal costs that the Company is projected to incur in the rating period and are developed from standard expense allocation methods. Administrative expenses do not vary by plan.

The proposed rate development assumes an average broker commission of $\$ 7.70$ PMPM for 2024. The assumed broker commission schedule and the development of the average value are included in Attachment D.

Expenses for Quality Improvement initiatives are assumed to be $2.79 \%$.
The following is a summary of the Taxes and Fees included in the rate development:

- Pennsylvania Premium Tax is not applicable to this issuer and thus is set to $0.0 \%$.
- Federal Income Tax is set to 0.0\%.
- Health Insurance Provider Fee is set to $0.0 \%$
- Risk Adjustment User Fee is set to $\$ 0.21$ PMPM consistent with Federal regulations.
- Patient-Centered Outcomes Research Institute (PCORI) fee is set to \$0.29 PMPM.

The Profit/Contingency for all plans is set to 0\%. HCA has voluntarily refrained from adding a risk and contingency factor in this filing. By this voluntary action, HCA is not waving any right to include a risk and contingency factor which HCA believes is consistent with historical and legal interpretations of HCA and the Pennsylvania Insurance Department.

## C. Normalized Market-Adjusted Projected Allowed Total Claims

The normalization factors presented in Table 7 are each determined from the underlying membership demographics expected in the projected rating period. The 2023 values are pulled from the prior year's filing, while the 2024 values represent our projection for 2024 assumed in the 2024 rate development.

## D. Components of Rate Change

Table 8 presents the components of change in the proposed 2024 Calibrated Plan Adjusted Index Rate (PMPM). Cell C73 is populated with the base period allowed charges found in the 2023 plan year rate filing (\$418.33).

Table 9 presents the data elements supporting the calculations in Table 8. The 2023 values are populated using the 2023 filed factors adjusted for the membership mix as of February 1, 2023.

## 3. Plan Rate Development

Table 10 shows the plan rate development for 2024. This table shows the plans that the Company intends to offer in 2024, as well as all plans offered in the 2023 portfolio. The calibrated plan adjusted index rates for 2023 are calculated according to the instructions. The 2024 rating factors are consistent with the factors found on Worksheet 2 of the URRT. The pricing effect on Table 10 is further broken out into Pricing AV, Benefit Richness, and Non-Funding of CSR Adjustment. Similar to the URRT, the admin effect on Table 10 is broken out into Admin Costs, Taxes and Fees, and Profit or Contingency.

The benefit richness factors in column $L$ are populated with the factors found in Attachment $C$ and the corresponding supporting spreadsheet included with this rate filing. The derivation of the AV and Cost Sharing factors can also be found in Attachment C. The values in column 8 of the attachment represent
the pure induced utilization for each plan. The Company's induced utilization factors are based on the following state-defined formula: (Plan AV)^2-(Plan AV) + 1.24. The "Plan AV" is the product of the "Pricing AV" and "Non-Funding of CSR Adjustment." Each plan's factor was then normalized by the average utilization factor. The average is a weighted average using projected membership as the weight. After normalization the average factor as shown in Attachment C is 1.000.

Note that the HHS Actuarial Value Calculator was unable to accommodate all of the Company's benefit designs. Plans needing certification are marked in column I of Table 10. Screen shots of all of the AV calculations and the appropriate certifications are included as a separate attachment within the Supporting Documentation section in SERFF.

For discontinuing plans where members are being mapped into a new plan, an effective rate increase is calculated by comparing the 2023 rate of the discontinuing plan to the 2024 rate of the plan to which the member is being mapped.

Columns AG through AP are populated with the February 1, 2023 enrollment by 2024 plan and rating area.

## Impact of Non-Payment of Cost Sharing Reduction Subsidies

In accordance with the Department's guidance, we have applied an additional adjustment to our AV pricing values for those Silver plans not offered exclusively off-exchange. This adjustment factor was 1.23 and represents the non-payment of Cost Sharing Reduction subsidies. Consistent with the Department's guidance, this adjustment was reflected in Table 10 in Column P.

## 4. Plan Premium Development for 21-Year-Old Non-Tobacco User

Table 11 presents the Company's 21-year-old non-tobacco premium in the Individual Market. As mentioned in Section 1.C above, the change in 21-year-old non-tobacco premium PMPM calculated in this table is $8.0 \%$.

## 5. Plan Factors

## A. Age and Tobacco Factors

Please see Table 12 for the Company's age and tobacco factors.

## B. Geographic Factors

Please see Table 13 for the Company's geographic factors. The Company's factors for the rating period are unchanged from the currently approved factors.

## C. Network Factors

Please see Table 14 for a summary of the Company's network rating factors. The factors presented here represent the medical network factors from the prior approved rate filing (if applicable) and the projected
medical network factors for the rating period. The Company's factors for the rating period are unchanged from the currently approved factors.

## D. Service Area Composition

The Plan Design Summary exhibit uploaded as a separate document contains the service areas related to this filing. As requested, service area maps are included.

## 6. Actuarial Certifications

I, , am a member of the American Academy of Actuaries and meet its qualification standards for actuaries issuing statements of actuarial opinions in the United States. All statements in this actuarial certification are accurate to the best of my knowledge and understanding. This filing is prepared in compliance with applicable Actuarial Standards of Practice. In completing this filing, I relied on data/information from other sources which was reviewed for reasonableness. This filing is prepared on behalf of HCA to accompany its rate filing (for calendar year 2024) for the Individual Market on and off the Pennsylvania Exchange.

I hereby certify that the projected index rate is, to the best of my knowledge and understanding:

- In compliance with all applicable State and Federal Statutes and Regulations (45 CFR 156.80 and 147.102),
- Developed in compliance with the applicable Actuarial Standards of Practice
- Reasonable in relation to the benefits provided and the population anticipated to be covered
- Neither excessive nor deficient.

I certify that the index rate and only the allowable modifiers as described in 45 CFR 156.80(d) (1) and 45 CFR 156.80(d)(2) were used to generate plan level rates.

I certify that all factors, benefit and other changes from the prior approved filing have been disclosed in the 2023 PA Actuarial Memorandum Rate Exhibits.

I certify that new plans are not considered modifications of existing plans (per the uniform modification standards in 45 CFR 147.106).

I certify that the AV Metal Values included in Table 10 were based entirely on the Federal AV Calculator or one of the approved alternative approaches.

I certify that the geographic rating factors reflect only differences in the costs of delivery (which can include unit cost and provider practice pattern differences) and do not include differences for population morbidity by geographic area.

I certify that the information presented in the PA Actuarial Memorandum and PA Actuarial Memorandum Rate Exhibits is consistent with the information presented in the 2024 Rate Filing Justification.


Title: Actuarial Director, Individual Markets
Date: 08/17/2023

# Highmark Coverage Advantage 

Individual Market Product Portfolio

## Supplemental Exhibits

| Attachment A | Change in Morbidity \& Non-Morbidity Changes Calculations |
| :--- | :--- |
| Attachment B | Risk Adjustment Calculation |
| Attachment C | Induced Demand Calculation |
| Attachment D | Broker Commission Calculation |
| Attachment E | Change in Demographics Calculation |
| Attachment F | URRT Average Increase |
| Attachment G | COVID Adjustment Calculation |
| Attachment H | MLR Exhibit |

Highmark Coverage Advantage

## Individual Market

Attachment A - 'Change in Morbidity' \& 'Non-Morbidity Changes' Calculations

| Components of 'Change in Morbidity' | 2022 Member Distribution | 2022 Normalized Allowed PMPM | 2024 Member Distribution | 2022 Normalized Allowed PMPM | Morbidity Change Relative to Total |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Population Source |  |  |  |  |  |
| HMCAI ACA | 100.0\% | \$323.77 | 76.0\% | \$317.14 | 0.980 |
| Other Highmark |  |  | 4.7\% | \$370.85 | 1.145 |
| Prior ACA |  |  | 0.8\% | \$288.14 | 0.890 |
| New-to-Blue |  |  | 18.5\% | \$317.14 | 0.980 |
| Morbidity Factor | 100.0\% | \$323.77 | 100.0\% | \$319.43 | 0.987 |
| Capitation and Dental Dampening Factor |  |  |  |  | 1.000 |
| Dampened Morbidity Factor |  |  |  |  | 0.987 |
| COVID-19 Adjustment Factor |  |  |  |  | 1.004 |
| Table 5 'Change in Morbidity' Factor |  |  |  |  | 0.991 |


| Components of 'Non-Morbidity Changes' | Factor |
| :--- | :---: |
| CY2022 Demographic Factor | 1.646 |
| CY2024 Demographic Factor | $\underline{1.656}$ |
| Change in Demographics | 1.006 |
| CY2022 Network Factor | 0.698 |
| CY2024 Network Factor | $\underline{0.698}$ |
| Change in Network | 1.000 |
| Change in Benefits | 1.000 |
| Change in Other | 0.956 |
| Table 5 'Non-Morbidity Changes' Factor | 0.962 |

## Attachment B-Risk Adjustment Calculation

Highmark Coverage Advantage
Individual Market
Attachment C-Induced Demand Calculation

| Induced Utilization Exhibit |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Plan ID <br> Metal Level <br> (1) <br> (2) | Projected Membership (3) | Projected Allowed Claims <br> (4) | Projected Paid Claims (5) | Paid to Allowed Factor (6) | AV \& Cost Sharing Factor <br> (7) | $(7) /(6)$ <br> (8) |
| 79279PA0080008 Gold | 85,740 | \$37,943,034.86 | \$31,275,059.97 | 0.824 | 0.828 | 1.004 |
| 79279PA0130005 Gold | 18,024 | \$8,661,355.11 | \$7,139,239.17 | 0.824 | 0.828 | 1.004 |
| 79279PA0140001 Gold | 39,780 | \$17,896,257.93 | \$15,084,568.23 | 0.843 | 0.856 | 1.016 |
| 79279PA0150001 Gold | 16,620 | \$8,094,780.16 | \$6,823,005.35 | 0.843 | 0.856 | 1.016 |
| 79279PA0090004 Gold | 4,224 | \$1,825,920.18 | \$1,428,564.88 | 0.782 | 0.768 | 0.981 |
| 79279PA0080013 Gold | 2,928 | \$1,270,215.50 | \$1,002,288.54 | 0.789 | 0.777 | 0.985 |
| 79279PA0140002 Silver | 3,564 | \$1,654,683.42 | \$1,475,692.53 | 0.892 | 0.935 | 1.049 |
| 79279PA0150002 Silver | 2,448 | \$1,222,548.72 | \$1,090,302.83 | 0.892 | 0.935 | 1.049 |
| 79279PA0080012 Silver | 33,216 | \$15,015,349.90 | \$12,894,489.21 | 0.859 | 0.881 | 1.026 |
| 79279PA0080010 Silver | 1,728 | \$725,761.61 | \$524,121.38 | 0.722 | 0.688 | 0.953 |
| 79279PA0130004 Silver | 612 | \$283,591.15 | \$204,800.28 | 0.722 | 0.688 | 0.953 |
| 79279PA0080001 Bronze | 16,224 | \$6,689,791.49 | \$4,511,123.72 | 0.674 | 0.631 | 0.936 |
| 79279PA0130002 Bronze | 3,504 | \$1,607,635.85 | \$1,084,076.27 | 0.674 | 0.631 | 0.936 |
| 79279PA0090001 Bronze | 4,740 | \$1,961,778.73 | \$1,343,678.78 | 0.685 | 0.643 | 0.939 |
| 79279PA0080011 Bronze | 5,880 | \$2,386,278.67 | \$1,478,253.34 | 0.619 | 0.571 | 0.921 |
| 79279PA0100001 Catastrophic | 2,664 | \$986,458.77 | \$569,715.56 | 0.578 | 0.528 | 0.913 |
| Total | 241,896 | \$108,225,442.04 | \$87,928,980.03 | 0.812 | 0.812 | 1.000 |


| Components of AV \& Cost Sharing Factor |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HIOS Plan ID | Metal Level | Paid-toAllowed Ratio | Induced Utilization Factor | Avg. Benefit Richness | AV \& Cost <br> Sharing <br> Factor |
| 79279PA0080008 | Gold | 0.824 | 1.095 | 1.090 | 0.828 |
| 79279PA0130005 | Gold | 0.824 | 1.095 | 1.090 | 0.828 |
| 79279PA0140001 | Gold | 0.843 | 1.108 | 1.090 | 0.856 |
| 79279PA0150001 | Gold | 0.843 | 1.108 | 1.090 | 0.856 |
| 79279PA0090004 | Gold | 0.782 | 1.070 | 1.090 | 0.768 |
| 79279PA0080013 | Gold | 0.789 | 1.074 | 1.090 | 0.777 |
| 79279PA0140002 | Silver | 0.892 | 1.144 | 1.090 | 0.935 |
| 79279PA0150002 | Silver | 0.892 | 1.144 | 1.090 | 0.935 |
| 79279PA0080012 | Silver | 0.859 | 1.119 | 1.090 | 0.881 |
| 79279PA0080010 | Silver | 0.722 | 1.039 | 1.090 | 0.688 |
| 79279PA0130004 | Silver | 0.722 | 1.039 | 1.090 | 0.688 |
| 79279PA0080001 | Bronze | 0.674 | 1.020 | 1.090 | 0.631 |
| 79279PA0130002 | Bronze | 0.674 | 1.020 | 1.090 | 0.631 |
| $79279 P A 0090001$ | Bronze | 0.685 | 1.024 | 1.090 | 0.643 |
| 79279PA0080011 | Bronze | 0.619 | 1.004 | 1.090 | 0.571 |
| $79279 P A 0100001$ | Catastrophic | 0.578 | 0.996 | 1.090 | 0.528 |

Highmark Coverage Advantage
Individual Market
Attachment D-Broker Commission Calculation


| Table E. 1 - Age \& Tobacco Factors |  |  | Table E. 2 - Experience Period Membership |  |  | Table E. 3 - Projection Period Membership |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & \text { Age } \\ & \text { Band } \end{aligned}$ | HHSAge Factor | Tobacco Factor | Membership Mix |  |  | Membership Mix |  |  |
|  |  |  | Non-Tobacco | Tobacco | Total | Non-Tobacco | Tobacco | Total |
| 0 |  | 1.000 | 0.59\% | 0.00\% | 0.59\% | 0.35\% | 0.00\% | 0.35\% |
| 1 | 0.765 | 1.000 | 0.36\% | 0.00\% | 0.36\% | 0.42\% | 0.00\% | 0.42\% |
| 2 | 0.765 | 1.000 | 0.38\% | 0.00\% | 0.38\% | 0.34\% | 0.00\% | 0.34\% |
| 3 | 0.765 | 1.000 | 0.40\% | 0.00\% | 0.40\% | 0.42\% | 0.00\% | 0.42\% |
| 4 | 0.765 | 1.000 | 0.29\% | 0.00\% | 0.29\% | 0.39\% | 0.00\% | 0.39\% |
| 5 | 0.765 | 1.000 | 0.33\% | 0.00\% | 0.33\% | 0.33\% | 0.00\% | 0.33\% |
| 6 | 0.765 | 1.000 | 0.30\% | 0.00\% | 0.30\% | 0.32\% | 0.00\% | 0.32\% |
| 7 | 0.765 | 1.000 | 0.27\% | 0.00\% | 0.27\% | 0.37\% | 0.00\% | 0.37\% |
| 8 | 0.765 | 1.000 | 0.21\% | 0.00\% | 0.21\% | 0.26\% | 0.00\% | 0.26\% |
| 9 | 0.765 | 1.000 | 0.27\% | 0.00\% | 0.27\% | 0.30\% | 0.00\% | 0.30\% |
| 10 | 0.765 | 1.000 | 0.30\% | 0.00\% | 0.30\% | 0.29\% | 0.00\% | 0.29\% |
| 11 | 0.765 | 1.000 | 0.21\% | 0.00\% | 0.21\% | 0.27\% | 0.00\% | 0.27\% |
| 12 | 0.765 | 1.000 | 0.24\% | 0.00\% | 0.24\% | 0.29\% | 0.00\% | 0.29\% |
| 13 | 0.765 | 1.000 | 0.28\% | 0.00\% | 0.28\% | 0.26\% | 0.00\% | 0.26\% |
| 14 | 0.765 | 1.000 | 0.29\% | 0.00\% | 0.29\% | 0.33\% | 0.00\% | 0.33\% |
| 15 | 0.833 | 1.000 | 0.30\% | 0.00\% | 0.30\% | 0.30\% | 0.00\% | 0.30\% |
| 16 | 0.859 | 1.000 | 0.25\% | 0.00\% | 0.25\% | 0.33\% | 0.00\% | 0.33\% |
| 17 | 0.885 | 1.000 | 0.31\% | 0.00\% | 0.31\% | 0.27\% | 0.00\% | 0.27\% |
| 18 | 0.913 | 1.000 | 0.35\% | 0.00\% | 0.35\% | 0.37\% | 0.00\% | 0.37\% |
| 19 | 0.941 | 1.000 | 0.64\% | 0.00\% | 0.64\% | 0.50\% | 0.00\% | 0.50\% |
| 20 | 0.970 | 1.000 | 0.74\% | 0.00\% | 0.74\% | 0.66\% | 0.00\% | 0.66\% |
| 21 | 1.000 | 1.025 | 0.86\% | 0.02\% | 0.88\% | 0.87\% | 0.02\% | 0.89\% |
| 22 | 1.000 | 1.025 | 1.03\% | 0.01\% | 1.04\% | 1.01\% | 0.01\% | 1.02\% |
| 23 | 1.000 | 1.025 | 1.12\% | 0.01\% | 1.13\% | 1.04\% | 0.00\% | 1.04\% |
| 24 | 1.000 | 1.025 | 1.10\% | 0.02\% | 1.12\% | 1.06\% | 0.02\% | 1.08\% |
| 25 | 1.004 | 1.025 | 1.33\% | 0.04\% | 1.38\% | 1.18\% | 0.03\% | 1.22\% |
| 26 | 1.024 | 1.025 | 4.40\% | 0.17\% | 4.58\% | 2.93\% | 0.11\% | 3.04\% |
| 27 | 1.048 | 1.025 | 3.19\% | 0.16\% | 3.34\% | 3.19\% | 0.15\% | 3.35\% |
| 28 | 1.087 | 1.025 | 2.38\% | 0.16\% | 2.54\% | 2.98\% | 0.15\% | 3.13\% |
| 29 | 1.119 | 1.025 | 2.41\% | 0.15\% | 2.56\% | 2.29\% | 0.14\% | 2.43\% |
| 30 | 1.135 | 1.025 | 2.17\% | 0.09\% | 2.26\% | 2.24\% | 0.13\% | 2.37\% |
| 31 | 1.159 | 1.025 | 1.99\% | 0.15\% | 2.14\% | 2.12\% | 0.19\% | 2.31\% |
| 32 | 1.183 | 1.025 | 1.92\% | 0.11\% | 2.04\% | 1.96\% | 0.15\% | 2.11\% |
| 33 | 1.198 | 1.025 | 1.93\% | 0.13\% | 2.06\% | 2.09\% | 0.10\% | 2.19\% |
| 34 | 1.214 | 1.025 | 1.76\% | 0.15\% | 1.90\% | 1.80\% | 0.12\% | 1.93\% |
| 35 | 1.222 | 1.025 | 1.72\% | 0.14\% | 1.86\% | 1.78\% | 0.15\% | 1.93\% |
| 36 | 1.230 | 1.025 | 1.67\% | 0.08\% | 1.75\% | 1.79\% | 0.15\% | 1.94\% |
| 37 | 1.238 | 1.025 | 1.76\% | 0.13\% | 1.90\% | 1.76\% | 0.07\% | 1.83\% |
| 38 | 1.246 | 1.025 | 1.49\% | 0.18\% | 1.67\% | 1.82\% | 0.14\% | 1.96\% |
| 39 | 1.262 | 1.025 | 1.41\% | 0.14\% | 1.56\% | 1.41\% | 0.12\% | 1.52\% |
| 40 | 1.278 | 1.100 | 1.38\% | 0.11\% | 1.50\% | 1.44\% | 0.14\% | 1.57\% |
| 41 | 1.302 | 1.105 | 1.30\% | 0.07\% | 1.37\% | 1.48\% | 0.15\% | 1.63\% |
| 42 | 1.325 | 1.112 | 1.47\% | 0.04\% | 1.51\% | 1.35\% | 0.07\% | 1.42\% |
| 43 | 1.357 | 1.121 | 1.33\% | 0.08\% | 1.41\% | 1.44\% | 0.08\% | 1.52\% |
| 44 | 1.397 | 1.132 | 1.22\% | 0.09\% | 1.31\% | 1.34\% | 0.08\% | 1.42\% |
| 45 | 1.444 | 1.145 | 1.20\% | 0.04\% | 1.24\% | 1.15\% | 0.08\% | 1.23\% |
| 46 | 1.500 | 1.160 | 1.17\% | 0.06\% | 1.23\% | 1.27\% | 0.05\% | 1.32\% |
| 47 | 1.563 | 1.177 | 1.13\% | 0.06\% | 1.19\% | 1.09\% | 0.07\% | 1.16\% |
| 48 | 1.635 | 1.196 | 1.32\% | 0.08\% | 1.40\% | 1.18\% | 0.08\% | 1.26\% |
| 49 | 1.706 | 1.217 | 1.30\% | 0.12\% | 1.42\% | 1.25\% | 0.08\% | 1.34\% |
| 50 | 1.786 | 1.225 | 1.56\% | 0.09\% | 1.65\% | 1.26\% | 0.09\% | 1.35\% |
| 51 | 1.865 | 1.225 | 1.73\% | 0.09\% | 1.82\% | 1.67\% | 0.06\% | 1.74\% |
| 52 | 1.952 | 1.225 | 1.75\% | 0.11\% | 1.86\% | 1.67\% | 0.11\% | 1.78\% |
| 53 | 2.040 | 1.225 | 1.77\% | 0.11\% | 1.89\% | 1.72\% | 0.10\% | 1.82\% |
| 54 | 2.135 | 1.225 | 1.73\% | 0.08\% | 1.80\% | 1.79\% | 0.12\% | 1.91\% |
| 55 | 2.230 | 1.225 | 1.81\% | 0.12\% | 1.93\% | 1.81\% | 0.08\% | 1.89\% |
| 56 | 2.333 | 1.225 | 1.94\% | 0.12\% | 2.06\% | 1.84\% | 0.15\% | 1.98\% |
| 57 | 2.437 | 1.225 | 2.14\% | 0.16\% | 2.30\% | 2.29\% | 0.12\% | 2.41\% |
| 58 | 2.548 | 1.225 | 2.55\% | 0.11\% | 2.66\% | 2.38\% | 0.15\% | 2.53\% |
| 59 | 2.603 | 1.225 | 2.54\% | 0.14\% | 2.69\% | 2.60\% | 0.13\% | 2.73\% |
| 60 | 2.714 | 1.225 | 3.00\% | 0.17\% | 3.17\% | 2.81\% | 0.11\% | 2.92\% |
| 61 | 2.810 | 1.225 | 3.56\% | 0.18\% | 3.73\% | 3.21\% | 0.20\% | 3.41\% |
| 62 | 2.873 | 1.225 | 4.66\% | 0.32\% | 4.98\% | 4.04\% | 0.15\% | 4.19\% |
| 63 | 2.952 | 1.225 | 4.80\% | 0.33\% | 5.13\% | 4.81\% | 0.27\% | 5.08\% |
| 64 | 3.000 | 1.225 | 3.56\% | 0.17\% | 3.73\% | 5.43\% | 0.30\% | 5.73\% |
|  |  |  | 94.89\% | 5.11\% | 100.00\% | 95.01\% | 4.99\% | 100.00\% |

Table E. 4 - Area Factors

| Rating <br> Area | Experience Period <br> Enrollment |  | Prea Factor |  |
| :---: | :---: | :---: | ---: | :---: | Enrollmention Period | Area Factor |
| :---: |
| 1 |

Table E. 5 - 'Change in Demographics' Calculation

|  | Experience <br> Period | Projection <br> Period | Change in <br> Demographics |
| :--- | :---: | :---: | :---: |
| Average Age Factor | 1.740 | 1.751 |  |
| Average Tobacco Factor | 1.007 | 1.007 |  |
| Average Area Factor | $\underline{0.940}$ | $\underline{0.940}$ |  |
| Average Demographic Factor | 1.647 | 1.657 |  |
| Capitation Dampening | $\underline{0.999}$ | $\underline{0.999}$ |  |
| Final Demographic Factor | 1.645 | 1.656 | 1.006 |

Highmark Coverage Advantage

## Individual Market

Attachment F - URRT Average Increase

| HIOS Plan ID | URRT Plan Category | URRT Current Enrollment | Current Enrollment in Renewing Plans | Current Avg Rate | Projected Avg Rate | Cumulative Rate Change \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 79279PA0080001 | Renewing | 1,646 | 1,646 | \$346.84 | \$375.07 | 8.14\% |
| 79279PA0080004 | Terminated | 0 | 0 | \$0.00 | \$0.00 | 0.00\% |
| 79279PA0080008 | Renewing | 6,361 | 6,361 | \$449.77 | \$492.05 | 9.40\% |
| 79279PA0080010 | Renewing | 171 | 171 | \$388.60 | \$409.16 | 5.29\% |
| 79279PA0080011 | Renewing | 268 | 268 | \$313.95 | \$339.13 | 8.02\% |
| 79279PA0080012 | Renewing | 2,671 | 2,671 | \$485.89 | \$523.64 | 7.77\% |
| 79279PA0080013 | New | 0 | 0 | \$0.00 | \$0.00 | 0.00\% |
| 79279PA0090001 | Renewing | 420 | 420 | \$359.38 | \$382.38 | 6.40\% |
| 79279PA0090002 | Terminated | 0 | 0 | \$0.00 | \$0.00 | 0.00\% |
| 79279PA0090004 | Renewing | 272 | 272 | \$421.47 | \$456.20 | 8.24\% |
| 79279PA0100001 | Renewing | 187 | 187 | \$262.54 | \$288.48 | 9.88\% |
| 79279PA0130002 | Renewing | 237 | 237 | \$391.81 | \$417.32 | 6.51\% |
| 79279PA0130003 | Terminated | 0 | 0 | \$0.00 | \$0.00 | 0.00\% |
| 79279PA0130004 | Renewing | 60 | 60 | \$433.57 | \$451.39 | 4.11\% |
| 79279PA0130005 | Renewing | 1,052 | 1,052 | \$494.74 | \$534.32 | 8.00\% |
| 79279PA0140001 | Renewing | 3,268 | 3,268 | \$476.91 | \$511.49 | 7.25\% |
| 79279PA0140002 | Renewing | 249 | 249 | \$528.23 | \$558.50 | 5.73\% |
| 79279PA0150001 | Renewing | 1,425 | 1,425 | \$521.88 | \$553.77 | 6.11\% |
| 79279PA0150002 | Renewing | 135 | 135 | \$573.21 | \$600.78 | 4.81\% |
| 79279PA0160001 | Terminated | 0 | 0 | \$0.00 | \$0.00 | 0.00\% |
| 79279PA0170001 | Terminated | 0 | 0 | \$0.00 | \$0.00 | 0.00\% |
| Total |  | 18,422 | 18,422 | \$453.01 | \$489.32 | 8.02\% |

Highmark Coverage Advantage
Individual Market
Attachment G - COVID Adjustment Calculation

|  | COVID-19 Impact |  |  |
| :---: | :---: | :---: | :---: |
|  | Medical | Drug | Total |
| CY2022 Adjustment |  |  |  |
| \% of Spend | 70.9\% | 29.1\% | 100.0\% |
| Category |  |  |  |
| Testing | 1.0\% | 0.6\% |  |
| Vaccines | 0.1\% | 0.6\% |  |
| Capacity | (1.5\%) | 0.0\% |  |
| Avoided Care | 0.0\% | 0.0\% |  |
| Total Impact | (0.4\%) | 1.2\% | 0.1\% |
| CY2022 Adjustment Factor |  |  | 0.999 |
| CY2024 Adjustment |  |  |  |
| \% of Spend | 70.9\% | 29.1\% | 100.0\% |
| Category |  |  |  |
| Testing | 0.7\% | 0.0\% |  |
| Vaccines | 0.1\% | 2.1\% |  |
| Capacity | 0.0\% | 0.0\% |  |
| Avoided Care | 0.0\% | 0.0\% |  |
| Total Impact | 0.8\% | 2.1\% | 1.2\% |
| Actuarial Judgement |  |  | (0.7\%) |
| Total Impact after Actuarial Judgement |  |  | 0.5\% |
| CY2024 Adjustment Factor |  |  | 1.005 |
| Total COVID-19 Adjustment Factor |  |  | 1.004 |

Highmark Coverage Advantage
Individual Market

Attachment H-MLR Exhibit

|  | MLR |  | Member Months |  |
| :---: | :---: | :---: | :---: | :---: |
| Calendar Year | Actual | Pricing | Actual | Pricing |
| 2019 | N/A | N/A | 0 | 0 |
| 2020 | $69.4 \%$ | $81.2 \%$ | 80,110 | 138,912 |
| 2021 | $81.4 \%$ | $82.4 \%$ | 128,970 | 123,144 |
| 3-yr Total | $\mathbf{7 7 . 2 \%}$ | $\mathbf{8 1 . 7 \%}$ | $\mathbf{2 0 9 , 0 8 0}$ | $\mathbf{2 6 2 , 0 5 6}$ |

## Standard Questions

## 1. Membership:

a. If the projected membership for plan year $\mathbf{2 0 2 4}$ significantly differs from the current 2/1/2023 membership, please explain why.

Response:
a. We anticipate significant growth in HCA primarily based on: 1) Maturity into the market, particularly in recent expansion counties Westmoreland and Butler; and 2) Resuming Medicaideligibility determinations will add additional lower-income/price-sensitive consumers to the ACA Individual market, who are the most likely to enroll in lower-cost products.

## 2. Experience Period Claims:

a. Please confirm that all claims which are capitated have been removed from the experience period claims.
b. Please confirm that all non-EHB claims have been removed from the experience period claims.
c. How are drug rebates projected to change from the base period to the rating period? How has this change been reflected in the rate development?

Response:
a. All capitation dollars are excluded from the experience period paid claims in Table 2. Capitation dollars are captured in the appropriate EHB Capitation and Non-EHB Capitation cells in Table 2.
b. All non-EHB claims have been removed from the experience period claims that are used to develop the Index Rate.

| c. |  |
| :--- | :--- | :--- |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

## 3. COVID:

a. Please confirm that Tables 2-4 of the PAAM Exhibits do not have any COVID adjustment. Additionally, please confirm that any COVID adjustment factor in the filing is reflected in Table 5 of the PAAM Exhibits.
b. If there is a COVID adjustment factor other than 1.0, please provide a quantitative exhibit supporting the factor.

Response:
a. Tables 2-4 of the PAAM Exhibits do not have any COVID adjustments. As discussed in Section 2.A of the PA Actuarial Memorandum, the COVID adjustments are included in the "Change in Morbidity" line of Table 5.
b. Attachment $G$ of the PA Actuarial Memorandum provides quantitative support for the COVID adjustment factor. A detailed discussion of the development of this factor is included in Section 2.A of the PA Actuarial Memorandum.

## 4. Trend:

a. [SG. Only] If the Total Annual Trend in Table 3 (weighted by credibility) and the Annual Trend used to calculate quarterly rates in Table 5A differ, please provide an explanation and exhibit in support of the variation.
b. [SG. Only] In Table 5A, if cells K32:M32 are left to equal J32, please explain why that is a reasonable assumption.

Response:
a. This question is not applicable to this filing.
b. This question is not applicable to this filing.

## 5. Table 6 - Retention:

a. Please confirm that the federal income tax is calculated using a Federal Income Tax Rate of $21 \%$. If other adjustments were made in Table 6, cell C57, please provide a demonstration of how this number was calculated and an explanation of the other adjustments included in the calculation.
b. Please confirm that the Risk Adjustment User Fee PMPM is consistent with HHS Final Notice of Benefit and Payment Parameters for plan year 2024.
c. Please provide an exhibit showing the commission PMPM amount to be paid to brokers in the following situations: Open-Enrollment Enrollee - Renewing, Open Enrollment Enrollee - New, Special Enrollment Period Enrollee - New, Special Enrollment Enrollee Renewing. If the commission PMPM is not consistent between the four options above, please provide a detailed explanation as to the reason for the difference.

Response:
a. The value in Table 6, cell C57 is $0.00 \%$.
b. As stated in Section 2.B of the PA Actuarial Memorandum, the rate development assumes a risk adjustment user fee of \$0.21 PMPM for plan year 2024, which is consistent with Final Notice of Benefit and Payment Parameters.
c. $\square$

## 6. Pricing AVs:

a. Please confirm that the Pricing AVs were calculated using a single risk pool (i.e., claims experience is not separated by metal level).
b. Please identify and support any differences between the company's metallic AV calculator results and the corresponding Pricing AVs.

Response:
a. Highmark's Pricing AV tool does not separate claims experience by metal level and the underlying claims experience is applied to the applicable cost sharing levels.
b. The differences in comparing the CMS metallic AV calculator to Highmark's corresponding Pricing AVs average approximately $2 \%$. These differences occur due to a number of factors such as the CMS metallic AV calculator is based on a completely different underlying population, assumptions regarding trends in deductible and copay tables, assumptions regarding mix of services, etc.

## 7. Expanded Bronze Plans:

a. Please provide an exhibit which demonstrates that the criteria for expanded bronze plans have been met.

Response:
a. Our expanded bronze plans satisfy the requirements as defined by 45 CFR 156.140(c) by either covering at least one major service, other than preventive services, before the deductible or meeting the requirements to be a high deductible health plan within the meaning of 26 U.S.C. 223(c)(2). For plans satisfying the requirement by covering at least one major service before the deductible, several major services are covered prior to the deductible including primary care and specialty care. The coinsurance percentages and certifications of the values corresponding to these categories can be found in the AV screenshots and Certifications document provided as a separate attachment with the initial SERFF submission.

## 8. PAAM Exhibits - Consumer Factors:

a. Please provide quantitative and qualitative support for the proposed geographic rating area factors, if different from the previous year.
b. Please provide quantitative and qualitative support for the proposed network factors, if different from the previous year.

Response:
a. The proposed geographic rating area factors are unchanged from the currently approved factors.
b. The proposed network factors are unchanged from the currently approved factors.

## 9. Public Health Emergency:

a. With the Public Health Emergency expected to end on May 11th, how has the rate development been affected? Please provide support for any adjustments, or support for making no adjustments, if applicable.
b. Furthermore, with the Public Health Emergency scheduled to end on May 11th, has any adjustment been made specifically to the morbidity assumption for Plan Year 2024?
c. Please provide commentary on how the Company believes services such as COVID vaccinations and COVID testing will be handled in PY24. Within your response please clarify if these services will be considered preventative and covered at $100 \%$.

Response:
a. No rate change impact has been assumed for the enrollment changes associated with the ending of the Public Health Emergency. This is due to the continued uncertainty regarding the underlying morbidity of the members impacted and the volume of membership expected. Some initial studies have indicated this membership could be favorable to ACA plans, while other studies indicate it could be unfavorable. However, in PA we expect a $5-6 \%$ increase in enrollment resulting from the PHE expiration. Therefore, as an example, a $+/-10 \%$ impact to morbidity for this population would result in a rate change of approximately $+/-0.5 \%$.
b. Please see the response to question 9 a above.
c. Highmark's medical policy review team is drafting coverage requirements for 2024 Covid vaccinations and testing. Policy is subject to updates and changes as needed to meet industry standards and regulatory/legal requirements. Current expectations are that in-network Covid vaccinations will be covered with no cost sharing and considered preventive. Expected coverage for Covid testing will follow cost share design/coverage of the plan for lab services with OTC Covid testing not covered.

## 10. MLR Exhibit:

a. Please complete table below which summarizes the most recent three years of complete MLR information.
i. Actual is the final information which was filed for the specified calendar year
ii. Pricing is the information which was projected in the final annual filing for the given year (i.e., 2020 pricing information is from the plan year 2020 annual filing submitted in 2019)

|  | MLR |  | Member Months |  |
| :---: | :---: | :---: | :---: | :---: |
| Calendar Year | Actual | Projected | Actual | Projected |
| $\mathbf{2 0 1 9}$ |  |  |  |  |
| $\mathbf{2 0 2 0}$ |  |  |  |  |
| $\mathbf{2 0 2 1}$ |  |  |  |  |

b. Are the MLRs and Member Months between Actual and Pricing comparable? If not, explain.
c. Does the insurer expect to pay MLR rebates for the 3-year period above?

Response:
a. Attachment H of the PA Actuarial Memorandum contains the historical MLR Exhibit as requested.
b. The differences between Actual and Pricing MLRs vary by year. In 2019, HCA had no enrollment since it was not in existence for ACA Individual. The 2020 variance was driven primarily by the COVID-19 pandemic. In 2021, there was no material MLR variance.

The Member Month differences also vary by year. In 2019, HCA had no enrollment since it was not in existence for ACA Individual. The 2020 variance was driven by lower-than-expected switching rates from competition after the new HCA product launch (Together Blue EPO). This was partially offset by increased market size resulting from the COVID PHE (due to employment losses and an internal decision to not terminate existing members for nonpayment). In 2021, there was no material enrollment variance.
c. No MLR rebates were payable for the 2021 MLR rebate reporting year (2019-2021 period).

## 11. Plan of Withdrawal:

a. Please confirm that a Plan of Withdrawal has been submitted if any plans are being discontinued.
b. For further information regarding the Plan of Withdrawal process, click here. Please send all Plan of Withdrawals to Jeffery Rohaly, wrohaly@pa.gov.

Response:
a. Based on the guidance from the PA Insurance Department regarding Plan of Withdrawal requirements, it is Highmark's understanding that a Plan of Withdrawal is not applicable for the 2024 plans submitted. In the event that a plan is discontinued, all members are being renewed into other plans.

Data Relevant to the Rate Filing
Table 0 . Identifying Information

|  |  |  | to |
| :---: | :---: | :---: | :---: |
| Table 1. Number of Members |  |  |  |
|  | Member-months | Members | Member-m |
|  | Experience Period | Current Period | Projected Rating Period |
| Average Age | 42.4 | 42.6 | 42.6 |
| Total | 184,994 | 18,548 | ${ }^{241,896}$ |
| ${ }_{18,24}^{18}$ | 10,308 <br> 10.036 | ${ }_{1}^{1,076}$ | ${ }^{14,107}$ |
| ${ }_{\text {l }}^{18.24}$ 25-29 | ${ }_{10,936}$ | 1,041 |  |
| ${ }_{30.39}^{25-29}$ | ${ }_{\text {2,066 }}^{1923}$ | ${ }_{2,510}^{2010}$ |  |
|  | 19,231 16,161 | ${ }_{\text {2,015 }}^{2,65}$ | ${ }_{2}^{26,381}$ |
| 40.44 | ${ }_{13,133}$ | $\stackrel{1,379}{ }$ | ${ }_{18,288}$ |
|  | ${ }_{\text {11,995 }}^{16,65}$ | (1,152 | 15,244 <br> 20795 <br> 209 |
| ${ }_{\text {cos. }}^{5 \text { S59 }}$ | ${ }_{21,683}^{10,}$ | ${ }_{\text {L }}^{1,514}$ | ${ }^{20,995}$ |
|  | ${ }_{31,477}$ | 2,902 | ${ }^{37,767}$ |
| $\underline{64+}$ | 6,906 | ${ }_{1,073}$ | ${ }^{13,864}$ |

Table 2. Experience Period Claims and Premium

| Earned Premium | Paid Claims | Utimate Incured Claims | Member Months | (Mstanted Cost Shaxing | Allowed Caims (Non-Capitated) | ${ }_{\substack{\text { Non-EHB portion of Allowed d } \\ \text { Clims }}}^{\text {a }}$ | Total Prescripion Prug Rebates* | Otal E EH C Capitaion | Ootal Non:EHB Capitation | Adjustment |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |

Table 3. Tend Componeris

-Should equal URRT T Tend

Table 4. Historical Experience



| Eared Premium | Paid claims | Ulimate Incurred Claims | Member Months | Estimated Cost Sharing (Member \& HHS) | Allowed Claims (Non-Capitated) | ${ }_{\text {Non-EHB Portion of thlowed }}^{\text {Clims }}$ | Total Prescription Prug Reabase | Total EHB Gapitation | Total Non:EHB Capitation | Estimated Risk Ajusument | $\begin{gathered} \text { Estimated Reinsurance } \\ \text { Recoveries } \\ \hline \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| erience Period Total Allowed EHB Claims + EHB Capitation PMPM (net of prescription drug reba |  |  |  |  |  |  |  |  |  |  |  |

Eppress Prescripiono orvg Rebotes ss an negative number
Table 3b. Manual Trend Components


## Table 4b. Historical Manual Experience

| Month.-ear | Total Annual Premium | Incurred Claims | Completion factors* | Ulitimate Incurred Clims | Members | Utitinte Incurred PMPM | (memer | Prescripition Drug Reabats** | Allowed Clims (Nee of | Alowed PMPM |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\underset{\substack{\mathrm{Jam}-19 \\ \mathrm{reb-19}}}{ }$ |  |  |  | $\substack{\text { HovVol } \\ \text { fovol }}$ |  | $\substack{\text { movVol } \\ \text { fovolo }}$ |  |  |  | $\substack{\text { HovVO! } \\ \text { HoVlol }}$ |
| Mar-19 |  |  |  | Hovol |  | Hovol |  |  |  | Hovol |
| ${ }_{\text {Apr }}^{\text {Apr-19 }}$ |  |  |  | $\substack{\text { tivV0! } \\ \text { fovolo }}$ |  | $\substack{\text { tivV0] } \\ \text { HoVlol }}$ |  |  |  | $\substack{\text { tivVol } \\ \text { fovolot }}$ |
| $\xrightarrow{\text { Jun-19 }}$ |  |  |  | $\substack{\text { HivVOI } \\ \text { Hovilot }}$ |  | $\substack{\text { tivVOI } \\ \text { Hov/lot }}$ |  |  |  | $\substack{\text { HevVOI } \\ \text { fovol }}$ |
| $\underset{\substack{\text { Aug } 19}}{\text { Sop }}$ |  |  |  | $\substack{\text { tovVol } \\ \text { Hovol }}$ |  | movol |  |  |  | Hovol |
| $\frac{\text { Sep-19 }}{\text { octiol }}$ |  |  |  | $\substack{\text { Hiovol } \\ \text { Hovol }}$ |  | ${ }_{\substack{\text { tiovvol } \\ \text { Hovol }}}^{\text {del }}$ |  |  |  | $\substack{\text { HivVol } \\ \text { Hovolot }}$ |
| ${ }^{\text {Noor } 19}$ |  |  |  | movol |  | Hovol |  |  |  | Hovol |
| Jan-20 |  |  |  | molvo! |  | folvol |  |  |  |  |
| $\underset{\substack{\text { feb-20 } \\ \text { Mar-20 }}}{\text { ene }}$ |  |  |  | $\substack{\text { HivVOI } \\ \text { Hovol }}$ |  | $\substack{\text { HivVol } \\ \text { Hovol }}$ |  |  |  | $\substack{\text { HovVOI } \\ \text { Hovol }}$ |
| $\frac{\text { Appr20 }}{\text { Mavz20 }}$ |  |  |  | $\substack{\text { HovV0! } \\ \text { HoVlot }}$ |  | $\substack{\text { Heplol } \\ \text { Hovol }}$ |  |  |  | $\substack{\text { fiovol } \\ \text { Hovol }}$ |
| ${ }^{\text {Jataz20 }}$ |  |  |  | HovVo! |  | uovol |  |  |  | $\xrightarrow{\text { Holvol }}$ |
| $\xrightarrow{\text { Aut } 20}$ |  |  |  | $\substack{\text { tivVOI } \\ \text { Hovol }}$ |  | $\substack{\text { HivV01 } \\ \text { tolvol }}$ |  |  |  | $\substack{\text { HivVOI } \\ \text { Hovol }}$ |
| ${ }_{\text {Sep } 20}$ |  |  |  | tuplo |  | $\substack{\text { Helvol } \\ \text { Hovol }}$ |  |  |  |  |
| Nor 20 |  |  |  | Hovol |  | \#ovol |  |  |  | movol |
| ${ }_{\text {joca } 20}$ |  |  |  |  |  |  |  |  |  | $\xrightarrow{\text { tiovol }}$ tovol |
|  |  |  |  |  |  |  |  |  |  | molvo! |
| $\xrightarrow{\text { APr } 21}$ |  |  |  | ${ }_{\substack{\text { fiovol } \\ \text { Hovolot }}}$ |  | $\substack{\text { Hiovol } \\ \text { HoVlol }}$ |  |  |  | $\substack{\text { HivV) } \\ \text { Hovol }}$ |
|  |  |  |  | $\underbrace{}_{\substack{\text { unovol } \\ \text { Hovol }}}$ |  | $\underbrace{}_{\substack{\text { unovol } \\ \text { Hovol }}}$ |  |  |  | $\underbrace{}_{\substack{\text { unovol } \\ \text { Hovol }}}$ |
| $\xrightarrow{\text { Jun-21 }} \mathrm{Jul}$ |  |  |  | $\substack{\text { Hevol } \\ \text { fovlol }}$ |  | $\substack{\text { movor } \\ \text { Hovolot }}$ |  |  |  | $\substack{\text { movor } \\ \text { Hovolo }}$ |
| $\mathrm{Aug}^{2}$ |  |  |  | Hevol |  | $\pm$ |  |  |  | $\pm$ |
|  |  |  |  | molvo! |  | $\substack{\text { HivVal } \\ \text { folvol }}$ |  |  |  | $\substack{\text { Hivol } \\ \text { Hov/lol }}$ |
| ${ }_{\text {Noor } 21}^{\text {Dec } 21}$ |  |  |  | $\substack{\text { Hiplol } \\ \text { Hovol }}$ |  | $\substack{\text { Hiplol } \\ \text { Hovol }}$ |  |  |  | $\substack{\text { Hiplol } \\ \text { Hovol }}$ |
| $\xrightarrow[\substack{\text { lan } 22 \\ \mathrm{feb} 22}]{ }$ |  |  |  | $\substack{\text { HivVOI } \\ \text { Hovlol }}$ |  | $\substack{\text { HovVlol } \\ \text { Hov/lot }}$ |  |  |  | $\substack{\text { HevV/0! } \\ \text { Hov/lot }}$ |
| Mar-22 |  |  |  | movol |  | movol |  |  |  | HoV/01 |
|  |  |  |  | $\xrightarrow{\text { tupvol }}$ tovol |  | $\substack{\text { tivVol } \\ \text { Hovol }}$ |  |  |  | $\substack{\text { HivVol } \\ \text { Hovol }}$ |
| Jun-22 |  |  |  | movol |  | \#ovol |  |  |  | \#ovol |
| $\xrightarrow[\substack{\text { Abe } 22 \\ \text { Se } 22}]{ }$ |  |  |  | $\substack{\text { Hevol } \\ \text { Hovol } \\ \text { tovo }}$ |  | $\substack{\text { undol } \\ \text { tovol } \\ \text { povol }}$ |  |  |  | tovol |
| Stat |  |  |  | \#ovol |  | HovVo! |  |  |  | tovol |
| ${ }_{\text {Noo } 22}^{\text {Dec } 22}$ |  |  |  | $\xrightarrow{\text { Hiplol }}$ (tovol |  | $\xrightarrow[\substack{\text { Hiplol } \\ \text { Hovol }}]{\text { del }}$ |  |  |  | $\xrightarrow[\substack{\text { Hiplol } \\ \text { Hovol }}]{\text { del }}$ |

[^0]Continuance Table for Calculating Reinsurance Impact - Individual Market Only, Experience Period Information

| Carrier Name: | HMCAI | Attachment Point: | \$60,000 |
| :---: | :---: | :---: | :---: |
| Product(s): | EPO | Reinsurance Cap: | \$100,000 |
| Market Segment: | Individual | Coinsurance Rate: | 50\% |
| Rate Effective Date: | 01/01/2024 |  |  |
| Incurred Dates: | 1/1/2022 to 12/31/2022 | Proj. Incurred Claim Impact: | -2.9\% |


| Individual ACA Compliant Policies Only: Incurred Dates 1/1/2022 to 12/31/2022 |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Annual Incurred Claims Range |  | Unique Members | Member Months | Total Incurred Claims | Total Incurred Claims with Reinsurance |
| \$0 | \$29,999 |  |  |  | \$38,662,745 |
| \$30,000 | \$34,999 |  |  |  | \$1,987,219 |
| \$35,000 | \$39,999 |  |  |  | \$1,863,262 |
| \$40,000 | \$44,999 |  |  |  | \$1,139,281 |
| \$45,000 | \$49,999 |  |  |  | \$1,561,389 |
| \$50,000 | \$54,999 |  |  |  | \$1,000,286 |
| \$55,000 | \$59,999 |  |  |  | \$689,164 |
| \$60,000 | \$64,999 |  |  |  | \$673,206 |
| \$65,000 | \$69,999 |  |  |  | \$896,986 |
| \$70,000 | \$74,999 |  |  |  | \$997,136 |
| \$75,000 | \$79,999 |  |  |  | \$692,269 |
| \$80,000 | \$84,999 |  |  |  | \$497,525 |
| \$85,000 | \$89,999 |  |  |  | \$592,725 |
| \$90,000 | \$94,999 |  |  |  | \$455,429 |
| \$95,000 | \$99,999 |  |  |  | \$79,144 |
| \$100,000 | \$109,999 |  |  |  | \$676,901 |
| \$110,000 | \$119,999 |  |  |  | \$1,130,336 |
| \$120,000 | \$129,999 |  |  |  | \$425,382 |
| \$130,000 | \$139,999 |  |  |  | \$687,573 |
| \$140,000 | \$149,999 |  |  |  | \$374,109 |
| \$150,000 | \$159,999 |  |  |  | \$794,047 |
| \$160,000 | \$169,999 |  |  |  | \$430,122 |
| \$170,000 | \$179,999 |  |  |  | \$470,543 |
| \$180,000 | \$189,999 |  |  |  | \$829,230 |
| \$190,000 | \$199,999 |  |  |  | \$351,379 |
| \$200,000 | \$209,999 |  |  |  | \$185,659 |
| \$210,000 | \$219,999 |  |  |  | \$192,252 |
| \$220,000 | \$229,999 |  |  |  | \$0 |
| \$230,000 | \$239,999 |  |  |  | \$430,650 |
| \$240,000 | \$249,999 |  |  |  | \$0 |
| \$250,000 | \$259,999 |  |  |  | \$0 |
| \$260,000 | \$269,999 |  |  |  | \$0 |
| \$270,000 | \$279,999 |  |  |  | \$257,555 |
| \$280,000 | \$289,999 |  |  |  | \$0 |
| \$290,000 | \$299,999 |  |  |  | \$272,288 |
| \$300,000 | \$324,999 |  |  |  | \$293,971 |
| \$325,000 | \$349,999 |  |  |  | \$0 |
| \$350,000 | \$374,999 |  |  |  | \$682,690 |
| \$375,000 | \$399,999 |  |  |  | \$359,737 |
| \$400,000 | \$424,999 |  |  |  | \$0 |
| \$425,000 | \$449,999 |  |  |  | \$0 |
| \$450,000 | \$474,999 |  |  |  | \$0 |
| \$475,000 | \$499,999 |  |  |  | \$469,913 |
| \$500,000 | \$599,999 |  |  |  | \$0 |
| \$600,000 | \$699,999 |  |  |  | \$0 |
| \$700,000 | \$799,999 |  |  |  | \$0 |
| \$800,000 | \$899,999 |  |  |  | \$806,754 |
| \$900,000 | \$999,999 |  |  |  | \$0 |
| \$1,000,000+ |  |  |  |  | \$1,273,867 |
| Total |  | 21,531 | 184,994 | \$65,047,142 | \$63,182,723 |

Continuance Table for Calculating Reinsurance Impact - Individual Market Only, Projection Period Information

| Carrier Name: | HMCAI | Attachment Point: | \$60,000 |
| :---: | :---: | :---: | :---: |
| Product(s): | EPO | Reinsurance Cap: | \$100,000 |
| Market Segment: | Individual | Coinsurance Rate: | 50\% |
| Rate Effective Date: | 01/01/2024 |  |  |
|  |  | Proj. Incurred Claim Impact: | -4.5\% |
|  |  | Proj. Morbidity Impact: | 0.0\% |


| Reinsurance Program Impact Continuance Table Development - Plan Year 2024 |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Annual | Range | Unique Members | Member Months | Total Incurred Claims | Total Incurred Claims with Reinsurance |
| \$0 | \$29,999 |  |  |  | \$284,346,083 |
| \$30,000 | \$34,999 |  |  |  | \$24,378,788 |
| \$35,000 | \$39,999 |  |  |  | \$21,235,892 |
| \$40,000 | \$44,999 |  |  |  | \$19,071,217 |
| \$45,000 | \$49,999 |  |  |  | \$16,605,787 |
| \$50,000 | \$54,999 |  |  |  | \$15,768,941 |
| \$55,000 | \$59,999 |  |  |  | \$13,801,161 |
| \$60,000 | \$64,999 |  |  |  | \$12,185,758 |
| \$65,000 | \$69,999 |  |  |  | \$12,197,462 |
| \$70,000 | \$74,999 |  |  |  | \$11,790,363 |
| \$75,000 | \$79,999 |  |  |  | \$9,761,530 |
| \$80,000 | \$84,999 |  |  |  | \$8,909,636 |
| \$85,000 | \$89,999 |  |  |  | \$9,284,190 |
| \$90,000 | \$94,999 |  |  |  | \$7,922,610 |
| \$95,000 | \$99,999 |  |  |  | \$7,160,692 |
| \$100,000 | \$109,999 |  |  |  | \$11,531,123 |
| \$110,000 | \$119,999 |  |  |  | \$10,151,061 |
| \$120,000 | \$129,999 |  |  |  | \$9,825,482 |
| \$130,000 | \$139,999 |  |  |  | \$9,233,486 |
| \$140,000 | \$149,999 |  |  |  | \$10,717,335 |
| \$150,000 | \$159,999 |  |  |  | \$9,454,715 |
| \$160,000 | \$169,999 |  |  |  | \$7,123,342 |
| \$170,000 | \$179,999 |  |  |  | \$8,368,405 |
| \$180,000 | \$189,999 |  |  |  | \$8,254,742 |
| \$190,000 | \$199,999 |  |  |  | \$6,117,725 |
| \$200,000 | \$209,999 |  |  |  | \$5,718,913 |
| \$210,000 | \$219,999 |  |  |  | \$5,254,065 |
| \$220,000 | \$229,999 |  |  |  | \$7,990,955 |
| \$230,000 | \$239,999 |  |  |  | \$5,160,232 |
| \$240,000 | \$249,999 |  |  |  | \$6,315,209 |
| \$250,000 | \$259,999 |  |  |  | \$4,234,695 |
| \$260,000 | \$269,999 |  |  |  | \$3,157,671 |
| \$270,000 | \$279,999 |  |  |  | \$2,793,619 |
| \$280,000 | \$289,999 |  |  |  | \$4,513,493 |
| \$290,000 | \$299,999 |  |  |  | \$5,804,474 |
| \$300,000 | \$324,999 |  |  |  | \$6,437,731 |
| \$325,000 | \$349,999 |  |  |  | \$5,056,972 |
| \$350,000 | \$374,999 |  |  |  | \$5,817,918 |
| \$375,000 | \$399,999 |  |  |  | \$5,468,959 |
| \$400,000 | \$424,999 |  |  |  | \$4,262,141 |
| \$425,000 | \$449,999 |  |  |  | \$4,584,138 |
| \$450,000 | \$474,999 |  |  |  | \$4,401,466 |
| \$475,000 | \$499,999 |  |  |  | \$2,327,581 |
| \$500,000 | \$599,999 |  |  |  | \$9,681,858 |
| \$600,000 | \$699,999 |  |  |  | \$8,172,965 |
| \$700,000 | \$799,999 |  |  |  | \$6,546,300 |
| \$800,000 | \$899,999 |  |  |  | \$8,298,138 |
| \$900,000 | \$999,999 |  |  |  | \$2,820,203 |
| \$1,000,000+ |  |  |  |  | \$17,392,480 |
| Total |  | 114,415 | 1,028,317 | \$740,481,942 | \$707,409,702 |

PA Rate Template Part II
Rate Development and Change

| Carrier Name: | HMCAI |
| :--- | :--- |
| Product(s): | EPO |
| Market Segment: | Individual |
| Rate Effective Date: | $01 / 01 / 2024$ |

Table 5. Development of the Projected Index Rate, Market-Adjusted Index Rate, and Total Allowed Claims


Table 6. Retention

| Retention Items-Express in percentages | Percentages | PMPM Amounts |
| :--- | ---: | ---: |
| Administrative Expenses | $13.97 \%$ | $\$ 68.02$ |
| General and Claims | $9.60 \%$ | $\$ 4.73$ |
| Agent/Broker Fees and Commissions | $1.58 \%$ | $\$ .71$ |
| Quality Improvement Initiatives | $2.79 \%$ | $\$ 13.59$ |
| Taxes and Fees | $0.10 \%$ | $\$ 0.50$ |
| Risk Adjustment User Fee | $0.04 \%$ | $\$ 0.21$ |
| PCORI Fee | $0.06 \%$ | $\$ 0.29$ |
| PA Premium \& Other Taxes (if applicable) | $0.00 \%$ | $\$ 0.00$ |
| Federal Income Tax | $0.00 \%$ | $\$ 0.00$ |
| Health Insurance Providers Fee (Prorated for Small Groups only) | $0.00 \%$ | $\$ 0.00$ |
| Profit/Contingency (after tax) | $0.00 \%$ | $\$ 0.00$ |
| Total Retention | $14.07 \%$ |  |
| Projected Required Revenue PMPM | $\$ 68.52$ |  |

## Table 8. Components of Rate Change



For Informational Purposes only - No input required.

| Blended Base Period Unadjusted Claims before Normalization | $\mathbf{\$}$ | $\mathbf{3 8 7 . 8 8}$ |
| :--- | ---: | ---: |
| Blended Earned Premium <br> Blended Loss Ratio | $\mathbf{7 9 , 3 7 5 , 6 1 4 . 5 3}$ |  |

Table 5A. Small Group Projected Index Rate with Quarterly Trend

| Effective Date | 01/01/2024 |  | 04/01/2024 |  | 07/01/2024 |  | 10/01/2024 |  | Total Single Risk Pool |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| \# of Member Months Renewing in Quarter |  |  |  |  |  |  |  |  |  |  |
| Adjusted Projected Allowed EHB Claims PMPM | \$ | 440.64 | \$ | 440.64 | \$ | 440.64 | \$ | 440.64 | \$ | 440.64 |
| Months of Trend |  | - |  | 3 |  | 6 |  | 9 |  |  |
| Annual Trend |  | 9.17\% |  | 9.17\% |  | 9.17\% |  | 9.17\% |  |  |
| Single Risk Pool Projected Allowed Claims | \$ | 440.64 | \$ | 450.41 | \$ | 460.39 | \$ | 470.60 | \$ |  |
| Quarterly Trend Factor |  | 1.000 |  | 1.022 |  | 1.045 |  | 1.068 |  | 0.000 |

Table 7. Normalized Market-Adjusted Projected Allowed Total Claims

| Normalization Factors | 2023 |  | 2024 |  |
| :---: | :---: | :---: | :---: | :---: |
| Average Age Factor |  | 1.777 |  | 1.752 |
| Average Geographic Factor |  | 0.940 |  | 0.940 |
| Average Tobacco Factor |  | 1.007 |  | 1.007 |
| Average Benefit Richness (induced demand) |  | 1.074 |  | 1.090 |
| Average Network Factor |  | 0.701 |  | 0.690 |
| Market-Adjusted Projected Allowed Total Claims PMPM | \$ | 492.38 | \$ | 515.06 |
| Normalized Market-Adjusted Projected Allowed Total Claims PMPM | \$ | 388.94 | \$ | 412.67 |

Table 9. Year-over-Year Data to Support Table 8

|  | 2023 | 2024 |  |
| :---: | :---: | :---: | :---: |
| Paid-to-Allowed | 0.783 | 0.812 |  |
| URRT Trend (Total Applied Trend Factor) | 1.150 | 1.192 | <- URRT W1, S2 |
| URRT Morbidity | 0.932 | 0.991 | <-URRT W1, S2 |
| URRT "Other" | 1.014 | 0.962 | <-URRT W1, S2 |
| Risk Adjustment | 27.57 | 56.85 | <- URRT W1, S3 |
| Exchange User Fee | 11.71 | 12.94 | <- URRT W1, S3 |
| Reinsurance Recoveries | 16.97 | 15.99 | <- URRT W1, S3 |
| Capitation | \$ 0.15 | 0.66 | <- URRT W1, S2 |
| Network | 0.701 | 0.690 |  |
| Pricing AV | 0.789 | 0.810 | <- For 2023 in cell J81, please include a factor equal to the product of the average Pricing AV and the Non-Funding of CSR Adjustment |
| Benefit Richness | 1.076 | 1.090 |  |
| Catastrophic Eligibility | 0.999 | 0.999 |  |
| Administrative Expenses | 14.64\% | 13.97\% |  |
| Taxes and Fees | 0.11\% | 0.10\% |  |
| Profit and/or Contingency | 0.00\% | 0.00\% |  |

## PA Rate Template Part III

Table 10. Plan Rates



| Admin Costs | $\begin{array}{\|c\|} \begin{array}{c} \text { Taxes \& Fees (not } \\ \text { including Exchange } \\ \text { fees) } \end{array} \\ \hline \end{array}$ | Profit or Contingency |  | Total Projected Lives |
| :---: | :---: | :---: | :---: | :---: |
| 14.0\% | 0.1\% | 0.0\% | 18,548 | 20,158 |
| 14.0\% | 0.1\% | 0.0\% |  |  |
| N/A | N/A | N/A | - |  |
| 14.0\% | 0.1\% | 0.0\% | 1,646 | 1,352 |
| 14.0\% | 0.1\% | 0.0\% | 6,361 | 7,145 |
| 14.0\% | 0.1\% | 0.0\% | 171 | 144 |
| 14.0\% | 0.1\% | 0.0\% | 268 | 490 |
| 14.0\% | 0.1\% | 0.0\% | 2,671 | 2,768 |
| 14.0\% | 0.1\% | 0.0\% |  | 244 |
| 14.0\% | 0.1\% | 0.0\% | 420 | 395 |
| 14.0\% | 0.1\% | 0.0\% | 272 | 352 |
| 14.0\% | 0.1\% | 0.0\% | 187 | 222 |
| 14.0\% | 0.1\% | 0.0\% | 237 | 292 |
| 14.0\% | 0.1\% | 0.0\% | 60 | 51 |
| 14.0\% | 0.1\% | 0.0\% | 1,052 | 1,502 |
| 14.0\% | 0.1\% | 0.0\% | 3,268 | 3,315 |
| 14.0\% | 0.1\% | 0.0\% | 249 | 297 |
| 14.0\% | 0.1\% | 0.0\% | 1,425 | 1,385 |
| 14.0\% | 0.1\% | 0.0\% | 135 | 204 |
| 14.0\% | 0.1\% | 0.0\% | 86 |  |
| 14.0\% | 0.1\% | 0.0\% | 40 |  |


| 2023 Calibrated Plan Adjusted Index Rate PMPM |  | 2024 Calibrated Plan Adjusted Index Rat PMPM |  |
| :---: | :---: | :---: | :---: |
| s | 271.31 | s | 292.98 |
| N/A |  | N/A |  |
| s | 207.62 | \$ | 224.52 |
| 5 | 269.24 | S | 294.54 |
| \$ | 232.62 | S | 244.92 |
| 5 | 187.94 | \$ | 203.00 |
| s | 290.86 | 5 | 313.46 |
| s |  | s | 276.41 |
| \$ | 215.13 | \$ | 228.90 |
| s | 252.30 | \$ | 273.09 |
| s | 157.16 | \$ | 172.69 |
| s | 234.55 | s | 249.82 |
| s | 259.54 | \$ | 270.22 |
| \$ | 296.16 | \$ | 319.84 |
| s | 285.49 | \$ | 306.20 |
|  | 316.21 | \$ | 334.34 |
| s | 312.41 | \$ | 331.49 |
| \$ | 343.13 | \$ | 359.64 |
| s | 281.43 | s | 294.54 |
| s | 308.35 | \$ | 319.84 |


| Proposed Rate Change Compared to Prior 12 months | \% of Total Covered lives Covered Lives |
| :---: | :---: |
| 8.0\% |  |
| N/A | N/A |
| 8.1\% | 8.9\% |
| 9.4\% | 34.3\% |
| 5.3\% | 0.9\% |
| 8.0\% | 1.4\% |
| 7.8\% | 14.4\% |
| 0.0\% | 0.0\% |
| 6.4\% | 2.3\% |
| 8.2\% | 1.5\% |
| 9.9\% | 1.0\% |
| 6.5\% | 1.3\% |
| 4.1\% | 0.3\% |
| 8.0\% | 5.7\% |
| 7.3\% | 17.6\% |
| 5.7\% | 1.3\% |
| 6.1\% | 7.7\% |
| 4.8\% | 0.7\% |
| 4.7\% | 0.5\% |
| 3.7\% | 0.2\% |



## PA Rate Template Part IV A - Individua

Table 11. Plan Premium Development for 21-Year-Old Non-Tobacco User
Carrier Name
Product(s):
Product $(s):$
Market Segm
Nate Effective Date:

## HMC

| EPO |
| :--- |
| Individ |

01/01/2024

| Plan Number | HIOS Plan ID (Standard Component) | $1 / 1 / 2023$ Plan Marketing Name | Discontinued, <br> New, Modified Existing ( $\mathrm{D}, \mathrm{N}, \mathrm{M}, \mathrm{E}$ ) for 2024 | 1/1/2024 Plan HIOS Plan <br> ID (If $\mathbf{1 / 1 / 2 0 2 3}$ Plan Discontinued \& Mapped) | Metallic Tier | $\begin{aligned} & \text { Exchange } \\ & \text { On/Off or } \end{aligned}$ Off |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| als | These cells auto-fill using the data entered in Table 10. |  |  |  |  |  |


| 2023 21-vear-old, Non-Tobacco Premium PMPM |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | Average (weighted by enrollment by rating area) |







|  | . | 227 | . | . | . | . | - | \| Match | . |  | - | \| Match | - | - |  | $\cdots$ | - | - |  | . | . | . | . | . |  | Match |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| . | - | 707 | - | . | . | . | - | Match | . | . | - | Match | . | . | . | . | . | . | . | . | . | . | . | . | - | Match |
| - | . | ${ }^{23}$ | . | . | . | . | . | Match | . | . | . | Match | . | - | . | . | . | . | . | . | - | . | . | . | - | Match |
| . | . | 25 | . | - | . | - | - | Match | . | . | - | Match | - | . | . | . | - | . | - | . | . | . | - | - | - | Match |
| . | . | 325 | . | . | . | . | - | Match | . | . | - | Match | . | . | . | . | . | . | . | . | . | - | . | . | - | Match |
| . | . |  | - | . | . | . | . | Match | . | . | . | Match | . | . | . | . | . | . | . | . | . | . | . | . |  | Match |
| . | - | 60 | . | . | . | . | . | Match | . | . | - | Match | . | . | . | . | . | . | . | . | . | . | - | . | - | Match |
| . | - | 20 | - | - | - | . | . | Match | - | - | . | Match | - | . | . | . | - | . | . | - | . | - | - | - | - | Match |
|  | $\checkmark$ | 17 | - | $\checkmark$ | . | - | - | Match | - | - |  | Match | . | - | $\checkmark$ | , | . | - | . | $\cdot$ | $\cdot$ | - | - |  |  | Match |
| . | . | 21 | - | - | - | - | - | Match | . | - | . | Match | - | - | - | . | . | - | . | . | - | - | . | - | . | Match |
| - | - | 2 | - | . | - | - | . | Match | - | - | . | Match | . | . | - | - | - | - | - | - | - | - | - | . | - | Match |
|  | . | 89 | . | - | - | . | - | Match | - |  | . | Match | - | . | - | . | - |  | . | . | - | - | . | - |  | Match |
|  | - | 416 | - | - | - | - | - | Match | - | - | - | Match | - | . | . | . | - | . | . | - | . | . | - | . | - | Match |
| . | - | 40 | $\cdots$ | - | - | - | - | Match | - | - | - | Match | - | - | - | . | - | - | - | - | - | - | - | - |  | Match |
| . | $\cdots$ | 141 | - | - | - | - | - | Match | - | - | - | Match | - | - | . | . | - | - | . | - | - | - | . | - | - | Match |
| . | - | 5 | - | - | - | - | . | Match | - | - | - | Match | - | - | . | - | . | . | . | - | - | - | - | - |  | Match |
| . | - | 14 | . | . | . | . | - | Match | . | - | . | Match | - | - | - | . | - | . | - | . | - | - | - | - | - | Match |
|  | - | 7 | - |  |  | - | - | Match |  |  |  | Match |  |  |  |  |  |  |  |  |  |  | . | - |  | Match |






## PA Rate Quarterly Template Part V

## Consumer Factors

Table 12. Age and Tobacco Factors

| Projection Period Age and Tobacco Factors |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Age Band | Age Factor | Tobacco Factor | Age <br> Band | Age Factor | Tobacco Factor |
| 0-14 | 0.765 | , | 40 | 1.278 | 1.100 |
| 15 | 0.833 |  | 41 | 1.302 | 1.105 |
| 16 | 0.859 |  | 42 | 1.325 | 1.112 |
| 17 | 0.885 |  | 43 | 1.357 | 1.121 |
| 18 | 0.913 |  | 44 | 1.397 | 1.132 |
| 19 | 0.941 |  | 45 | 1.444 | 1.145 |
| 20 | 0.970 | , | 46 | 1.500 | 1.160 |
| 21 | 1.000 | 1.025 | 47 | 1.563 | 1.177 |
| 22 | 1.000 | 1.025 | 48 | 1.635 | 1.196 |
| 23 | 1.000 | 1.025 | 49 | 1.706 | 1.217 |
| 24 | 1.000 | 1.025 | 50 | 1.786 | 1.225 |
| 25 | 1.004 | 1.025 | 51 | 1.865 | 1.225 |
| 26 | 1.024 | 1.025 | 52 | 1.952 | 1.225 |
| 27 | 1.048 | 1.025 | 53 | 2.040 | 1.225 |
| 28 | 1.087 | 1.025 | 54 | 2.135 | 1.225 |
| 29 | 1.119 | 1.025 | 55 | 2.230 | 1.225 |
| 30 | 1.135 | 1.025 | 56 | 2.333 | 1.225 |
| 31 | 1.159 | 1.025 | 57 | 2.437 | 1.225 |
| 32 | 1.183 | 1.025 | 58 | 2.548 | 1.225 |
| 33 | 1.198 | 1.025 | 59 | 2.603 | 1.225 |
| 34 | 1.214 | 1.025 | 60 | 2.714 | 1.225 |
| 35 | 1.222 | 1.025 | 61 | 2.810 | 1.225 |
| 36 | 1.230 | 1.025 | 62 | 2.873 | 1.225 |
| 37 | 1.238 | 1.025 | 63 | 2.952 | 1.225 |
| 38 | 1.246 | 1.025 | 64+ | 3.000 | 1.225 |
| 39 | 1.262 | 1.025 |  |  |  |

[^1]| Carrier Name: | HMCAI |
| :--- | :--- |
| Product(s): | EPO |
| Market Segment: | Individual |
| Rate Effective Date: | $\mathbf{0 1 / 0 1 / 2 0 2 4}$ |

Table 13. Geographic Factors

| Geographic Area Factors |  |  |  |
| :--- | :--- | ---: | ---: |
| Area | Counties | Current <br> Factor | Proposed <br> Factor |
| Rating Area 1 | Erie | 0.940 | 0.940 |
| Rating Area 2 |  |  |  |
| Rating Area 3 |  |  |  |
| Rating Area 4 | Allegheny, Washington, Butler, Westmoreland | 0.940 | 0.940 |
| Rating Area 5 |  |  |  |
| Rating Area 6 |  |  |  |
| Rating Area 7 |  |  |  |
| Rating Area 8 |  |  |  |
| Rating Area 9 |  |  |  |

Table 14. Network Factors

| Projection Period Network Factors |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Network Name | Rating Area | Current <br> Factor | Proposed <br> Factor | Approval <br> Date |  |  |  |
| Together Blue | Zone L (see Plan Design Summary) | 0.620 | 0.620 | $04 / 26 / 2019$ |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |

## PA Rate Template Part VI - Rate Change Summary

## Table 15. Rate Change Summary Information

## Overview

Initial Requested Average Rate Change: Revised Requested Average Rate Change

|  | 0.136218935 |
| ---: | ---: |
| $7.99 \%$ |  |
| $3.73 \%$ |  |
|  | $9.88 \%$ |
| Rating Areas 1 and 4 | 18,548 |

Maximum Requested Rate Change:

Rating Areas 1 and 4

## Key Information

Jan. 2022 - Dec. 2022 Financial Experience
Premium
Claims
Administrative Expenses
Taxes \& Fees
Company Made After Taxes

| $\$$ | $73,876,269.44$ |
| :--- | ---: |
| $\$$ | $57,070,121.32$ |
| $\$$ | $12,784,364.74$ |
| $\$$ | $2,218,186.36$ |
| $\$$ | $1,803,597.02$ |

The company expects its annual medical costs to increase:

Carrier Name:
Product(s):
Market Segment
Rate Effective Date:

## HMCAI

EPO Individual

## How It Plans to Spend Your Premium

This is how the company plans to spend the premium it
collects in 2024:
Claims:
Administrative Expenses: 14\%
3\%
Profit

Explanation of requested rate change:
The primary drivers of the rate increase are cost and utilization trend.




| $\begin{array}{r} \text { Company Name: } \\ \text { Market: } \\ \text { Product: } \\ \text { Effective Date of Rates: } \end{array}$ |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HIOS Plan ID (On Exchange)=> | 79279PA0090001 |  | 79279PA0080011 |  | $79279 P A 0080011$ |  | $79279 P A 0100001$ |  | $79279 P$ A0100001 |  |
| HIOS Plan ID (off Exchange)=> | 79279PA0090001 |  | 79279PA0080011 |  | 79279PA0080011 |  | 79279PA0100001 |  | 79279PA0100001 |  |
| Plan Marketing Name => | Together Blue EPO Bronze 7100 HSA - Custom Drug Benefit |  | Together Blue EPO Bronze 8900 |  | Together Blue EPO Bronze 8900 |  | Together Blue Major Events EPO Catastrophic 9450-3 Free PCP Visits |  | Together Blue Major Events EPO Catastrophic 9450-3 Free PCP Catastrophic 9450 <br> Visits |  |
| Form\# $=>$ | TB/EPO/HDHP/HCA/DP-4 |  | TB/EPO/HCA/DP-4 |  | TB/EPO/HCA/DP-4 |  | TB/CAT/EPO/HCA/DP-4 |  | TB/CAT/EPO/HCA/DP-4 |  |
| Rating Area $=>$ | Area 4 |  | Area 1 |  | Area 4 |  |  |  | Area 4 |  |
| Network $=>$ | L |  | 1 |  | 1 |  | Area 1 |  | 1 |  |
| Metal => | Bronze |  | Bronze |  | Bronze |  | Catastrophic |  | $\underset{\substack{\text { Catastrophic } \\ \$ 9,450}}{\text { a }}$ |  |
| Deductible => | \$7,100100\% |  |  |  | \$9,450$100 \%$ |  |  |  |
| Coinsurance $=>$ |  |  |  |  |  |  | \$8,900100\% |  |  |  |
| Copays $=>$ | N/A |  | 100/A |  | N/A |  | $\begin{array}{\|c\|} \hline \text { Visits } 1-3) ; \text { then } 100 \% \text { after Ded. } \\ \hline \$ 9,450 \\ \hline \end{array}$ |  | 100\% |  |
| OOP Maximum $=>$ | \$7,100 |  | \$8,900 |  | \$8,900 |  |  |  | \$9,450 |  |
| Pediatric Dental (Yes/No) => | Yes |  | Yes |  | Yes |  | $\frac{59,450}{\text { Yes }}$ |  |  |  |
| Age Band | $\underset{\text { Non-Tobacco }}{\text { S164.61 }}$ | Tobacco | Non-Tobacco | Tobacco | Non-Tobacco | Tobacco | Non-Tobacco | Tobacco | Non-Tobacco ${ }^{\text {a }}$ Tobacco |  |
| 0-14 |  | \$164.61 | \$145.98 | \$145.98 | \$145.98 ${ }^{\text {S }}$ \$145.98 |  | \$124.17 ${ }_{\text {\% }}$ \$124.17 |  | \$124.17 | $\xrightarrow{\text { Tobacco }}$ |
| 15 | \$179.24 | \$179.24 | \$158.95 | \$158.95 | \$158.95 | \$158.95 | $\begin{aligned} & \$ 135.21 \\ & \$ 139.43 \end{aligned}$ | \$1355.21$\$ 139.43$ | $\begin{aligned} & \$ 139.43 \\ & \$ 143.65 \end{aligned}$ | $\begin{aligned} & \$ 135.21 \\ & \$ 139.43 \\ & \$ 143.65 \end{aligned}$ |
| 16 | \$184.83 | \$184.83 | \$163.91 | \$163.91 | $\begin{aligned} & \$ 163.91 \\ & \$ 168.88 \end{aligned}$ | \$163.91 |  |  |  |  |
| 17 | \$190.43 | \$190.43 | \$168.88 | \$168.88 |  | \$168.88 | $\begin{aligned} & \$ 143.65 \\ & \$ 148.20 \end{aligned}$ | \$143.65$\$ 1488.20$ |  |  |
| 18 | \$196.45 | \$196.45 | \$174.22 | \$174.22 | $\begin{aligned} & \$ 174.22 \\ & \$ 179.56 \end{aligned}$ | \$174.22 |  |  | $\begin{aligned} & \$ 143.65 \\ & \$ 148.20 \end{aligned}$ |  |
| 19 | \$202.47 | \$202.47 | \$179.56 | \$179.56 |  | \$179.56 | \$152.74 <br> $\$ 157.45$ | \$152.74 | \$152.74 S17.45 | \$152.74$\$ 157.45$ |
| 20 | \$208.71 | \$208.71 | \$185.10 | \$185.10 | \$1795.10 | \$185.10 |  | \$157.45 <br> $\$ 166.38$ | $\$ 157.45$ <br> $\$ 162.32$ |  |
| 21 | \$215.17 | \$220.55 | \$190.82 | \$195.59 | \$190.82 | \$195.59 | \$162.32 |  |  | \$157.45 <br> $\$ 166.38$ |
| 22 | \$215.17 | \$220.55 | \$190.82 | \$195.59 | \$190.82 | \$195.59 | \$162.32 <br> $\$ 162.32$ | \$166.38 | \$162.32 | \$166.38 <br> $\$ 166.38$ |
| 23 | \$215.17 | \$220.55 | \$190.82 | \$195.59 | \$190.82 $\$ 190.82$ $\$ 190.82$ | \$195.59 |  | \$166.38 <br> $\$ 166.38$ <br> 1 | $\$ 162.32$$\$ 162.32$ |  |
| 24 | \$215.17 | \$220.55 | \$190.82 | \$195.59 | \$190.82 | \$195.59 | \$162.32 |  |  | \$166.38 \$166.38 |
| 25 | \$216.03 | \$221.43 | \$191.58 | \$196.37 | \$191.58$\$ 195.40$ | \$196.37 | \$162.97$\$ 166.22$$\$ 176$ | \$166.38 <br> $\$ 167.04$ | \$162.32 <br> $\$ 162.97$ | $\$ 167.04$$\$ 170.38$ |
| 26 | \$220.33 | \$225.84 | \$195.40 | \$200.29 |  | \$200.29 |  | \$177.38 <br> S174.36 <br> 1 | \$166.22$\$ 170.11$$\$$ |  |
| 27 | \$225.50 | \$231.14 | \$199.98 | \$204.98 | \$199.98 | \$204.98 | \$170.11 <br> $\$ 176.44$ <br> 18 |  |  | \$170.38 <br> $\$ 174.36$ |
| 28 | \$233.89 | \$239.74 | \$207.42 | \$212.61 | $\begin{aligned} & \$ 207.42 \\ & \$ 213.53 \end{aligned}$ | \$212.61 |  | \$174.36 $\$ 180.85$ | \$176.44 | \$180.85$\$ 188.18$\$ |
| 29 | \$240.78 | \$246.80 | \$213.53 | \$218.87 |  | \$218.87 | \$181.64$\$ 184.23$ | \$186.18 | \$181.64$\$ 184.23$ |  |
| 30 | \$244.22 | \$250.33 | \$216.58 | \$221.99 | \$216.58 | \$221.99 |  | $\begin{aligned} & \$ 188.84 \\ & \$ 192.83 \end{aligned}$ |  | \$186.18 $\$ 188.84$ |
| 31 | \$249.38 | \$255.61 | \$221.16 | \$226.69 | \$221.16 | \$226.69 | \$184.23 $\$ 188.13$ |  | \$184.23 $\$ 188.13$ | $\$ 189.84$$\$ 1923$ \$196.82 |
| 32 | \$254.55 | \$260.91 | \$225.74 | \$231.38 | \$225.74 <br> $\$ 228.60$ | \$231.38 | \$192.02 | \$196.82$\$ 199.32$ | $\begin{aligned} & \$ 192.02 \\ & \$ 194.46 \end{aligned}$ |  |
| 33 | \$257.77 | \$264.21 | \$228.60 | \$234.32 |  | \$234.32 |  |  |  | \$196.82 $\$ 199.32$ |
| 34 | \$261.22 | \$267.75 | \$231.66 | \$237.45 | $\begin{aligned} & \$ 231.66 \\ & \$ 233.18 \end{aligned}$ | \$237.45 | \$197.06 | \$201.99 | \$197.06 | \$201.99 <br> $\$ 203.32$ |
| 35 | \$262.94 | \$269.51 | \$233.18 | \$239.01 |  | \$239.01 | \$198.36 <br> $\$ 199.65$ | $\begin{aligned} & \$ 203.32 \\ & \$ 204.64 \end{aligned}$ | $\begin{aligned} & \$ 198.36 \\ & \$ 199.65 \end{aligned}$ |  |
| 36 | \$264.66 | \$271.28 | \$234.71 | \$240.58 | \$234.71 | \$240.58 |  |  |  | \$203.32 <br> $\$ 204.64$ <br> $\$ 20597$ |
| 37 | \$266.38 | \$273.04 | \$236.24 | \$242.15 | \$236.24 <br> $\$ 237.76$ | \$242.15 | $\$ 200.95$ <br> $\$ 202.25$ | \$204.64 <br> $\$ 205.97$ | \$190.65 <br> $\$ 200.95$ |  |
| 38 | \$268.10 | \$274.80 | \$237.76 | \$243.70 |  | \$243.70 |  | \$207.31 <br> $\$ 209.97$ | $\begin{aligned} & \$ 202.25 \\ & \$ 204.85 \end{aligned}$ | \$205.97 <br> $\$ 207.31$ <br> $\$ 2093$ |
| 39 | \$271.54 | \$278.33 | \$240.81 | \$246.83 | $\begin{aligned} & \$ 240.81 \\ & \$ 243.87 \end{aligned}$ | \$246.83 | \$204.85 |  |  | \$200.97$\$ 229.97$$\$ 228.18$ |
| 40 | \$274.99 | \$302.49 | \$243.87 | \$268.26 |  | \$268.26 | \$207.44$\$ 211.34$ | \$228.18S233.53 | \$207.44 |  |
| 41 | \$280.15 | \$309.57 | \$248.45 | \$274.54 | $\begin{aligned} & \$ 248.45 \\ & \$ 252.84 \end{aligned}$ | \$274.54 |  |  |  | \$228.18 |
| 42 | \$285.10 | \$317.03 | \$252.84 | \$281.16 |  | \$281.16 | $\begin{aligned} & \$ 215.07 \\ & \$ 220.27 \end{aligned}$ | \$239.16 | \$215.07 | \$233.18 <br>  <br> $\$ 246.92$ |
| 43 | \$291.99 | \$327.32 | \$258.94 | \$290.27 | \$258.94 | \$290.27 |  | \$246.92 | \$220.27 |  |
| 44 | \$300.59 | \$340.27 | \$266.58 | \$301.77 | $\begin{aligned} & \$ 266.58 \\ & \$ 275.54 \end{aligned}$ | \$301.77 | \$226.76 | \$256.69 | \$226.76 | \$256.69 |
| 45 | \$310.71 | \$355.76 | \$275.54 | \$315.49 |  | \$315.49 | \$234.39 | \$268.38 | \$234.39 | \$268.38 |
| 46 | \$322.76 | \$374.40 | \$286.23 | \$332.03 | \$286.23 | \$332.03 | \$243.48 | \$282.44 | \$243.48 | \$282.44 |
| 47 | \$336.31 | \$395.84 | \$298.25 | \$351.04 | \$298.25 | \$351.04 | \$253.71 | \$298.62 | \$253.71 | \$298.62 |
| 48 | \$351.80 | \$420.75 | \$311.99 | \$373.14 | \$311.99 | \$373.14 | \$265.39 | \$317.41 | \$265.39 | \$317.41 |
| 49 | \$367.08 | \$446.74 | \$325.54 | \$396.18 | \$325.54 | \$396.18 | \$276.92 | \$337.01 | \$276.92 | \$337.01 |
| 50 | \$384.29 | \$470.76 | \$340.80 | \$417.48 | \$340.80 | \$417.48 | \$289.90 | \$355.13 | \$289.90 | \$355.13 |
| 51 | \$401.29 | \$491.58 | \$355.88 | \$435.95 | \$355.88 | \$435.95 | \$302.73 | \$370.84 | \$302.73 | \$370.84 |
| 52 | \$420.01 | \$514.51 | \$372.48 | \$456.29 | \$372.48 | \$456.29 | \$316.85 | \$388.14 | \$316.85 | \$388.14 |
| 53 | \$438.95 | \$537.71 | \$389.27 | \$476.86 | \$389.27 | \$476.86 | \$331.13 | \$405.63 | \$331.13 | \$405.63 |
| 54 | \$459.39 | \$562.75 | \$407.40 | \$499.07 | \$407.40 | \$499.07 | \$346.55 | \$424.52 | \$346.55 | \$424.52 |
| 55 | \$479.83 | \$587.79 | \$425.53 | \$521.27 | \$425.53 | \$521.27 | \$361.97 | \$443.41 | \$361.97 | \$443.41 |
| 56 | \$501.99 | \$614.94 | \$445.18 | \$545.35 | \$445.18 | \$545.35 | \$378.69 | \$463.90 | \$378.69 | \$463.90 |
| 57 | \$524.37 | \$642.35 | \$465.03 | \$569.66 | \$465.03 | \$569.66 | \$395.57 | \$484.57 | \$395.57 | \$484.57 |
| 58 | \$548.25 | \$671.61 | \$486.21 | \$595.61 | \$486.21 | \$595.61 | \$413.59 | \$506.65 | \$413.59 | \$506.65 |
| 59 | \$560.09 | \$686.11 | \$496.70 | \$608.46 | \$496.70 | \$608.46 | \$422.52 | \$517.59 | \$422.52 | \$517.59 |
| 60 | \$583.97 | \$715.36 | \$517.89 | \$634.42 | \$517.89 | \$634.42 | \$440.54 | \$539.66 | \$440.54 | \$539.66 |
| 61 | \$604.63 | \$740.67 | \$536.20 | \$656.85 | \$536.20 | \$656.85 | \$456.12 | \$558.75 | \$456.12 | \$558.75 |
| 62 | \$618.18 | \$757.27 | \$548.23 | \$671.58 | \$548.23 | \$671.58 | \$466.35 | \$571.28 | \$466.35 | \$571.28 |
| 63 | \$635.18 | \$778.10 | \$567.30 | \$690.04 | \$567.30 | \$690.04 | \$479.17 | \$586.98 | \$479.17 | \$586.98 |
| $64+$ | \$645.51 | \$790.75 | \$572.46 | \$701.26 | \$572.46 | \$701.26 | \$486.96 | \$596.53 | \$486.96 | \$596.53 |

## Highmark Coverage Advantage

Individual
Plan Design Summary

| HIOS Plan ID | Plan Marketing Name | Product | Metal | On/Off <br> Exchange | Network | Rating Area | Counties Covered |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 79279PA0080008 | Together Blue EPO Gold 0 | EPO | Gold | On/Off | L | 1, 4 | Allegheny, Erie, Washington, Butler, Westmoreland Allegheny, Erie, Washington, Butler, |
| 79279PA0130005 | Together Blue EPO Gold 0 + Adult Dental and Vision | EPO | Gold | On/Off | L | 1, 4 | Westmoreland Allegheny, Erie, Washington, Butler, |
| 79279PA0140001 | Together Blue EPO Premier Gold 0 | EPO | Gold | On/Off | L | 1, 4 | Westmoreland <br> Allegheny, Erie, Washington, Butler, |
| 79279PA0150001 | Together Blue EPO Premier Gold 0 + Adult Dental and Vision | EPO | Gold | On/Off | L | 1, 4 | Westmoreland <br> Allegheny, Erie, Washington, Butler, |
| 79279PA0090004 | Together Blue EPO Gold 1700 HSA | EPO | Gold | On/Off | L | 1, 4 | Westmoreland <br> Allegheny, Erie, Washington, Butler, |
| 79279PA0080013 | Together Blue Virtual Choice EPO Gold 1500 | EPO | Gold | On/Off | L | 1, 4 | Westmoreland <br> Allegheny, Erie, Washington, Butler, |
| 79279PA0140002 | Together Blue EPO Premier Silver 2900 | EPO | Silver | On/Off | L | 1, 4 | Westmoreland <br> Allegheny, Erie, Washington, Butler, |
| 79279PA0150002 | Together Blue EPO Premier Silver 2900 + Adult Dental and Vision | EPO | Silver | On/Off | L | 1, 4 | Westmoreland <br> Allegheny, Erie, Washington, Butler, |
| 79279PA0080012 | Together Blue EPO Silver 7000 | EPO | Silver | On/Off | L | 1, 4 | Westmoreland <br> Allegheny, Erie, Washington, Butler, |
| 79279PA0080010 | Together Blue EPO Silver 3500 | EPO | Silver | Off | L | 1, 4 | Westmoreland <br> Allegheny, Erie, Washington, Butler, |
| 79279PA0130004 | Together Blue EPO Silver 3500 + Adult Dental and Vision | EPO | Silver | Off | L | 1, 4 | Westmoreland <br> Allegheny, Erie, Washington, Butler, |
| 79279PA0080001 | Together Blue EPO Bronze 3800 | EPO | Bronze | On/Off | L | 1, 4 | Westmoreland <br> Allegheny, Erie, Washington, Butler, |
| 79279PA0130002 | Together Blue EPO Bronze 3800 + Adult Dental and Vision | EPO | Bronze | On/Off | L | 1, 4 | Westmoreland <br> Allegheny, Erie, Washington, Butler, |
| 79279PA0090001 | Together Blue EPO Bronze 7100 HSA - Custom Drug Benefit | EPO | Bronze | On/Off | L | 1, 4 | Westmoreland <br> Allegheny, Erie, Washington, Butler, |
| 79279PA0080011 | Together Blue EPO Bronze 8900 | EPO | Bronze | On/Off | L | 1, 4 | Westmoreland <br> Allegheny, Erie, Washington, Butler, |
| 79279PA0100001 | Together Blue Major Events EPO Catastrophic 9450-3 Free PCP Visits | EPO | Catastrophic | On/Off | L | 1, 4 | Westmoreland |

RATES FOR AGE 21, NON-TOBACCO USER, BY RATING AREA AND COUNTY

| 02-01-2023 Number of Covered Lives by Rating County |  |  |  |  | rating area 1 |  |  |  |  |  |  |  | RAting area 2 |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | 0 | 0 | 2,139 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIOS Plan ID | Plan Marketing Name | Product | Metal | On/Off Exchange | Crawford | Clarion | Erie | Forest | Mckean | Mercer | Venango | Warren | Elk | Cameron | Potter |
| 79279PA0080008 | Together Blue EPO Gold 0 | EPO | Gold | On/off |  |  | \$276.87 |  |  |  |  |  |  |  |  |
| 79279PA0130005 | Together Blue EPO Gold 0+ Adult Dental and Vision | EPO | Gold | On/off |  |  | \$300.65 |  |  |  |  |  |  |  |  |
| 79279PA0140001 | Together Blue EPO Premier Gold 0 | EPO | Gold | On/off |  |  | \$287.82 |  |  |  |  |  |  |  |  |
| 79279PA0150001 | Together Blue EPO Premier Gold 0 + Adult Dental and Vision | EPO | Gold | On/off |  |  | \$311.61 |  |  |  |  |  |  |  |  |
| 79279PA0090004 | Together Blue EPO Gold 1700 HSA | EPO | Gold | On/off |  |  | \$256.71 |  |  |  |  |  |  |  |  |
| 79279PA0080013 | Together Blue Virtual Choice EPO Gold 1500 | EPO | Gold | On/off |  |  | \$259.83 |  |  |  |  |  |  |  |  |
| $79279 P A 0140002$ | Together Blue EPO Premier Silver 2900 | EPO | Silver | On/off |  |  | \$314.28 |  |  |  |  |  |  |  |  |
| 79279PA0150002 | Together Blue EPO Premier Silver 2900 + Adult Dental and Vision | EPO | Silver | On/off |  |  | \$338.06 |  |  |  |  |  |  |  |  |
| $79279 P A 0080012$ | Together Blue EPO Silver 7000 | EPO | Silver | On/off |  |  | \$294.66 |  |  |  |  |  |  |  |  |
| 79279PA0080010 | Together Blue EPO Silver 3500 | EPO | Silver | off |  |  | \$230.22 |  |  |  |  |  |  |  |  |
| 79279PA0130004 | Together Blue EPO Silver $3500+$ Adult Dental and Vision | EPO | Silver | off |  |  | \$254.00 |  |  |  |  |  |  |  |  |
| $79279 P A 0080001$ | Together Blue EPO Bronze 3800 | EPO | Bronze | On/off |  |  | \$211.05 |  |  |  |  |  |  |  |  |
| 79279PA0130002 | Together Blue EPO Bronze 3800 + Adult Dental and Vision | EPO | Bronze | On/off |  |  | \$234.83 |  |  |  |  |  |  |  |  |
| 79279PA0090001 | Together Blue EPO Bronze 7100 HSA - Custom Drug Benefit | EPO | Bronze | On/off |  |  | \$215.17 |  |  |  |  |  |  |  |  |
| $79279 P A 0080011$ | Together Blue EPO Bronze 8900 | EPO | Bronze | On/off |  |  | \$190.82 |  |  |  |  |  |  |  |  |
| 79279PA0100001 | Together Blue Major Events EPO Catastrophic 9450-3 Free PCP Visiss | EPO | Catastrophic | On/Off |  |  | \$162.32 |  |  |  |  |  |  |  |  |

RATES FOR AGE 21, NON-TOBACCO USER, BY RATING AREA AND COUNTY

|  |  |  |  |  | RAting are |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 02-01-2023 Number of Covered Lives b | ounty |  |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIOS Plan ID | Plan Marketing Name | Product | Metal | $\begin{aligned} & \hline \text { on/Off } \\ & \text { Exchange } \end{aligned}$ | Bradford | Carbon | Clinton | Lackawanna | Luzerne | Lycoming | Monroe | Pike | Sullivan | Susquehanna | Tioga | Wayne | Wyoming |
| 79279 PA0080008 | Together Blue EPO Gold 0 | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 79279PA0130005 | Together Blue EPO Gold 0+ Adult Dental and Vision | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $79279 P A 0140001$ | Together Blue EPO Premier Gold 0 | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $79279 P A 0150001$ | Together Blue EPO Premier Gold 0 + Adult Dental and Vision | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 79279PA0090004 | Together Blue EPO Gold 1700 HSA | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $79279 P A 0080013$ | Together Blue Virtual Choice EPO Gold 1500 | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 79279PA0140002 | Together Blue EPO Premier Silver 2900 | EPO | Silver | On/off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $79279 P A 0150002$ | Together Blue EPO Premier Silver 2900 + Adult Dental and Vision | EPO | Silver | On/off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $79279 P A 0080012$ | Together Blue EPO Silver 7000 | EPO | Silver | On/off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 79279PA0080010 | Together Blue EPO Silver 3500 | EPO | Silver | Off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 79279PA0130004 | Together Blue EPO Silver $3500+$ Adult Dental and Vision | EPO | Silver | off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 79279PA0080001 | Together Blue EPO Bronze 3800 | EPO | Bronze | On/off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $79279 P A 0130002$ | Together Blue EPO Bronze 3800 + Adult Dental and Vision | EPO | Bronze | On/off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 79279PA0090001 | Together Blue EPO Bronze 7100 HSA - Custom Drug Benefit | EPO | Bronze | On/off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| $79279 P 40080011$ | Together Blue EPO Bronze 8900 | EPO | Bronze | On/Off |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 79279PA0100001 | Together Blue Major Events EPO Catastrophic 9450-3 Free PCP Visits | EPO | Catastrophic | On/off |  |  |  |  |  |  |  |  |  |  |  |  |  |



| Company Name Market | Highmark Coverage Advantage |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| RATES FOR AGE 21, NON-TOBACCO USER, BY RATING AREA AND COUNTY |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  | RATING AREA 5 |  |  |  |  |  |  |
|  | 02-01-2023 Number of Covered Lives by Rating County |  |  |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIOS Plan ID | Plan Marketing Name | Product | Metal | On/off Exchange | Bedford | Blair | Clearfield | Cambria | Huntingdon | Jefferson | Somerset |
| 79279PA0080008 | Together Blue EPO Gold 0 | EPO | Gold | On/off |  |  |  |  |  |  |  |
| 79279PA0130005 | Together Blue EPO Gold 0 + Adult Dental and Vision | EPO | Gold | On/off |  |  |  |  |  |  |  |
| $79279 P$ A014000 | Together Blue EPO Premier Gold 0 | EPO | Gold | On/off |  |  |  |  |  |  |  |
| 79279PA0150001 | Together Blue EPO Premier Gold 0 + Adult Dental and Vision | EPO | Gold | On/off |  |  |  |  |  |  |  |
| 79279PA0090004 | Together Blue EPO Gold 1700 HSA | EPO | Gold | On/off |  |  |  |  |  |  |  |
| 79279PA0080013 | Together Blue Virtual Choice EPO Gold 1500 | EPO | Gold | On/off |  |  |  |  |  |  |  |
| 79279PA0140002 | Together Blue EPO Premier Silver 2900 | EPO | Silver | On/off |  |  |  |  |  |  |  |
| 79279PA0150002 | Together Blue EPO Premier Silver 2900 + Adult Dental and Vision | EPO | Silver | On/off |  |  |  |  |  |  |  |
| 79279PA0080012 | Together Blue EPO Silver 7000 | EPO | Silver | On/off |  |  |  |  |  |  |  |
| 79279PA0080010 | Together Blue EPO Silver 3500 | EPO | Silver | Off |  |  |  |  |  |  |  |
| 79279PA0130004 | Together Blue EPO Silver $3500+$ Adult Dental and Vision | EPO | Silver | off |  |  |  |  |  |  |  |
| 79279PA0080001 | Together Blue EPO Bronze 3800 | EPO | Bronze | On/off |  |  |  |  |  |  |  |
| 79279PA0130002 | Together Blue EPO Bronze 3800 + Adult Dental and Vision | EPO | Bronze | On/off |  |  |  |  |  |  |  |
| 79279PA0090001 | Together Blue EPO Bronze 7100 HSA - Custom Drug Benefit | EPO | Bronze | On/off |  |  |  |  |  |  |  |
| 79279PA0080011 | Together Blue EPO Bronze 8900 | EPO | Bronze | On/off |  |  |  |  |  |  |  |
| 79279PA0100001 | Together Blue Major Events EPO Catastrophic 9450-3 Free PCP Visits | EPO | Catastrophic | On/off |  |  |  |  |  |  |  |


| Company Name Market | Highmark Coverage Advantage |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| RATES FOR AGE 21, NON-TOBACCO USER, BY RATING AREA AND COUNTY |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  | RATING AREA 6 |  |  |  |  |  |  |  |  |  |
|  | 02-01-2023 Number of Covered Lives by Rating County |  |  |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIOS Plan ID | Plan Marketing Name | Product | Metal | On/Off Exchange | Centre | Columbia | Lehigh | Mifflin | Montour | Northampton | Northumberland | Schuylkill | Snyder | Union |
| 79279PA0080008 | Together Blue EPO Gold 0 | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |  |
| 79279PA0130005 | Together Blue EPO Gold $0+$ Adult Dental and Vision | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |  |
| 79279PA0140001 | Together Blue EPO Premier Gold 0 | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |  |
| $79279 P A 0150001$ | Together Blue EPO Premier Gold 0 + Adult Dental and Vision | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |  |
| 79279PA0090004 | Together Blue EPO Gold 1700 HSA | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |  |
| $79279 P A 0080013$ | Together Blue Virtual Choice EPO Gold 1500 | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |  |
| 79279PA0140002 | Together Blue EPO Premier Silver 2900 | EPO | Silver | On/off |  |  |  |  |  |  |  |  |  |  |
| $79279 P A 0150002$ | Together Blue EPO Premier Silver $2900+$ Adult Dental and Vision | EPO | Silver | On/off |  |  |  |  |  |  |  |  |  |  |
| $79279 P A 0080012$ | Together Blue EPO Silver 7000 | EPO | Silver | On/off |  |  |  |  |  |  |  |  |  |  |
| 79279PA0080010 | Together Blue EPO Silver 3500 | EPO | Silver | Off |  |  |  |  |  |  |  |  |  |  |
| 79279PA0130004 | Together Blue EPO Silver $3500+$ Adult Dental and Vision | EPO | Silver | Off |  |  |  |  |  |  |  |  |  |  |
| 79279PA0080001 | Together Blue EPO Bronze 3800 | EPO | Bronze | On/off |  |  |  |  |  |  |  |  |  |  |
| 79279PA0130002 | Together Blue EPO Bronze 3800 + Adult Dental and Vision | EPO | Bronze | On/off |  |  |  |  |  |  |  |  |  |  |
| 79279PA0090001 | Together Blue EPO Bronze 7100 HSA - Custom Drug Benefit | EPO | Bronze | On/off |  |  |  |  |  |  |  |  |  |  |
| 79279PA0080011 | Together Blue EPO Bronze 8900 | EPO | Bronze | On/off |  |  |  |  |  |  |  |  |  |  |
| 79279PA0100001 | Together Blue Major Events EPO Catastrophic 9450-3 Free PCP Visits | EPO | Catastrophic | On/off |  |  |  |  |  |  |  |  |  |  |

## Market Individual

RATES FOR AGE 21, NON-TOBACCO USER, BY RATING AREA AND COUNTY

| 02-01-2023 Number of Covered Lives by Rating County |  |  |  |  | rating area 7 |  |  |  | rating area 8 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIOS Plan ID | Plan Marketing Name | Product | Metal | On/Off Exchange | Adams | Berks | Lancaster | York | Bucks | Chester | Delaware | Montgomery | Philadelphia |
| 79279PA0080008 | Together Blue EPO Gold 0 | EPO | Gold | On/Off |  |  |  |  |  |  |  |  |  |
| 79279PA0130005 | Together Blue EPO Gold 0 + Adult Dental and Vision | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |
| $79279 P A 0140001$ | Together Blue EPO Premier Gold 0 | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |
| 79279PA0150001 | Together Blue EPO Premier Gold 0 + Adult Dental and Vision | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |
| 79279PA0090004 | Together Blue EPO Gold 1700 HSA | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |
| 79279PA0080013 | Together Blue Virtual Choice EPO Gold 1500 | EPO | Gold | On/off |  |  |  |  |  |  |  |  |  |
| 79279PA0140002 | Together Blue EPO Premier Silver 2900 | EPO | Silver | On/off |  |  |  |  |  |  |  |  |  |
| 79279PA0150002 | Together Blue EPO Premier Silver 2900 + Adult Dental and Vision | EPO | Silver | On/off |  |  |  |  |  |  |  |  |  |
| 79279PA0080012 | Together Blue EPO Silver 7000 | EPO | Silver | On/off |  |  |  |  |  |  |  |  |  |
| $79279 P A 0080010$ | Together Blue EPO Silver 3500 | EPO | Silver | Off |  |  |  |  |  |  |  |  |  |
| 79279PA0130004 | Together Blue EPO Silver $3500+$ Adult Dental and Vision | EPO | Silver | Off |  |  |  |  |  |  |  |  |  |
| $79279 P A 0080001$ | Together Blue EPO Bronze 3800 | EPO | Bronze | On/off |  |  |  |  |  |  |  |  |  |
| $79279 P A 0130002$ | Together Blue EPO Bronze 3800 + Adult Dental and Vision | EPO | Bronze | On/off |  |  |  |  |  |  |  |  |  |
| $79279 P A 0090001$ | Together Blue EPO Bronze 7100 HSA - Custom Drug Benefit | EPO | Bronze | On/off |  |  |  |  |  |  |  |  |  |
| 79279 PA0080011 | Together Blue EPO Bronze 8900 | EPO | Bronze | On/off |  |  |  |  |  |  |  |  |  |
| 79279PA0100001 | Together Blue Major Events EPO Catastrophic 9450-3 Free PCP Visits | EPO | Catastrophic | On/off |  |  |  |  |  |  |  |  |  |

## $\begin{array}{ll}\text { Company Name } & \text { Highmark Coverage Advantage } \\ \text { Market } & \text { Individual }\end{array}$

RATES FOR AGE 21, NON-TOBACCO USER, BY RATING AREA AND COUNTY

| 02-01-2023 Number of Covered Lives by Rating County |  |  |  |  | Rating area 9 |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIOS Plan ID | Plan Marketing Name | Product | Metal | On/Off Exchange | Cumberland | Dauphin | Franklin | Fulton | Juniata | Lebanon | Perry |
| 79279PA0080008 | Together Blue EPO Gold 0 | EPO | Gold | On/off |  |  |  |  |  |  |  |
| 79279PA0130005 | Together Blue EPO Gold 0 + Adult Dental and Vision | EPO | Gold | On/off |  |  |  |  |  |  |  |
| 79279PA0140001 | Together Blue EPO Premier Gold 0 | EPO | Gold | On/off |  |  |  |  |  |  |  |
| 79279PA0150001 | Together Blue EPO Premier Gold 0 + Adult Dental and Vision | EPO | Gold | On/off |  |  |  |  |  |  |  |
| 79279PA0090004 | Together Blue EPO Gold 1700 HSA | EPO | Gold | On/off |  |  |  |  |  |  |  |
| 79279PA0080013 | Together Blue Virtual Choice EPO Gold 1500 | EPO | Gold | On/off |  |  |  |  |  |  |  |
| 79279PA0140002 | Together Blue EPO Premier Silver 2900 | EPO | Silver | On/off |  |  |  |  |  |  |  |
| 79279PA0150002 | Together Blue EPO Premier Silver 2900 + Adult Dental and Vision | EPO | Silver | On/off |  |  |  |  |  |  |  |
| $79279 P A 0080012$ | Together Blue EPO Silver 7000 | EPO | Silver | On/off |  |  |  |  |  |  |  |
| 79279PA0080010 | Together Blue EPO Silver 3500 | Epo | Silver | Off |  |  |  |  |  |  |  |
| 79279PA0130004 | Together Blue EPO Silver $3500+$ Adult Dental and Vision | EPO | Silver | Off |  |  |  |  |  |  |  |
| $79279 P$ A0080001 | Together Blue EPO Bronze 3800 | EPO | Bronze | On/off |  |  |  |  |  |  |  |
| $79279 P A 0130002$ | Together Blue EPO Bronze 3800 + Adult Dental and Vision | EPO | Bronze | On/off |  |  |  |  |  |  |  |
| 79279PA0090001 | Together Blue EPO Bronze 7100 HSA - Custom Drug Benefit | EPO | Bronze | On/off |  |  |  |  |  |  |  |
| $79279 P A 0080011$ | Together Blue EPO Bronze 8900 | EPO | Bronze | On/off |  |  |  |  |  |  |  |
| 79279PA0100001 | Together Blue Major Events EPO Catastrophic 9450-3 Free PCP Visits | EPO | Catastrophic | On/off |  |  |  |  |  |  |  |

## 2023 Service Area

## Issuer: Highmark Coverage Advantage (HCA) <br> Market: Individual



[^2]
## 2024 Service Area

## Issuer: Highmark Coverage Advantage (HCA) <br> Market: Individual



## Key (modify as needed)

: 2024 on-exchange service area
: 2024 off-exchange only service area

June 21, 2023

Ms. Lorraine Badarzynski, Actuary
Bureau of Life, Accident \& Health Insurance
Commonwealth of Pennsylvania Insurance Department
1311 Strawberry Square
Harrisburg, PA 17120
Re: Highmark Coverage Advantage 2024 ACA Rate Filing (Individual Market)
Highmark Filing \# 1A-DP-23-HCA (SERFF Filing \# HGHM-133630381)
Dear Ms. Badarzynski:

Enclosed are responses to your June 9, 2023 questions regarding SERFF Filing \# HGHM133630381. We have included your questions along with our responses for your convenience.

Should you have any further questions regarding this Filing, please feel free to contact me at or via e-mail at:

Sincerely,


Actuarial Manager, Individual Markets
Highmark Inc.

1. Why doesn't the current enrollment on I Data in the PAAM match the current enrollment in the URRT Wkst 2 ?

Response:
HCA has some plans that were offered only in 2023 (not offered in the experience period or in the projection period). These plans are not captured in the URRT; therefore, the enrollment is excluded as well. For the list of these terminated plans, see Section XV - Terminated Plans and Products of the URRT Part III actuarial memorandum.
2. The administrative expenses for HCA are a larger percent of premium ( $\mathbf{1 3 . 3 \%}$ ) than found in other individual market issuers in Pennsylvania. Please give some reasons why the administrative expenses are high for this company.

Response:
The Company's administrative expense as a percentage of the total projected required revenue is higher primarily because the projected incurred claims are very low as a result of the network factor found in Table 14.
3. The Department is interested in the issuer's estimate of the drivers of the rate change. What portion of the indicated rate change from Table 11 is due to changes in various components such as reinsurance, utilization trend, unit cost trend, expenses, morbidity, benefits, risk adjustment, or other relevant factors?

Response:
Please see the attached exhibit labeled Q3 Response for a summary of the estimated drivers of the rate change from Table 11.

Highmark Coverage Advantage

## Individual Market

Response to Objection 1 - Question 3

| Rate Change Driver | Estimated <br> Impact |
| :--- | :---: |
|  |  |
| Change in base claims trended to 2023 | $(10.9 \%)$ |
| Trend (2023 to 2024) | $9.0 \%$ |
| Morbidity/COVID | $7.5 \%$ |
| Risk Adjustment | $8.2 \%$ |
| Reinsurance Claim Impact | $5.0 \%$ |
| Retention | $(1.6 \%)$ |
| Other | $(2.7 \%)$ |
| Total Rate Change (Table 11) | $13.6 \%$ |

July 14, 2023

Ms. Lorraine Badarzynski, Actuary
Bureau of Life, Accident \& Health Insurance
Commonwealth of Pennsylvania Insurance Department
1311 Strawberry Square
Harrisburg, PA 17120
Re: Highmark Coverage Advantage 2024 ACA Rate Filing (Individual Market)
Highmark Filing \# 1A-DP-23-HCA (SERFF Filing \# HGHM-133630381)
Dear Ms. Badarzynski:
Enclosed are responses to your July 7, 2023 questions regarding SERFF Filing \# HGHM133630381. We have included your questions along with our responses for your convenience. In conjunction with these responses, we are also submitting revisions to relevant filing documents to reflect the following changes:

- In response to Question 1 of the Department's objection letter dated July 7, 2023, the 2022 experience period risk adjustment amount found in Table 2 of the PAAM Exhibits has been updated to reflect the final amount released by CMS on June 30, 2023.
- In response to Question 3 of the Department's objection letter dated July 7, 2023, the reinsurance parameters have been updated to reflect a $\$ 60,000$ attachment point, a $50 \%$ coinsurance rate, and a $\$ 100,000$ reinsurance cap.
- In response to Question 9 of the Department's objection letter dated July 7, 2023, the projected member distribution for the Prior ACA source in the morbidity development has been round to the nearest tenth of a percentage point.

Should you have any further questions regarding this Filing, please feel free to contact me at $\square$ or via e-mail at: $\square$.

Sincerely,


Actuarial Manager, Individual Markets
Highmark Inc.

1. Please update the 2022 experience period risk adjustment amount in Table 2 to reflect the final CMS risk adjustment amount released on June 30th.

Response:
The 2022 experience period risk adjustment amount in Table 2 has been updated to reflect the final amount released by CMS on June 30, 2023.
2. If the projected risk adjustment transfer amount in Table 5 will be modified, due to the final CMS transfer amount published on June 30th, please provide narrative and detailed supporting data to justify the proposed changes.

Response:
The Company does not intend to modify its projected 2024 risk adjustment transfer amounts based on the 2022 results.
3. Please update your filing to reflect the reinsurance coinsurance percentage of $\mathbf{5 0}$ percent.

Response:
The Company is submitting a revised filing to reflect this change in the coinsurance rate in conjunction with these responses.
4. Please confirm that you have tested to ensure that the rates in Table 11 of the Actuarial Memorandum Exhibits, PA Plan Design Summary and Rate Tables, and Federal Rate Templates are identical.

Response:
We have tested and confirmed that the rates in Table 11 of the Actuarial Memorandum Exhibits, the PA Plan Design Summary and Rate Tables, and the Federal Rates Template are identical.
5. Please provide a detailed quantitative exhibit that supports Attachment G's COVID-19 impact on CY22 Capacity.
a. Please provide a similar exhibit utilizing CY21 data
b. Please provide a similar exhibit utilizing CY20 data
c. Please provide a detailed narrative that explains why the Capacity issue is only an issue in the Individual market, and not also the SG market
d. Please provide a detailed narrative that describes what actions the company is taking to eliminate the capacity issues for PY24. If a narrative cannot be provided, please remove the capacity adjustment.

Response:
Please see the attached exhibit labeled Q5 Response for the quantitative development of the CY2022 Capacity adjustment found in Attachment G.
a. Significant capacity constraints were an issue that we believe mostly impacted 2022 claims. Any capacity constraints in CY20 and CY21 are expected to be minimal, and they would have been embedded within the deferred, avoided, and rescheduled care buckets of the COVID-19 support exhibits from the prior years' rate filings.
b. Significant capacity constraints were an issue that we believe mostly impacted 2022 claims. Any capacity constraints in CY20 and CY21 are expected to be minimal, and they would have been
embedded within the deferred, avoided, and rescheduled care buckets of the COVID-19 support exhibits from the prior years' rate filings.
c. In the SG rate development, COVID-19 was assumed to be endemic going forward. As such, any COVID-19 adjustment, including any capacity constraints, was not called out as a separate factor. It was included in the general trend development.
d. This is primarily a provider issue rather than an insurer issue. However, we have been in contact with providers including our own provider system, Allegheny Health Network. Providers have indicated volumes are returning in late 2022 and early 2023, suggesting they have solved for the capacity constraints. This is corroborated by publicly available reports from large insurers such as United and Humana, which indicate higher trends in 2023, especially related to deferred surgeries that are being rescheduled.
6. Based on what has been provided in attachment $E$, please explain why the company believes age 64+'s member mix will increase 2.0 percentage points from the experience period to the rating period. Please also explain why this is dissimilar for ages 60-63.

## Response:

The member mix in Table E. 3 of Attachment E is simply a function of the observed actual member mix as of the February 1, 2023 snapshot date. One possible explanation for this shift could be that the enhanced ACA subsidies are incentivizing more individuals in this age range to consider early retirement and utilize ACA coverage as a bridge to Medicare eligibility.
7. It is noted that the Change in Other adjustment includes an impact for both pharmacy rebates and expected changes in hospital/physician settlements, and is included as a hardcoded number in Attachment A. Please provide separately what both these adjustments are.
a. In addition, please provide a detailed quantitative exhibit, with all formulas preserved, that supports the development of the expected change in pharmacy rebates. Please ensure that this supplemental exhibit supports the historical pharmacy rebates that have been provided in Table 4 of the PAAME.

Response:
Please see the attached exhibit labeled Q7 Response for the development of the "Change in Other" factor.
a. Please see the attached exhibit labeled Q7a Response for the development of the expected change in pharmacy rebates. The estimated pharmacy rebate PMPMs for both the base experience period and the projection period can be found in Table 1 of the Q7a Response exhibit. This table also demonstrates how the experience period pharmacy rebate dollars in Table 4 of the PAAM Exhibits can be derived from the experience period PMPM. Table 2 of the Q7a Response exhibit demonstrates the quantitative development of the change in pharmacy rebate factor that is shown in the Q7 Response exhibit.
8. The following questions pertain to attachment $B$ :
a. On May 8, 2023, the Department provided the company with RA transfer results for BY22. While comparing those results to the support included in attachment $B$, it is noted that the PLRS, ARF, and AV are quite similar. However, it is noted that the premium PMPM given in attachment $B$ is not. Please provide a detailed quantitative exhibit that retains all formulas and supports cell D13 of attachment B.

Response:
a. The statewide factors included in rows 13 and 18 of Attachment B for the 2024 projection were developed by starting with information from the following sources: (1) the PID's 2022 RATEE study released on May 8, 2023, (2) the PID's 1Q2023 Enrollment Survey released on April 26, 2023, and (3) the CMS Interim Summary Report for 2022 released on March 17, 2023. The attached exhibit labeled Q8a Response demonstrates how this information was used to develop the 2024 statewide average premium PMPM shown in Attachment B. Specifically, we anticipate that the statewide average premium will be approximately $\square$ higher in 2024 compared to 2022. This is a function of an assumed statewide average rate increase of $\quad$ for 2023 and $\quad$ for 2024. Please see the attached exhibit labeled Q8a Response for the numerical development of the value found in cell D13 of Attachment B.
9. The following questions pertain to attachment A :
a. Please provide more detail on what "Other Highmark" includes. In addition, please provide a detailed quantitative exhibit that supports both the 2022 normalized allowed PMPM and the $\mathbf{2 0 2 4}$ projected member distribution. If additional support cannot be provided please remove "Other Highmark" from the 2024 projected member distribution.
b. Please confirm that the $\mathbf{4 . 7 \%}$ assumed to migrate from other Highmark entities has been included within other corresponding company ACA filings. If not, please remove "Other Highmark" from the $\mathbf{2 0 2 4}$ projected member distribution.

Response:
a. The "Other Highmark" source includes members that were enrolled in one of Highmark's nonACA insurance products in 2022 and then selected a Highmark Coverage Advantage ACA plan for 2023.

Please see the attached exhibit labeled Q9a Response for the development of the 2022 normalized allowed PMPM and the 2024 projected member distribution. The calculation of the 2022 normalized allowed PMPM started with the actual underlying 2022 allowed PMPMs for this source. The projected member distribution is a function of the actual member distribution observed as of the February 1, 2023 snapshot date. The assumed values that were incorporated into Attachment A reflect very minor adjustments in order to use more rounded assumptions. In the course of preparing this response, we noticed that the value for the Prior ACA source had previously been left unrounded as $0.803437 \%$. The intent was to round this value to the nearest tenth of a percentage point so that the total member distribution for all of the sources sums to exactly $100 \%$. This issue has been fixed by setting the value for the Prior ACA source to $0.8 \%$. The impact of this change was immaterial.
b. The $4.7 \%$ represents the share of the projected 2024 membership assumed for members migrating from Highmark's non-ACA products. This does not represent membership migrating from Highmark's other ACA entities.
10. Please ensure that the 7/14/23 versions of the following items are posted in SERFF with your July 14th response to this data call.
a. Cover Letter identifying all changes made and the reasons for the change. Also, show the revised rate change.
b. PA Actuarial Memorandum
c. PA Actuarial Memorandum Exhibits (don't forget to update the "VI Rate Change Summary" tab, if necessary)
d. Department's Plan Design Summary and Rate Template Exhibits (please ensure that the rate template by county is populated with only numeric values - no "NA")
e. URRT
f. Federal Rate Template
g. Part III: Actuarial Memorandum
h. Public PDF with limited redactions as previously directed in the Guidance (includes all correspondence and supporting exhibits after the initial submission, in addition to all the above items).

Response:
All of the relevant rate filing documents are being updated and submitted in SERFF in conjunction with these responses.
11. Please provide a revised Table 3 that shows the trends by service category. At the very minimum, the company should be able to show a separate medical and drug trend.
a. Please provide a detailed narrative that describes how projected changes in provider contracting arrangements has been considered within the trend development.
b. Please provide a detailed narrative that describes how current and future cost of care initiatives have been considered within the trend development. In addition, please provide a detailed quantitative exhibit that summarizes the cost of care initiatives that the company has in place or expects to be in place for PY24 and the favorable adjustment to trend as a result of the initiatives.

Response:
Please see the attached exhibits labeled Q11 Response1 and Q11 Response2 for the development of the trend estimates produced by the regression analysis. The medical and pharmacy trends are developed separately as shown in the exhibit but were combined in the filing submission because the final trend applied was a total trend. An assumed Cost trend of $5 \%$ was assigned based on historical and projected cost trend patterns with the remaining trend component assigned to Utilization.
a. Highmark's provider contracting area has analyzed future expected contracting changes and provided factors to account for these future changes. The changes are included in the Allowed PMPM streams provided in column C of the Q11 Response1 exhibit.

For in-area facilities, the timing and impact of increases by facility are provided by the provider contracting area. For out of area facilities, we use a standard assumption based on historical data. For professional services, we use the aggregate change in our fee schedule. These are all composited using actual utilization into the provider contracting factors, which are incorporated in the trend development.
b. The realized value of current cost of care initiatives are included in the base period data. As a result, ongoing and future levels are assumed to increase at the same rate as the trend assumption. Any further improvement due to Highmark's continued efforts to lower cost of care would be reflected in future experience as it emerges and could offset unexpected trend drivers that emerge after the filing trend development.

The attached exhibit labeled Q11b Response has a column showing the cost of care initiatives estimated value that is part of the "Cumul Factor" column in the trend development.

Highmark Coverage Advantage Inc.

## Individual Market

## Response to Objection 2 - Question 5

Table 1 - CY2022 Medical Development

| Month | Actual ACA 2022 <br> Member Months | Commercial 2022 <br> Medical <br> Allowed PMPM | PMPM | $\%$ |
| :---: | :---: | :---: | :---: | :---: |
| 202201 | 14,245 | $\$ 433.50$ |  |  |
| 202202 | 15,760 | $\$ 431.16$ |  |  |
| 202203 | 15,549 | $\$ 434.07$ |  |  |
| 202204 | 15,504 | $\$ 437.10$ |  |  |
| 202205 | 15,409 | $\$ 433.29$ |  |  |
| 202206 | 15,378 | $\$ 443.24$ |  |  |
| 202207 | 15,552 | $\$ 456.55$ |  |  |
| 202208 | 15,602 | $\$ 431.41$ |  |  |
| 202209 | 15,614 | $\$ 442.49$ |  |  |
| 202210 | 15,618 | $\$ 458.76$ |  |  |
| 202211 | 15,635 | $\$ 460.34$ |  |  |
| $\frac{15,547}{202212}$ | 185,413 | $\$ 461.98$ |  |  |
| Total |  |  | $\$ 43.73$ |  |
| Estimated 2022 Medical Allowed Baseline |  |  |  |  |
| Commercial 2022 COVID-19 Costs |  | $\$ 4.0 \%$ |  |  |
| Testing |  |  |  |  |
| Vaccines |  | $\$ 439.11$ |  |  |
| Actual 2022 Medical Allowed w/o COVID-19 Costs | $(\$ 12.93)$ | $(2.9 \%)$ |  |  |
| Impact of Capacity / Avoided Care |  |  |  |  |
| Total Medical Impact of COVID-19 |  |  |  |  |

Capacity / Avoided Care is net of Treatment Costs

Highmark Coverage Advantage

## Individual Market

## Response to Objection 2 - Question 7

| Description | Factor |
| :--- | :---: |
| Change in Rx Rebates | 0.957 |
| Change in Hospital/Physician Settlements | 0.999 |
| Total "Change in Other" | $\mathbf{0 . 9 5 6}$ |

## Highmark Coverage Advantage

Individual Market

Response to Objection 2 - Question 7a

Table 1

| Description | 2022 | 2024 |
| :--- | :---: | :---: |
| Prescription Drug Allowed PMPM (w/ Rx Rebates; URRT Wksh1) <br> Rx Rebates PMPM <br> Member Months |  |  |
| Rx Rebate Dollars (Table 4) |  |  |

Table 2

|  |  |  |  |
| :--- | :---: | :---: | :---: |
| Description | Medical | $\mathbf{R x}$ | Total |
| Change in Rx Rebates | 1.000 | 0.852 |  |
| Change in Other (Table 5) |  |  | 0.956 |
| Adjusted Projected Allowed EHB Claims PMPM (Table 5) |  | $\$ 445.41$ |  |
| Adjusted Projected Allowed EHB Claims PMPM (prior to change in other) | $\$ 330.11$ | $\$ 135.76$ | $\$ 465.86$ |
| Final Change in Rx Rebates |  |  | $\mathbf{0 . 9 5 7}$ |

## Highmark Coverage Advantage

## Individual Market

## Response to Objection 2 - Question 8a

|  | Statewide Average <br> Non-Catastrophic Pool |
| :--- | :---: |
| 2022 Average Premium PMPM |  |
| Assumed 2023 Rate Increase |  |
| Assumed 2024 Rate Increase |  |
| 2024 Average Premium PMPM |  |

## Highmark Coverage Advantage

## Individual Market

Response to Objection 2 - Question 9a

Table 1 - Projected Member Distribution

| Population Source | Member Distribution |  |
| :--- | :---: | :---: |
|  | 2023 Actual | 2024 Assumed |
| HCA ACA | $76.0 \%$ | $76.0 \%$ |
| Other Highmark | $4.6 \%$ | $4.7 \%$ |
| Prior ACA | $0.8 \%$ | $0.8 \%$ |
| New-to-Blue | $\underline{18.5 \%}$ | $\underline{18.5 \%}$ |
| Subtotal | $100.0 \%$ | $100.0 \%$ |

Table 2-2022 Normalized Allowed PMPM Using 2024 Projected Member Distribution

|  | HCA |  |  |  | Combined |
| :--- | :---: | :---: | :---: | :---: | :---: |
|  | Renewal | Other <br> Highmark | Prior ACA | New | Total |
|  |  |  |  |  |  |
| 2024 Member Months | 183,841 | 11,369 | 1,935 | 44,751 | 241,896 |
| 2024 Member Months \% | $76.0 \%$ | $4.7 \%$ | $0.8 \%$ | $18.5 \%$ | $100.0 \%$ |
|  |  |  |  |  |  |
| 2022 or 2021 Allowed PMPM* | $\$ 417.71$ | $\$ 617.01$ | $\$ 432.95$ | $\mathrm{~N} / \mathrm{A}$ |  |
| Trend from 2021 to 2022 | $\mathrm{N} / \mathrm{A}$ | $\mathrm{N} / \mathrm{A}$ | 1.097 | $\mathrm{~N} / \mathrm{A}$ |  |
| Death Load Adjustment | 1.030 | 1.030 | 1.030 | $\mathrm{~N} / \mathrm{A}$ |  |
| Adjusted Allowed PMPM | $\$ 430.24$ | $\$ 635.52$ | $\$ 489.19$ | $\$ 523.67$ | $\$ 457.65$ |
|  |  |  |  |  |  |
| Demographic Factor | 1.707 | 1.587 | 1.572 | 1.529 | 1.657 |
| Network Factor | 0.730 | 1.000 | 1.000 | 1.000 | 0.796 |
| Benefit Richness Factor | 1.088 | 1.080 | 1.080 | 1.080 | 1.086 |
| Normalized Allowed PMPM | $\$ \mathbf{3 1 7 . 1 4}$ | $\mathbf{\$ 3 7 0 . 8 5}$ | $\mathbf{\$ 2 8 8 . 1 4}$ | $\mathbf{\$ 3 1 7 . 1 4}$ | $\mathbf{\$ 3 1 9 . 4 3}$ |

*The 'Renewal' \& 'Other Highmark' sources start with 2022 experience. The 'Prior ACA' source starts with 2021 experien

Highmark Coverage Advantage
Individual Market

Response to Objection 2 - Question 11

|  | Medical |  |  |  |  |  |  |  | Rx |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Incurred <br> Month | Members | Allowed PMPM | AGING | Cumul Factor | Monthly Factor | Pricing PMPM | 12 Mo . PMPM | Annual Trend | Members | Allowed PMPM | AGING | Cumul Factor | Monthly Factor | Pricing PMPM | 12 Mo . PMPM | Annual Trend |
| 1/20 | 5,976 | \$244.38 | 1.000 | 1.056 | 0.947 | \$231.34 |  |  | 5,976 | \$83.04 | 1.000 | 0.939 | 1.065 | \$88.41 |  |  |
| 2/20 | 6,063 | \$207.31 | 1.000 | 1.061 | 0.943 | \$195.41 |  |  | 6,063 | \$93.48 | 1.000 | 0.964 | 1.037 | \$96.98 |  |  |
| 3/20 | 6,287 | \$217.43 | 1.000 | 1.046 | 0.956 | \$207.89 |  |  | 6,287 | \$123.18 | 1.000 | 0.974 | 1.027 | \$126.50 |  |  |
| 4/20 | 6,551 | \$141.59 | 1.000 | 1.024 | 0.977 | \$138.29 |  |  | 6,551 | \$110.88 | 1.000 | 0.984 | 1.017 | \$112.71 |  |  |
| 5/20 | 6,762 | \$185.86 | 1.000 | 0.994 | 1.006 | \$187.02 |  |  | 6,762 | \$111.64 | 1.000 | 0.996 | 1.004 | \$112.11 |  |  |
| 6/20 | 6,913 | \$226.31 | 1.000 | 0.976 | 1.024 | \$231.85 |  |  | 6,913 | \$139.75 | 1.000 | 0.979 | 1.022 | \$142.80 |  |  |
| 7/20 | 6,917 | \$263.21 | 1.000 | 0.976 | 1.025 | \$269.69 |  |  | 6,917 | \$129.53 | 1.000 | 0.981 | 1.020 | \$132.06 |  |  |
| 8/20 | 6,822 | \$296.70 | 1.000 | 0.971 | 1.030 | \$305.56 |  |  | 6,822 | \$128.18 | 1.000 | 0.999 | 1.001 | \$128.29 |  |  |
| 9/20 | 6,974 | \$239.75 | 1.000 | 0.945 | 1.058 | \$253.57 |  |  | 6,974 | \$127.14 | 1.000 | 0.981 | 1.019 | \$129.57 |  |  |
| 10/20 | 6,992 | \$228.05 | 1.000 | 0.936 | 1.068 | \$243.62 |  |  | 6,992 | \$146.76 | 1.000 | 0.980 | 1.020 | \$149.73 |  |  |
| 11/20 | 6,990 | \$238.84 | 1.000 | 0.924 | 1.083 | \$258.62 |  |  | 6,990 | \$130.93 | 1.000 | 0.944 | 1.059 | \$138.68 |  |  |
| 12/20 | 6,847 | \$249.06 | 1.000 | 0.920 | 1.087 | \$270.61 | \$233.85 |  | 6,847 | \$151.53 | 1.000 | 0.957 | 1.045 | \$158.38 | \$127.20 |  |
| 1/21 | 9,261 | \$248.86 | 1.000 | 0.922 | 1.085 | \$270.02 | \$238.05 |  | 9,261 | \$113.90 | 1.000 | 0.875 | 1.143 | \$130.14 | \$130.31 |  |
| 2/21 | 9,964 | \$271.14 | 1.000 | 0.921 | 1.086 | \$294.45 | \$247.45 |  | 9,964 | \$116.85 | 1.000 | 0.845 | 1.184 | \$138.32 | \$133.54 |  |
| 3/21 | 9,955 | \$320.89 | 1.000 | 0.927 | 1.078 | \$346.00 | \$260.97 |  | 9,955 | \$147.11 | 1.000 | 0.854 | 1.171 | \$172.25 | \$138.26 |  |
| 4/21 | 10,136 | \$271.68 | 1.000 | 0.907 | 1.103 | \$299.65 | \$273.62 |  | 10,136 | \$162.47 | 1.000 | 0.936 | 1.068 | \$173.53 | \$143.82 |  |
| 5/21 | 10,438 | \$249.05 | 1.000 | 0.903 | 1.108 | \$275.89 | \$279.82 |  | 10,438 | \$160.55 | 1.000 | 0.933 | 1.071 | \$172.03 | \$149.00 |  |
| 6/21 | 10,695 | \$305.78 | 1.000 | 0.896 | 1.116 | \$341.17 | \$289.51 |  | 10,695 | \$160.77 | 1.000 | 0.942 | 1.061 | \$170.64 | \$151.69 |  |
| 7/21 | 11,018 | \$321.25 | 1.000 | 0.899 | 1.113 | \$357.47 | \$297.86 |  | 11,018 | \$174.25 | 1.000 | 0.955 | 1.047 | \$182.40 | \$156.16 |  |
| 8/21 | 11,287 | \$280.18 | 1.000 | 0.886 | 1.128 | \$316.08 | \$299.24 |  | 11,287 | \$174.04 | 1.000 | 0.969 | 1.032 | \$179.57 | \$160.27 |  |
| 9/21 | 11,573 | \$310.70 | 1.000 | 0.886 | 1.128 | \$350.48 | \$307.16 |  | 11,573 | \$172.04 | 1.000 | 0.965 | 1.036 | \$178.21 | \$163.93 |  |
| 10/21 | 11,615 | \$284.25 | 1.000 | 0.883 | 1.132 | \$321.84 | \$312.29 |  | 11,615 | \$164.89 | 1.000 | 0.964 | 1.038 | \$171.08 | \$165.45 |  |
| 11/21 | 11,561 | \$260.66 | 1.000 | 0.875 | 1.143 | \$298.03 | \$313.98 |  | 11,561 | \$190.34 | 1.000 | 0.975 | 1.026 | \$195.20 | \$169.72 |  |
| 12/21 | 11,479 | \$261.08 | 1.000 | 0.879 | 1.137 | \$296.90 | \$314.76 | 34.6\% | 11,479 | \$201.60 | 1.000 | 0.980 | 1.020 | \$205.71 | \$173.53 | 36.4\% |
| 1/22 | 14,245 | \$244.63 | 1.000 | 0.856 | 1.168 | \$285.83 | \$314.78 | 32.2\% | 14,245 | \$145.79 | 1.000 | 0.852 | 1.174 | \$171.15 | \$176.27 | 35.3\% |
| 2/22 | 15,760 | \$267.78 | 1.000 | 0.836 | 1.197 | \$320.49 | \$316.87 | 28.1\% | 15,760 | \$127.28 | 1.000 | 0.805 | 1.243 | \$158.17 | \$176.94 | 32.5\% |
| 3/22 | 15,549 | \$280.16 | 1.000 | 0.832 | 1.202 | \$336.74 | \$317.00 | 21.5\% | 15,549 | \$153.08 | 1.000 | 0.817 | 1.224 | \$187.38 | \$178.38 | 29.0\% |
| 4/22 | 15,504 | \$253.72 | 1.000 | 0.827 | 1.209 | \$306.75 | \$317.12 | 15.9\% | 15,504 | \$142.69 | 1.000 | 0.826 | 1.210 | \$172.68 | \$178.12 | 23.8\% |
| 5/22 | 15,409 | \$262.99 | 1.000 | 0.833 | 1.201 | \$315.80 | \$319.75 | 14.3\% | 15,409 | \$148.32 | 1.000 | 0.836 | 1.196 | \$177.43 | \$178.46 | 19.8\% |
| 6/22 | 15,378 | \$297.76 | 1.000 | 0.842 | 1.187 | \$353.50 | \$321.56 | 11.1\% | 15,378 | \$152.71 | 1.000 | 0.842 | 1.187 | \$181.31 | \$179.25 | 18.2\% |
| 7/22 | 15,552 | \$240.55 | 1.000 | 0.853 | 1.173 | \$282.06 | \$315.43 | 5.9\% | 15,552 | \$141.82 | 1.000 | 0.825 | 1.212 | \$171.89 | \$178.35 | 14.2\% |
| 8/22 | 15,602 | \$273.24 | 1.000 | 0.906 | 1.104 | \$301.60 | \$314.11 | 5.0\% | 15,602 | \$164.81 | 1.000 | 0.811 | 1.233 | \$203.15 | \$180.55 | 12.7\% |
| 9/22 | 15,614 | \$302.84 | 1.000 | 0.900 | 1.111 | \$336.34 | \$313.69 | 2.1\% | 15,614 | \$151.38 | 1.000 | 0.812 | 1.231 | \$186.32 | \$181.23 | 10.6\% |
| 10/22 | 15,618 | \$291.04 | 1.000 | 0.891 | 1.122 | \$326.67 | \$314.30 | 0.6\% | 15,618 | \$161.96 | 1.000 | 0.816 | 1.226 | \$198.49 | \$183.41 | 10.9\% |
| 11/22 | 15,635 | \$306.64 | 1.000 | 0.905 | 1.105 | \$338.94 | \$317.46 | 1.1\% | 15,635 | \$156.84 | 1.000 | 0.819 | 1.222 | \$191.60 | \$183.37 | 8.0\% |
| 12/22 | 15,547 | \$284.22 | 1.000 | 0.899 | 1.112 | \$316.10 | \$318.62 | 1.2\% | 15,547 | \$148.40 | 1.000 | 0.821 | 1.219 | \$180.83 | \$181.77 | 4.8\% |
| 1/23 | 15,547 | \$258.61 | 1.000 | 0.763 | 1.310 | \$338.80 | \$322.80 | 2.5\% | 15,547 | \$144.49 | 1.000 | 0.795 | 1.257 | \$181.64 | \$182.57 | 3.6\% |
| 2/23 | 15,547 | \$287.63 | 1.000 | 0.838 | 1.194 | \$343.36 | \$324.71 | 2.5\% | 15,547 | \$147.81 | 1.000 | 0.817 | 1.224 | \$180.87 | \$184.49 | 4.3\% |
| 3/23 | 15,547 | \$323.94 | 1.000 | 0.837 | 1.195 | \$387.03 | \$328.90 | 3.8\% | 15,547 | \$181.91 | 1.000 | 0.817 | 1.224 | \$222.58 | \$187.43 | 5.1\% |
| 4/23 | 15,547 | \$282.37 | 1.000 | 0.836 | 1.196 | \$337.62 | \$331.47 | 4.5\% | 15,547 | \$158.87 | 1.000 | 0.817 | 1.223 | \$194.37 | \$189.23 | 6.2\% |
| 5/23 | 15,547 | \$306.39 | 1.000 | 0.836 | 1.197 | \$366.67 | \$335.69 | 5.0\% | 15,547 | \$174.76 | 1.000 | 0.817 | 1.223 | \$213.79 | \$192.25 | 7.7\% |
| 6/23 | 15,547 | \$298.34 | 1.000 | 0.835 | 1.198 | \$357.26 | \$336.02 | 4.5\% | 15,547 | \$174.88 | 1.000 | 0.818 | 1.223 | \$213.92 | \$194.95 | 8.8\% |
| 7/23 | 15,547 | \$278.85 | 1.000 | 0.834 | 1.199 | \$334.40 | \$340.38 | 7.9\% | 15,547 | \$164.85 | 1.000 | 0.818 | 1.223 | \$201.63 | \$197.43 | 10.7\% |
| 8/23 | 15,547 | \$319.92 | 1.000 | 0.828 | 1.208 | \$386.35 | \$347.45 | 10.6\% | 15,547 | \$178.81 | 1.000 | 0.818 | 1.223 | \$218.68 | \$198.72 | 10.1\% |
| 9/23 | 15,547 | \$291.64 | 1.000 | 0.828 | 1.208 | \$352.39 | \$348.79 | 11.2\% | 15,547 | \$160.33 | 1.000 | 0.818 | 1.223 | \$196.07 | \$199.53 | 10.1\% |
| 10/23 | 15,547 | \$299.32 | 1.000 | 0.827 | 1.209 | \$361.99 | \$351.74 | 11.9\% | 15,547 | \$176.27 | 1.000 | 0.818 | 1.223 | \$215.54 | \$200.95 | 9.6\% |
| 11/23 | 15,547 | \$289.89 | 1.000 | 0.825 | 1.212 | \$351.47 | \$352.79 | 11.1\% | 15,547 | \$171.95 | 1.000 | 0.818 | 1.223 | \$210.24 | \$202.51 | 10.4\% |
| 12/23 | 15,547 | \$273.20 | 1.000 | 0.825 | 1.212 | \$331.19 | \$354.04 | 11.1\% | 15,547 | \$165.73 | 1.000 | 0.818 | 1.223 | \$202.62 | \$204.33 | 12.4\% |
| 1/24 | 15,547 | \$308.67 | 1.000 | 0.819 | 1.222 | \$377.05 | \$357.23 | 10.7\% | 15,547 | \$166.17 | 1.000 | 0.818 | 1.222 | \$203.14 | \$206.12 | 12.9\% |
| 2/24 | 15,547 | \$315.31 | 1.000 | 0.819 | 1.221 | \$385.13 | \$360.71 | 11.1\% | 15,547 | \$167.42 | 1.000 | 0.818 | 1.222 | \$204.65 | \$208.10 | 12.8\% |
| 3/24 | 15,547 | \$319.15 | 1.000 | 0.819 | 1.221 | \$389.76 | \$360.94 | 9.7\% | 15,547 | \$185.17 | 1.000 | 0.818 | 1.222 | \$226.32 | \$208.41 | 11.2\% |
| 4/24 | 15,547 | \$312.97 | 1.000 | 0.817 | 1.223 | \$382.89 | \$364.71 | 10.0\% | 15,547 | \$184.34 | 1.000 | 0.818 | 1.222 | \$225.29 | \$210.99 | 11.5\% |
| 5/24 | 15,547 | \$315.45 | 1.000 | 0.817 | 1.224 | \$386.03 | \$366.33 | 9.1\% | 15,547 | \$188.19 | 1.000 | 0.818 | 1.222 | \$229.98 | \$212.34 | 10.5\% |
| 6/24 | 15,547 | \$290.72 | 1.000 | 0.817 | 1.224 | \$355.73 | \$366.20 | 9.0\% | 15,547 | \$178.06 | 1.000 | 0.818 | 1.222 | \$217.58 | \$212.64 | 9.1\% |
| 7/24 | 15,547 | \$313.59 | 1.000 | 0.817 | 1.223 | \$383.66 | \$370.30 | 8.8\% | 15,547 | \$190.94 | 1.000 | 0.818 | 1.222 | \$233.30 | \$215.28 | 9.0\% |
| 8/24 | 15,547 | \$327.79 | 1.000 | 0.817 | 1.224 | \$401.12 | \$371.54 | 6.9\% | 15,547 | \$187.36 | 1.000 | 0.819 | 1.222 | \$228.90 | \$216.13 | 8.8\% |
| 9/24 | 15,547 | \$309.84 | 1.000 | 0.817 | 1.224 | \$379.10 | \$373.76 | 7.2\% | 15,547 | \$174.29 | 1.000 | 0.819 | 1.222 | \$212.92 | \$217.54 | 9.0\% |
| 10/24 | 15,547 | \$326.45 | 1.000 | 0.817 | 1.223 | \$399.38 | \$376.88 | 7.1\% | 15,547 | \$196.68 | 1.000 | 0.819 | 1.221 | \$240.25 | \$219.60 | 9.3\% |
| 11/24 | 15,547 | \$298.57 | 1.000 | 0.817 | 1.224 | \$365.36 | \$378.03 | 7.2\% | 15,547 | \$179.79 | 1.000 | 0.819 | 1.221 | \$219.59 | \$220.38 | 8.8\% |
| 12/24 | 15,547 | \$303.91 | 1.000 | 0.817 | 1.224 | \$371.85 | \$381.42 | 7.7\% | 15,547 | \$186.98 | 1.000 | 0.819 | 1.221 | \$228.36 | \$222.52 | 8.9\% |

Highmark Coverage Advantage

## Individual Market

Response to Objection 2 - Question 11

| Description | Medical | Rx | Total | Notes |
| :---: | :---: | :---: | :---: | :---: |
| 2022 Allowed 12-Month PMPM With Covid | \$ 318.62 | \$ 181.77 | \$ 500.39 | Source is supporting monthly PMPMs streams with Covid included. |
| 2024 Allowed 12-Month PMPM With Covid | \$ 381.42 | \$ 222.52 | \$ 603.94 | Source is supporting monthly PMPMs streams with Covid included. |
| 2022 Covid Adjustment |  |  | 1.010 | Please see Attachment G from filing submission |
| 2024 Covid Adjustment |  |  | 1.012 | Please see Attachment G from filing submission (prior to actuarial judgment) |
| 2022 Allowed 12-Month PMPM Without Covid |  |  | \$ 505.45 | Increase Claims to Remove Covid in 2022 |
| 2024 Allowed 12-Month PMPM Without Covid |  |  | \$ 596.78 | Decrease Claims to Remove Covid in 2024 |
| Allowed Annual Trend 2022 to 2024 |  |  | 8.7\% |  |
| Actuarial Judgment |  |  | 0.3\% | Reasonable range around deterministic estimate applied including consideration for enrollment changes and limited long-term historical data availability due to entity starting in 2020 |
| Required Annual Trend Before Induced Demand Factor |  |  | 9.00\% |  |
| Induced Demand Factor | 0.15\% | 0.15\% | 0.15\% | Difference in average metal AV from current benefits to 2024 benefits. |
| Required Annual Trend w/Induced Demand* |  |  | 9.17\% |  |

[^3]Highmark Coverage Advantage

## Individual Market

Response to Objection 2 - Question 11b

|  | Medical |  |  |  | Rx |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Incurred <br> Month | Population Mix | Cost Savings | Provider Shift | Cumul Factor | Population Mix | Cost Savings | Provider Shift | Cumul Factor |
| 1/20 | 1.06 | 1.00 | 1.00 | 1.06 | 0.94 | 1.00 | 1.00 | 0.94 |
| 2/20 | 1.06 | 1.00 | 1.00 | 1.06 | 0.96 | 1.00 | 1.00 | 0.96 |
| 3/20 | 1.05 | 1.00 | 1.00 | 1.05 | 0.97 | 1.00 | 1.00 | 0.97 |
| 4/20 | 1.03 | 0.99 | 1.00 | 1.02 | 0.98 | 1.00 | 1.00 | 0.98 |
| 5/20 | 1.00 | 0.99 | 1.00 | 0.99 | 1.00 | 1.00 | 1.00 | 1.00 |
| 6/20 | 0.99 | 0.99 | 1.00 | 0.98 | 0.98 | 1.00 | 1.00 | 0.98 |
| 7/20 | 0.99 | 0.99 | 1.00 | 0.98 | 0.98 | 1.00 | 1.00 | 0.98 |
| 8/20 | 0.98 | 0.99 | 1.00 | 0.97 | 1.00 | 1.00 | 1.00 | 1.00 |
| 9/20 | 0.96 | 0.99 | 1.00 | 0.95 | 0.98 | 1.00 | 1.00 | 0.98 |
| 10/20 | 0.95 | 0.99 | 1.00 | 0.94 | 0.98 | 1.00 | 1.00 | 0.98 |
| 11/20 | 0.94 | 0.99 | 1.00 | 0.92 | 0.95 | 1.00 | 1.00 | 0.94 |
| 12/20 | 0.93 | 0.99 | 1.00 | 0.92 | 0.96 | 1.00 | 1.00 | 0.96 |
| 1/21 | 0.94 | 0.98 | 1.00 | 0.92 | 0.88 | 0.99 | 1.00 | 0.88 |
| 2/21 | 0.95 | 0.97 | 1.00 | 0.92 | 0.86 | 0.99 | 1.00 | 0.84 |
| 3/21 | 0.96 | 0.97 | 1.00 | 0.93 | 0.87 | 0.99 | 1.00 | 0.85 |
| 4/21 | 0.94 | 0.96 | 1.00 | 0.91 | 0.95 | 0.99 | 1.00 | 0.94 |
| 5/21 | 0.94 | 0.96 | 1.00 | 0.90 | 0.95 | 0.99 | 1.00 | 0.93 |
| 6/21 | 0.94 | 0.96 | 1.00 | 0.90 | 0.96 | 0.98 | 1.00 | 0.94 |
| 7/21 | 0.94 | 0.95 | 1.00 | 0.90 | 0.97 | 0.98 | 1.00 | 0.96 |
| 8/21 | 0.93 | 0.95 | 1.00 | 0.89 | 0.99 | 0.98 | 1.00 | 0.97 |
| 9/21 | 0.93 | 0.95 | 1.00 | 0.89 | 0.98 | 0.98 | 1.00 | 0.97 |
| 10/21 | 0.93 | 0.95 | 1.00 | 0.88 | 0.98 | 0.98 | 1.00 | 0.96 |
| 11/21 | 0.92 | 0.95 | 1.00 | 0.87 | 0.99 | 0.98 | 1.00 | 0.98 |
| 12/21 | 0.93 | 0.95 | 1.00 | 0.88 | 1.00 | 0.98 | 1.00 | 0.98 |
| 1/22 | 0.91 | 0.94 | 1.00 | 0.86 | 0.87 | 0.98 | 1.00 | 0.85 |
| 2/22 | 0.89 | 0.94 | 1.00 | 0.84 | 0.82 | 0.98 | 1.00 | 0.80 |
| 3/22 | 0.89 | 0.94 | 1.00 | 0.83 | 0.84 | 0.98 | 1.00 | 0.82 |
| 4/22 | 0.89 | 0.93 | 1.00 | 0.83 | 0.85 | 0.98 | 1.00 | 0.83 |
| 5/22 | 0.89 | 0.93 | 1.00 | 0.83 | 0.86 | 0.98 | 1.00 | 0.84 |
| 6/22 | 0.90 | 0.93 | 1.00 | 0.84 | 0.86 | 0.98 | 1.00 | 0.84 |
| 7/22 | 0.92 | 0.93 | 1.00 | 0.85 | 0.85 | 0.98 | 1.00 | 0.83 |
| 8/22 | 0.97 | 0.93 | 1.00 | 0.91 | 0.83 | 0.98 | 1.00 | 0.81 |
| 9/22 | 0.98 | 0.92 | 1.00 | 0.90 | 0.83 | 0.98 | 1.00 | 0.81 |
| 10/22 | 0.97 | 0.92 | 1.00 | 0.89 | 0.84 | 0.98 | 1.00 | 0.82 |
| 11/22 | 0.98 | 0.92 | 1.00 | 0.90 | 0.84 | 0.98 | 1.00 | 0.82 |
| 12/22 | 0.98 | 0.92 | 1.00 | 0.90 | 0.84 | 0.98 | 1.00 | 0.82 |
| 1/23 | 0.84 | 0.91 | 1.00 | 0.76 | 0.82 | 0.97 | 1.00 | 0.80 |
| 2/23 | 0.92 | 0.91 | 1.00 | 0.84 | 0.84 | 0.97 | 1.00 | 0.82 |
| 3/23 | 0.92 | 0.91 | 1.00 | 0.84 | 0.84 | 0.97 | 1.00 | 0.82 |
| 4/23 | 0.92 | 0.91 | 1.00 | 0.84 | 0.84 | 0.97 | 1.00 | 0.82 |
| 5/23 | 0.92 | 0.91 | 1.00 | 0.84 | 0.84 | 0.97 | 1.00 | 0.82 |
| 6/23 | 0.92 | 0.91 | 1.00 | 0.84 | 0.84 | 0.97 | 1.00 | 0.82 |
| 7/23 | 0.92 | 0.91 | 1.00 | 0.83 | 0.84 | 0.97 | 1.00 | 0.82 |
| 8/23 | 0.92 | 0.90 | 1.00 | 0.83 | 0.84 | 0.97 | 1.00 | 0.82 |
| 9/23 | 0.92 | 0.90 | 1.00 | 0.83 | 0.84 | 0.97 | 1.00 | 0.82 |
| 10/23 | 0.92 | 0.90 | 1.00 | 0.83 | 0.84 | 0.97 | 1.00 | 0.82 |
| 11/23 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |
| 12/23 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |
| 1/24 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |
| 2/24 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |
| 3/24 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |
| 4/24 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |
| 5/24 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |
| 6/24 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |
| 7/24 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |
| 8/24 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |
| 9/24 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |
| 10/24 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |
| 11/24 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |
| 12/24 | 0.92 | 0.89 | 1.00 | 0.82 | 0.84 | 0.97 | 1.00 | 0.82 |

August 8, 2023

Mr. Michael Hibbert, Actuary
Bureau of Life, Accident \& Health Insurance
Commonwealth of Pennsylvania Insurance Department
1311 Strawberry Square
Harrisburg, PA 17120
Re: Highmark Coverage Advantage 2024 ACA Rate Filing (Individual Market)
Highmark Filing \# 1A-DP-23-HCA (SERFF Filing \# HGHM-133630381)
Dear Mr. Hibbert:
Enclosed are responses to your August 4, 2023 questions regarding SERFF Filing \# HGHM133630381. We have included your questions along with our responses for your convenience.

Should you have any further questions regarding this Filing, please feel free to contact me at or via e-mail at:

Sincerely,


Actuarial Director, Individual Markets Highmark Inc.

1. The following questions pertain to the COVID-19 adjustment factor:
a. Please provide a detailed quantitative exhibit displaying the development of the Company's adjustments to reflect the impact of COVID-19 on claims in 2022 due to testing, COVID-19 treatment, vaccines, and deferred care. In providing your response, please include the actual 2022 monthly claims experience that was considered, the estimated claims experience that was developed to estimate a 2022 non-COVID-19 baseline, and the detailed figures/adjustments that were utilized to develop the estimated claims experience for the 2022 non-COVID-19 baseline. Additionally, please provide a list of identifiers such as ICD codes by category used to identify COVID-19 claims.
b. Please provide a detailed quantitative exhibit displaying the development of the Company's adjustments to reflect the impact of COVID-19 on claims in 2024 due to testing, COVID-19 treatment, vaccines, and deferred care.

Response:
a. Please see the Objection 2, Question 5 response dated July 14, 2023 for the development of the Company's 2022 adjustment to medical claims for COVID-19. Please see the attached exhibit labeled Q1a Response for the development of the Company's 2022 adjustment to drug claims for COVID-19. The impact of Capacity / Avoided Care is net of Treatment Costs. The CPT/HCPCS codes used to identify COVID testing and vaccine claims are provided in Table 2.
b. Please see the attached exhibit labeled Q1b Response for the development of the Company's 2024 adjustment to claims for COVID-19.
2. Please provide a detailed quantitative exhibit displaying the underlying assumptions and justify numerically the ' 2022 Medical Allowed Baseline' as shown in row 27 of the Q5 Response tab of the Objection 2 Response Exhibits.

Response:
Please see the attached exhibit labeled Q2 Response for the development of the ' 2022 Medical Allowed Baseline' value shown in the Objection 2, Question 5 response dated July 14, 2023.
3. Please list what lines of business are included in the Commercial experience from the Q5 Response tab of the Objection 2 Response Exhibits.

Response:
Commercial Experience includes all Commercial Direct Pay, Small Group, and Large Group members living in that region.
4. Please explain why the difference between the Actual 2022 Medical Allowed w/o COVID-19 costs and the Estimated 2022 Medical Allowed Baseline from the Q5 Response tab of the Objection 2 Response Exhibits is fully attributable to impacts due to capacity and avoided care.

Response:
Evaluating and quantifying the impact of COVID-19 has been a complex process since the start of the pandemic and remains that way even now. Although there may be several reasonable approaches to take in an attempt to assess these impacts, we have chosen to evaluate the capacity and avoided care impacts by comparing actual claim costs to a baseline as described previously. Our belief was that, by using such
a large population, we would minimize the need to make further adjustments (for things like risk or product type mix) and isolate just these specific COVID-19 related costs.

## 5. Please provide a detailed quantitative exhibit and qualitative narrative that explains the $\mathbf{2 . 1 \%}$ CY24 adjustment due to drug vaccines since it was only worth $0.5 \%$ in CY22. Please note that these values are from the drug portion of the COVID-19 adjustment.

Response:
The quantitative development of the $2.1 \%$ CY24 adjustment factor can be found in the Question 1b Table 2 response.

The federal public health emergency ended on May 11, 2023, resulting in a shift in costs for the COVID19 vaccine to the private market. Since COVID-19 vaccines will remain free as long as federally purchased supply is available, we expect costs to increase over time, starting at the end of 2023 and grading upward through 2025.

Additional details have emerged since the time of this rate filing that support the Company's view regarding the federally purchased supply. The federal supply is likely to become obsolete based on recent FDA recommendations for single strain booster shots targeting the currently circulating Omicron variant. This may result in a shift to private suppliers sooner than originally anticipated.

As described in the Actuarial Memorandum, it is important to note that the Company reviewed the composite COVID-19 impact and elected to temper the adjustment in light of the inherent unpredictability of these estimates. The actuarial judgement factor of $(0.7 \%)$ can be found in Attachment $G$.

Highmark Coverage Advantage

## Individual Market

## Response to Objection 3 -Question 1a

Table 1 - Drug Development

| CY2022 COVID-19 Adjustment Development | PMPM | $\%$ |
| :--- | :---: | :---: |
| Estimated Total Drug PMPM | $\$ 113.04$ |  |
|  |  |  |
| Estimated 2022 COVID-19 Drug Costs |  |  |
| $\quad$ Testing | $\$ 0.69$ | $0.6 \%$ |
| Vaccines | $\$ 0.66$ | $0.6 \%$ |
| Capacity / Avoided Care | $\$ 0.00$ | $\underline{0.0 \%}$ |
| Total Drug Impact of COVID-19 | $\$ 1.35$ | $1.2 \%$ |

Table 2 - COVID Testing \& Vaccine CPT/HCPCS Codes

| Testing Codes |  |
| :---: | :---: |
| 86328 | 0202 U |
| 86408 | 0223 U |
| 86409 | 0224 U |
| 86413 | 0225 U |
| 86769 | 0226 U |
| 87426 | 0240 U |
| 87428 | 0241 U |
| 87635 | U 0001 |
| 87636 | U 0002 |
| 87637 | U 0003 |
| 87811 | $\mathrm{U0004}$ |
|  | U 0005 |


| Vaccine Codes |  |  |  |  |
| :--- | :--- | :---: | :--- | :--- |
| 0001A | 0042A | 0083 A | 0154 A | 91312 |
| 0002A | 0051A | 0091 A | 91300 | 91313 |
| 0003A | 0052A | 0092 A | 91301 | 91314 |
| 0004A | 0053A | 0093 A | 91302 | 91315 |
| 0011A | 0054A | 0094 A | 91303 | 93108 |
| 0012A | 0064A | 0104 A | 91304 | M0201 |
| 0013A | 0071A | 0111A | 91305 |  |
| 0021A | 0072A | 0112A | 91306 |  |
| 0022A | 0073A | 0113A | 91307 |  |
| 0031A | 0074A | 0124A | 91309 |  |
| 0034A | 0081A | 0134A | 91310 |  |
| 0041A | 0082A | 0144A | 91311 |  |

## Highmark Coverage Advantage

## Individual Market

## Response to Objection 3 - Question 1b

Table 1 - Medical Development

| CY2024 COVID-19 Adjustment Development | PMPM | $\%$ |
| :--- | :---: | :---: |
| Estimated 2024 Medical Allowed Baseline | $\$ 481.41$ |  |
|  |  |  |
| Estimated 2024 COVID-19 Costs | $\$ 3.17$ | $0.7 \%$ |
| $\quad$ Testing | $\$ 0.55$ | $0.1 \%$ |
| $\quad$ Vaccines | $\$ 0.00$ | $\underline{0.0 \%}$ |
| Capacity / Avoided Care | $\$ 3.72$ | $0.8 \%$ |
| Total Medical Impact of COVID-19 |  |  |

Table 2 - Drug Development

| CY2024 COVID-19 Adjustment Development | PMPM | $\%$ |
| :--- | :---: | :---: |
| Estimated Total Drug PMPM | $\$ 113.04$ |  |
|  |  |  |
| Estimated 2024 COVID-19 Drug Costs |  |  |
| $\quad$ Testing | $\$ 0.00$ | $0.0 \%$ |
| Vaccines | $\$ 2.38$ | $2.1 \%$ |
| $\quad$ Capacity / Avoided Care | $\$ 0.00$ | $\underline{0.0 \%}$ |
| Total Drug Impact of COVID-19 | $\$ 2.38$ | $2.1 \%$ |

## Highmark Coverage Advantage

Individual Market

## Response to Objection 3 - Question 2

|  | Commercial |  |  |  | Direct Pay ACA |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\mathbf{2 0 1 9}$ | Annualized | 2022 Baseline | 2022 Average | 2022 Average | 2022 Member | Composite PMPM |
|  | PMPM | Baseline Trend $^{\mathbf{1}}$ | PMPM $^{\mathbf{2}}$ | Members | Members | Weight | Using ACA Weights |
| Child | $\$ 184.73$ | $5.2 \%$ | $\$ 214.99$ | 152,438 | 841 | $5.4 \%$ |  |
| Adult | $\$ 421.82$ | $3.4 \%$ | $\$ 465.77$ | 575,256 | 14,610 | $94.6 \%$ |  |
| Total |  |  |  |  | $\mathbf{1 5 , 4 5 1}$ | $\mathbf{1 0 0 . 0 \%}$ | \$452.11 |

[^4]


# Rating Area Data Collection 

Specify the total number of Rating Areas in your State by selecting the Create Rating Areas button or Ctrl + Shift + R Select only the Rating Areas you are offering plans within and add a factor for each area.
To validate, select the Validate button or Ctrl + Shift + I.

| Rating Area | Rating Factor |  |
| :--- | :--- | :--- |
| Rating Area 1 | 0.9400 |  |
| Rating Area 4 | 0.9400 |  |

# Part III Actuarial Memorandum 

## Highmark Coverage Advantage

Individual Rate Filing
Effective January 1, 2024

## TABLE OF CONTENTS

I. General Information ..... 3
II. Proposed Rate Changes ..... 4
III. Experience and Current Period Premium, Claims, and Enrollment ..... 4
IV. Benefit Categories ..... 5
V. Projection Factors ..... 6
VI. Manual Rate Adjustments ..... 8
VII. Credibility of Experience ..... 8
VIII. Index Rate ..... 8
IX. Market Adjusted Index Rate [MAIR] ..... 8
X. Plan Adjusted Index Rate [PAIR] ..... 9
XI. Calibration ..... 10
XII. Projected Loss Ratio ..... 11
XIII. AV Metal Values ..... 11
XIV. Membership Projections ..... 11
XV. Terminated Plans and Products ..... 12
XVI. Plan Type ..... 12
XVII. Actuarial Certification ..... 12
XVIII. Exhibit I ..... 14

## I. General Information

## Document Overview

This document contains the Part III Actuarial Memorandum for Highmark Coverage Advantage's (HCA) individual block of business rate filing, for products with an effective date of January 1, 2024. This actuarial memorandum is submitted in conjunction with the Part I Unified Rate Review Template.

The purpose of the actuarial memorandum is to provide certain information related to the submission, including support for the values entered into the Part I Unified Rate Review Template, which supports compliance with the market rating rules and reasonableness of applicable rate increases. This information may not be appropriate for other purposes.

This information is intended for use by the Pennsylvania Insurance Department ("Department"), the Center for Consumer Information and Insurance Oversight (CCIIO), and their subcontractors to assist in the review of HCA's rate filing. However, we recognize that this certification may become a public document. HCA makes no representations or warranties regarding the contents of this letter to third parties. Likewise, third parties are instructed that they are to place no reliance upon this actuarial memorandum that would result in the creation of any duty or liability under any theory of law by HCA.

The results are actuarial projections. Actual experience is likely to differ for a number of reasons, including population changes, claims experience, and random deviations from assumptions.

## I. 1 Company Identifying Information:

- Company Legal Name: Highmark Coverage Advantage
- State: The Commonwealth of Pennsylvania has regulatory authority over these policies.
- HIOS Issuer ID: 79279
- Market: Individual
- Effective Date: January 1, 2024


## I. 2 Company Contact Information:

- Primary Contact Name:
- Primary Contact Telephone Number:
- Primary Contact Email Address:


## II. Proposed Rate Changes

For all rate changes by plan, see the 'Cumulative Rate Change \% (over 12 mos prior)' found in Worksheet 2, line 1.11 of the URRT. The rate change varies by plan due to an update in several of our pricing factors and changes in cost sharing required to meet Actuarial Value and other cost sharing restrictions under the Affordable Care Act as well as mappings between discontinued and new plans.

The primary drivers of the rate increase are cost and utilization trend.
In accordance with the Department's updated recent rate filing guidance, the impact of the state 1332 Reinsurance program is captured using the prescribed parameters of $\$ 60,000$ attachment point, $50 \%$ coinsurance rate, and $\$ 100,000$ reinsurance cap. If the finalized parameters differ from those described in this filing, a revised submission would be required.

Other assumptions in the filing account for the ongoing impact of COVID-19 and the lack of Federal CSR funding. Finally, modifications to the rate development may be necessary if significant unforeseen events occur. Examples include, but are not limited to, changes in legislation/regulations (including rules, regulatory guidance, etc.), changes in the participation of QHP issuers that would materially impact risk adjustment transfer amounts, Medicaid redetermination policy impacts, or material developments in COVID-19 impacts. As a result, HCA reserves the right to submit a revised filing.

## III. Experience and Current Period Premium, Claims, and Enrollment

## III. 1 Paid through Date:

Experience Period claims were based on incurred calendar year 2022, paid through February 2023. This includes 2022 experience in Affordable Care Act compliant plans. HCA did not offer any transitional plans in 2022.

## III. 2 Current Date:

The current date shown represents a snapshot of February 1, 2023.

## III. 3 Allowed and Paid Claims Incurred During the Experience Period:

- Historical Experience: We chose HCA's current experience for the individual block of business for the period January 1, 2022 through December 31, 2022, with claims paid through February, 2023 as the basis for the 2024 projected individual market pricing.
- Claims Incurred During the 12-month Experience Period: Worksheet 1, Section I shows our best estimate of the amount of claims that were incurred during the 12month experience period for HCA's individual book-of-business. This section includes:
- The amount of claims which were processed through Company's claims system,
- Claims processed outside of the Company's claims system, and
- Our best estimate of claims incurred but not paid as of the paid through date stated above.
- Method for Determining Allowed Claims: For non-capitated claims, the allowed charges are summarized from The Company's detailed claim-level historical data. This experience includes 2022 claims for Affordable Care Act compliant business. For capitated and other off-system claims, historical capitations and experience were tabulated and added to the claims.
- Paid Claims: We also summarized the paid claims from detailed member records. The paid-to-allowed ratio for the experience period reflects the 2022 plan designs chosen by each member.
- Incurred but Not Paid (IBNR) Claims Estimate: The Company is using a completion factor of 0.9846 to include IBNR claims in allowed charges. The IBNR completion factor was developed using our corporate reserving system for The Company's individual business. We applied it equally to both paid and allowed total claims (as a change to utilization) to complete the experience.


## IV. Benefit Categories

The index rate of the experience period was summarized at the defined benefit categories included in Worksheet 1, Section II of the URRT.

The data provided in this section closely adheres to the preferred definitions of the Benefit Categories included in the URRT instructions, including the "Other Medical" category. The "Other Medical" category units reflect visits for PDN/home health, trips for ambulance and procedures for DME/prosthetics. Prescription drugs utilization were converted to a "per 30day" script count.

## V. Projection Factors

## V. 1 Trend Factors

This development of the CY2024 rates reflects an annual trend rate of $9.0 \%$ ( $5.0 \%$ cost, $3.8 \%$ utilization). These trends reflect HCA's expectations regarding increases in in-network contractual reimbursement and out-of-network costs. These estimates measure and normalize for some of the more explainable variables such as high dollar claims, work days, provider contracting, demographics, and seasonality.

The trend represents a blended average for all types of service and is applied to the aggregate experience for pricing. These trends represent assumed community-wide expectations. Claim variations due to the specific projected enrolled population in this single risk pool are reflected in the morbidity adjustment.

## V. 2 Changes in the Morbidity of the Population Insured

The Change in Morbidity adjustment of 0.991 is comprised of the following: the morbidity impact from claims experience and an adjustment to account for the impact of Covid-19. In accordance with the Department's guidance, the morbidity change related to the Reinsurance program is set to 1.000 . Each of the components is described in more detail below.

## The Morbidity Impact from Claims Experience

This adjustment reflects the change in the population mix/claim levels from the experience period to the projection period. We continue to observe a high degree of membership churn from year-to-year, which impacts the morbidity. This factor also takes into consideration the effects of adverse selection inherent to guaranteed issue markets. The Individual ACA risk pool continues to have a significantly higher proportion of older members with a high prevalence of chronic conditions compared to group business, which adds to the uncertainty of any future claim projections.

## Covid-19 Impact

In order to account for the impact of COVID-19 on projected claim costs, the Company took the following steps:

1. Adjusted the claims in the base experience period to a non-COVID-19 baseline. This was done to stabilize the base from which claims are being projected. The base period adjustment accounts for the impacts of testing, treatment, vaccines, capacity constraints, and deferred/rescheduled/induced care. Claims in the base experience period were decreased by a factor of 0.999 to remove the impact of COVID-19.
2. Projected claims to the projection period using trends with the impact of COVID-19 excluded. Again, this provides for a more stable projection of future claims, before applying the anticipated impact of COVID-19 in the projection period. This was
accomplished by applying a trend of $9.0 \%$ (which excludes any impact from COVID19) to our adjusted BEP claims.
3. The projected claims were then further adjusted by applying the anticipated impacts of COVID costs expected in the projection period. The following components were accounted for:
a. COVID Testing ( $0.7 \%$ medical claims impact) - Proportional to new cases, which are assumed to diminish over time and be lower in the projection period than in previous years.
b. Vaccines ( $0.1 \%$ medical and $2.1 \%$ drug claims impact) - The federal public health emergency ended on May 11, 2023, resulting in a shift in costs for the COVID-19 vaccine to the private market. Since COVID-19 vaccines will remain free as long as federally purchased supply is available, we expect costs to increase over time, starting at the end of 2023 and grading upward through 2025. Due to a decline in demand, we also assumed utilization will decrease through 2024.
c. Actuarial Judgement ( $-0.7 \%$ claims impact) - The Company reviewed the composite CY2024 COVID impact resulting from the components outlined above and elected to temper the adjustment in light of the inherent unpredictability of these estimates.
The application of the above COVID claim adjustments to the rating period results in a COVID adjustment factor of 1.004 .

## V. 3 Changes in Demographics

We project that the average rating factor (age, tobacco load and area combined) will increase by about $0.6 \%$ due to the change in the population. This is primarily due to the expectation that the new members from the group and/or uninsured populations to be slightly older than the population in the underlying experience. This increases the projected allowed claims (utilization) by the same amount.

## V. 4 Changes in Benefits

There is no change in benefits related to the essential health benefit (EHB) categories so the factor is set to 1.0. The cost sharing changes for the EHBs are captured in the paid to allowed ratio factors discussed in the AV and Cost Sharing Design of Plan section X.1.

## V. 5 Changes in Other

The 0.959 factor represents the combined impact of changes in network, induced demand, pharmacy rebates, hospital/physician settlements, and state mandates/laws (when applicable).

## VI. Manual Rate Adjustments

HCA's individual experience is fully credible. No manual rate is developed or used in this projection.

## VII. Credibility of Experience

The experience is from HCA's individual book of business in 2022. It is large enough to be fully credible. Our results are based $100 \%$ on the experience rate, as adjusted.

## VIII. Index Rate

The index rates as shown on Worksheet 1 of the URRT are simply the single risk pool average allowed claims for the Essential Health Benefits for the experience and projected populations, respectively, for HCA. For the experience period, only non-grandfathered plans are included. The projection period Index Rate is not adjusted for reinsurance or risk adjustment programs or any other fee.

## IX. Market Adjusted Index Rate [MAIR]

The Market Adjusted Index Rate is the Projected Index Rate further adjusted for risk adjustment and the exchange fee.

## IX. 1 Projected Reinsurance PMPM

In accordance with the Department's updated recent rate filing guidance, the impact of the state 1332 Reinsurance Program is captured using the following parameters for 2024: an attachment point of $\$ 60,000$, a coinsurance rate of $50 \%$, and a cap of $\$ 100,000$. HCA estimated the impact of the reinsurance program under these tentative parameters by trending Highmark PA individual ACA CY2022 incurred claims by member to the CY2024 rating period, applying the parameters, and calculating the amount of incurred claims expected to be reimbursed by the program. The modeling produced an estimated incurred claims savings of $4.5 \%$. This percentage was converted to a PMPM and adjusted to an equivalent allowed claim basis by dividing the PMPM by the paid-to-allowed factor and the composite effect of catastrophic eligibility. This amount is reflected in worksheet 1 of the URRT.

## IX. 2 Projected Risk Adjustment PMPM

The estimated average risk score for HCA's projected 2024 population was developed by using HCA's 2022 claim diagnoses and the risk adjustment coefficients as finalized in the Notice of Benefit and Payment Parameters. Similarly, actuarial value factors and induced demand factors were estimated for HCA based upon its projected 2024 population.

We estimated the statewide average risk transfer factors based on current market assumptions. We estimated the statewide average premium using current market premium assumptions with adjustments for anticipated rate changes for 2024.

The actual calculation of the risk transfer followed the risk transfer methodology as prescribed.
The analysis resulted in HCA paying to the risk adjustment pool. The (69.98) PMPM value shown in worksheet 1 of the URRT is developed by taking the expected risk transfer amount plus the projected High Cost Risk Pool charge and adjusting it to an equivalent allowed claims basis by dividing it by the paid-to-allowed factor and the composite effect of catastrophic eligibility and benefits in addition to EHB.

For the purposes of this rate filing, HCA has assumed no adjustment to the projected risk adjustment transfer for the Risk Adjustment Data Validation (RADV) program.

## IX. 3 Exchange User Fee \%

The $3.14 \%$ value shown in worksheet 1 of the URRT is developed by multiplying the $3 \%$ exchange user fee by the assumed percentage of on exchange membership. This calculated amount is then divided by the paid-to-allowed factor to bring it to an equivalent allowed claims basis and adjusted further for the composite effect of catastrophic eligibility and benefits in addition to EHB.

## X. Plan Adjusted Index Rate [PAIR]

The Plan Adjusted Index Rates can be found on line 3.10, Worksheet 2 of the URRT. The PAIR rates are calculated by applying the allowable rating factors as described below to the Market Adjusted Index Rate.

## X. 1 AV and Cost Sharing Design of Plan

The AV and Cost Sharing allowable rating factor is comprised of the following components:

- The utilization due to differences in cost sharing is based on the factors calculated using a methodology prescribed in the Department's guidance relative to the weighted average. No differences due to health status are in these adjustments.
- The pricing AV for the benefits and cost sharing of the plan and a CSR load for the on exchange silver plans.


## Impact of Non-Payment of Cost Sharing Reduction Subsidies

In accordance with the Department's guidance, we have applied an additional adjustment to our AV pricing values for those Silver plans not offered exclusively off-exchange. This adjustment factor was 1.23 and represents the non-payment of Cost Sharing Reduction subsidies.

## X. 2 Provider Network Adjustment

The provider network adjustments are developed by dividing the plan level network factors by the overall weighted average from all plans.

## X. 3 Benefits in Addition to EHB

Non-EHB benefits have been added to several plans. Five plans have an adult dental and vision benefit and four plans have a hearing and an OTC benefit.

## X. 4 Administrative Expense

The proposed rates reflect internal administrative costs including quality improvement administrative expenses. This cost was developed based on standard expense allocation methods.

## X. 5 Taxes and Fees:

The following fees were added:

- \$0.21 PMPM for Risk Transfer User Fee
- \$0.29 PMPM for Patient Centered Outcomes Research Insitute (PCORI) Fee
- $0.0 \%$ for the Health Insurance Provider Fee
- $0.0 \%$ for the PA Premium Tax


## X. 6 Profit (or Contribution to Surplus) \& Risk Margin:

HCA has voluntarily refrained from including a risk and contingency factor in this filing. By this voluntary restraint, HCA is not waiving any right to include a risk and contingency factor which HCA believes is consistent with historical and legal interpretations of HCA and the Pennsylvania Insurance Department.

## X. 7 Catastrophic Adjustment

For catastrophic plans, we use a 0.92 factor for the specific eligibility adjustment.

## XI. Calibration

## XI. 1 Age Curve Calibration:

The projected weighted average age factor for billable members is 1.7522 . This factor is calculated by dividing the all members age factor of 1.7511 by the ratio of billable members to total members 0.9994 . The age curve calibration factor is $1 / 1.7522=0.5707$.

## XI. 2 Geographic Calibration Factor:

The projected weighted average geographic factor is 0.940 . Each Plan Adjusted Index Rate represents the rate for an average member with a geographic factor of 0.940 . The geographic calibration factor is $1 / 0.940=1.0638$.

## XI. 3 Tobacco Calibration Factor:

The projected weighted average tobacco factor is 1.0065 . Each Plan Adjusted Index Rate represents the rate for an average member with a tobacco factor of 1.0065 . The tobacco calibration factor is $1 / 1.0065=0.9935$.

## XI. 4 Consumer Adjusted Premium Rate Development:

The calibrated plan adjusted index rate represents the base rate for an age factor of 1.0, geographic rating factor of 1.0 and tobacco rating factor of 1.0 . Thus, the approximate premium for a specific member can be derived by multiplying this rate by the HHS age curve factor, the rating area factor on Worksheet 3 of the URRT, and the appropriate tobacco factor. Please note that this method will only produce approximate rates due to URRT rounding constraints.

## XII. Projected Loss Ratio

The projected loss ratio for 2024 using the federally-prescribed MLR methodology is $88.5 \%$.

## XIII. AV Metal Values

The AV Metal Values included in Worksheet 2 of the Part I Unified Rate Review Template were based the Federal AV Calculator. Some plans did require an adjustment to the inputs entered into the AV calculator. Screen shots and certifications for these plans were submitted as part of HCA's QHP application. Per CMS's guidance, a dummy AV Metal Value was applied to any terminated plans that fell out of the new de minimis range.

## XIV. Membership Projections

Membership projections reflect HCA's expectations for 2024. These projections reflect expected changes in market share due to market competition, relative price levels, and changes in plan offerings (where applicable).

HCA expects membership in 2024 to follow a similar metal level distribution as the Individual ACA experience period in the markets where plans will continue to be offered.

For the Silver level plans, the projected membership by cost sharing subsidy levels is based on the observed distribution of ACA members that were eligible under the federal poverty levels as determined by the federal health insurance exchange. The projected enrollment by plan and subsidy level is as follows:

| CSR Silver Plan Membership Distribution |  |  |  |
| :--- | :---: | :---: | :---: |
| FPL | Subsidy Level | \% of <br> Silver Membership | \% of <br> Total Membership |
| $<150 \%$ | $94 \%$ | $42.1 \%$ | $7.3 \%$ |
| $150 \%-200 \%$ | $87 \%$ | $45.3 \%$ | $7.8 \%$ |
| $200 \%-250 \%$ | $73 \%$ | $3.1 \%$ | $0.5 \%$ |
| $>250 \%$ | $\underline{90 \%}$ | $\underline{9.5 \%}$ | $\underline{1.6 \%}$ |
| Total |  | $100.0 \%$ | $17.2 \%$ |

## XV. Terminated Plans and Products

Plans in the 2022 experience period that will no longer be available in 2024 can be found in Exhibit I.

HCA also has some plans that were offered only in 2023 (not offered in the experience period or in the projection period). These plans are shown in Exhibit I.

## XVI. Plan Type

The Plan types listed in Worksheet 2, Section I of the Part I Unified Rate Review Template describe HCA's plans adequately.

## XVII. Actuarial Certification

I, , am a member of the American Academy of Actuaries and meet its qualification standards for actuaries issuing statements of actuarial opinions in the United States. All statements in this actuarial certification are accurate to the best of my knowledge and understanding. This filing is prepared in compliance with applicable Actuarial Standards of Practice. In completing this filing, I relied on data/information from other sources which was reviewed for reasonableness. This filing is prepared on behalf of HCA to accompany its rate filing for the Individual Market on and off the Pennsylvania Exchange.

I hereby certify that the projected index rate is, to the best of my knowledge and understanding:

- In compliance with all applicable State and Federal Statutes and Regulations (45 CFR 156.80 and 147.102),
- Developed in compliance with the applicable Actuarial Standards of Practice
- Reasonable in relation to the benefits provided and the population anticipated to be covered
- Neither excessive nor deficient.

I certify that the index rate and only the allowable modifiers as described in 45 CFR 156.80(d)(1) and 45 CFR 156.80 (d)(2) were used to generate plan level rates.

I certify that the AV Calculator was used to determine the AV Metal Values shown in Worksheet 2 of the Part I Unified Rate Review Template for all plans. The AV Metal Values included in Worksheet 2 of the Part I Unified Rate Review Template were based on the Federal AV Calculator. If any adjustments were required outside of the AV Calculator, appropriate certification has been provided to CMS through the QHP application process.

I certify that the geographic rating reflect only differences in the costs of delivery (which can include unit cost and provider practice pattern differences) and do not include differences for population morbidity by geographic area.

The Part I Unified Rate Review Template does not demonstrate the process used by HCA to develop the rates. Rather, it represents information required by Federal regulation to be provided in support of the review of rate increases, for certification of qualified health plans for Federally facilitated exchanges and for certification that the index rate is developed in accordance with Federal regulation and used consistently and only adjusted by the allowable modifiers.


Title: Actuarial Director, Individual Markets
Date: August 17, 2023

## XVIII. Exhibit I

## Highmark Coverage Advantage

## Terminated Experience Period Plans

| HIOS ID | Metal | Plan Name | 2024 Mapping |
| :--- | :--- | :--- | :--- |
| 79279PA0080004 | Silver | Together Blue EPO Silver 2900 | N/A |
| 79279PA0130003 | Silver | Together Blue EPO Silver 2900 + Adult Dental and Vision | N/A |
| 79279PA0090002 | Silver | Together Blue EPO Silver 3250 HSA | N/A |
| 79279PA0160001 | Gold | Together Blue Care Advantage EPO Premier Gold 0 | N/A |
| 79279PA0170001 | Gold | Together Blue Care Advantage EPO Premier Gold 0 + Adult Dental and Vision | N/A |

Terminated Plans Offered in 2023 Only

| HIOS ID | Metal | Plan Name | 2024 Mapping |
| :--- | :--- | :--- | :--- |
| 79279PA0260001 | Gold | Together Blue Diabetes EPO Gold 0 | 79279PA0080008 |
| 79279PA0270001 | Gold | Together Blue Diabetes EPO Gold 0 + Adult Dental and Vision | 79279PA0130005 |
















[^0]:    Expeses compention Factor as os perce entoge

[^1]:    *PA follows the federal default age curve

[^2]:    Key (modify as needed)
    : 2023 on-exchange service area
    : 2023 off-exchange only service area

[^3]:    * Trends are then applied to the relevant mix for the entity and adjusted for Capitation to produce the resulting $9.17 \%$ as shown in Table 3.

[^4]:    ${ }^{1}$ Annual Baseline Trend is based on pre-COVID experience for all Commercial members
    ${ }^{2} 2022$ PMPM is the estimated baseline if COVID hadn't happened

